DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Overall O
CVD B-PHE
, O
Others O

-DOCSTART- O


Cyclandelate O
produces O
peripheral B-PHE
vasodilation I-PHE
by O
a O
direct O
effect O
on O
vascular B-PHE
smooth I-PHE
muscle I-PHE
. O

Pharmacological O
action O
may O
be O
due O
to O
calcium-channel O
antagonism O
. O

-DOCSTART- O


Cholestyramine O
binds O
bile B-PHE
in O
the O
gastrointestinal O
tract O
to O
prevent O
its O
reabsorption O
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
, O
a O
Chinese O
prescription O
, O
inhibits O
both O
herpes B-PHE
simplex I-PHE
virus I-PHE
type-1 I-PHE
and I-PHE
type-2 I-PHE
infections I-PHE
in O
vitro O
. O

-DOCSTART- O


Treatment O
of O
palpitation B-PHE
and O
insomnia B-PHE
, O
convulsion B-PHE
, O
epilepsy B-PHE
, O
nebula B-PHE
, O
skin B-PHE
ulcerations I-PHE
difficult O
to O
heal O
. O

-DOCSTART- O


Used O
in O
the O
treatment O
of O
Kaposi's B-PHE
sarcoma I-PHE
and O
cancer B-PHE
of O
the O
lung O
, O
ovarian O
, O
and O
breast O
. O

Abraxane O
is O
specfically O
indicated O
for O
the O
treatment O
of O
metastatic B-PHE
breast I-PHE
cancer I-PHE
and O
locally O
advanced B-PHE
or I-PHE
metastatic I-PHE
non-small I-PHE
cell I-PHE
lung I-PHE
cancer I-PHE
. O

-DOCSTART- O


Acute B-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Carcinoma B-PHE
of I-PHE
mammary I-PHE
glands I-PHE
, O
nasopharyngeal B-PHE
carcinoma I-PHE
, O
carcinoma B-PHE
of I-PHE
salivary I-PHE
gland I-PHE
, O
scrofula B-PHE
, O
swelling B-PHE
of I-PHE
skin I-PHE
, O
pain B-PHE
wind I-PHE
. O

-DOCSTART- O


To O
cause O
diuresis B-PHE
, O
to O
invigorate O
the O
spleen B-PHE
function I-PHE
, O
and O
to O
calm O
the O
mind B-PHE
. O

-DOCSTART- O


clear O
heat B-PHE
and O
calm O
the O
fetus O

-DOCSTART- O


Damp-heat B-PHE
dysentery I-PHE
, O
enteritis B-PHE
and O
diarrhea B-PHE
. O

-DOCSTART- O


dry B-PHE
cough I-PHE
due O
to O
lung-heat B-PHE

-DOCSTART- O


For O
clearing O
weakness B-PHE
and O
heat B-PHE

-DOCSTART- O


Exenatide O
is O
a O
functional O
analog O
of O
the O
human O
incretin O
Glucagon-Like O
Peptide-1 O
( O
GLP-1 O
) O
. O

Incretins B-PHE
enhance O
glucose-dependent B-PHE
insulin I-PHE
secretion I-PHE
and O
exhibit O
other O
antihyperglycemic B-PHE
actions I-PHE
following O
their O
release O
into O
the O
circulation O
from O
the O
gut O
. O

The O
GLP-1 B-PHE
system I-PHE
increases O
insulin B-PHE
secretion I-PHE
only O
in O
the O
presence O
of O
elevated O
plasma O
glucose O
levels O
, O
avoiding O
inappropriately O
high B-PHE
insulin I-PHE
levels I-PHE
during O
fasting O
. O

The O
drug O
also O
moderates O
peak O
serum B-PHE
glucagon I-PHE
levels I-PHE
during O
hyperglycemic O
periods O
following O
meals O
, O
but O
does O
not O
interfere O
with O
glucagon B-PHE
release I-PHE
in O
response O
to O
hypoglycemia O
. O

Secondary O
effects O
of O
drug O
administration O
reduces O
the O
rate B-PHE
of I-PHE
gastric I-PHE
emptying I-PHE
and O
decreases O
food B-PHE
intake I-PHE
, O
mitigating O
the O
potential O
severity B-PHE
of I-PHE
hyperglycemic I-PHE
events I-PHE
after O
meals O
. O

-DOCSTART- O


Intelligence O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
parkinson's B-PHE
disease I-PHE
. O

-DOCSTART- O


Good O
evidence O
exists O
that O
this O
drug O
bind O
strongly O
, O
but O
reversibly O
, O
to O
DNA B-PHE
, O
interfering O
with O
synthesis B-PHE
of I-PHE
RNA I-PHE
( O
prevention O
of O
RNA B-PHE
polymerase I-PHE
elongation I-PHE
) O
and O
, O
consequently O
, O
with O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
paralysis B-PHE
, O
painful O
wound B-PHE
from O
knocks O
and O
falls O
, O
tetanus O
. O

-DOCSTART- O


Halobetasol O
propionate O
is O
thought O
to O
act O
by O
the O
induction O
of O
phospholipase O
A2 O
inhibitory O
proteins O
, O
collectively O
called O
lipocortins O
. O

It O
is O
postulated O
that O
these O
proteins O
control O
the O
biosynthesis B-PHE
of O
potent O
mediators O
of O
inflammation O
such O
as O
prostaglandins B-PHE
and O
leukotrienes B-PHE
by O
inhibiting O
the O
release O
of O
their O
common O
precursor O
arachidonic B-PHE
acid I-PHE
. O

Arachidonic O
acid O
is O
released O
from O
membrane O
phospholipids O
by O
phospholipase O
A2 O
. O

The O
initial O
interaction O
, O
however O
, O
is O
due O
to O
the O
drug O
binding O
to O
the O
cytosolic O
glucocorticoid O
receptor O
. O

After O
binding O
the O
receptor O
the O
newly O
formed O
receptor-ligand O
complex O
translocates O
itself O
into O
the O
cell O
nucleus O
, O
where O
it O
binds O
to O
many O
glucocorticoid O
response O
elements O
( O
GRE O
) O
in O
the O
promoter O
region O
of O
the O
target O
genes O
. O

The O
DNA O
bound O
receptor O
then O
interacts O
with O
basic O
transcription B-PHE
factors I-PHE
, O
causing O
the O
increase O
in O
expression B-PHE
of I-PHE
specific I-PHE
target I-PHE
genes I-PHE
. O

-DOCSTART- O


fetal B-PHE
irritability I-PHE
; O
threatened B-PHE
abortion I-PHE
; O
excessive O
fetal O
movements O
continuous O
moving O
of O
the O
fetus O
causing O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE
. O

-DOCSTART- O


Cisplatin O
complexes O
react O
in O
vivo O
, O
binding O
to O
and O
causing O
crosslinking O
of O
DNA B-PHE
which O
ultimately O
triggers O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
. O

Gemcitabine O
is O
converted O
intracellularly O
to O
the O
active O
metabolites O
difluorodeoxycytidine O
di- O
and O
triphosphate O
( O
dFdCDP O
, O
dFdCTP O
) O
. O

dFdCDP O
inhibits O
ribonucleotide B-PHE
reductase I-PHE
, O
thereby O
decreasing O
the O
deoxynucleotide O
pool O
available O
for O
DNA B-PHE
synthesis I-PHE
; O
dFdCTP O
is O
incorporated O
into O
DNA B-PHE
, O
resulting O
in O
DNA B-PHE
strand I-PHE
termination I-PHE
and O
apoptosis B-PHE
. O

-DOCSTART- O


For O
breaking O
blood B-PHE
and O
desolving O
stasis B-PHE

-DOCSTART- O


A O
high O
performance O
liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
( O
HPLC-HG-AFS O
) O
method O
was O
developed O
for O
the O
simultaneous O
determination O
of O
four O
arsenic O
species O
( O
As(III) O
) O
, O
dimethylarsinic O
acid O
( O
DMA O
) O
, O
monomethylarsonic O
acid O
( O
MMA O
) O
and O
arsenate O
As(V) O
in O
dog O
plasma O
. O

Good O
separation O
of O
the O
four O
arsenic O
species O
was O
achieved O
within O
15min O
on O
an O
anion-exchange O
column O
with O
isocratic O
elution O
using O
15mmol/L O
KH(2)PO(4 O
) O
( O
pH O
5.9 O
) O
as O
eluent O
at O
a O
flow O
rate O
of O
1.0mL/min O
. O

The O
assay O
was O
linear O
over O
the O
range O
of O
1.25-200 O
, O
1.56-200 O
, O
1.34-172 O
, O
and O
2.50-200ng/mL O
with O
the O
detection O
limits O
of O
0.8 O
, O
1 O
, O
0.86 O
and O
2.00ng/mL O
for O
As O
( O
III O
) O
, O
DMA O
, O
MMA O
and O
As O
( O
V O
) O
, O
respectively O
. O

The O
method O
was O
validated O
for O
selectivity O
, O
precision O
, O
accuracy O
and O
recovery O
and O
then O
applied O
to O
a O
comparative O
pharmacokinetic O
study O
of O
the O
arsenic O
species O
in O
beagle O
dogs O
after O
a O
single O
oral O
administration O
of O
Realgar O
( O
24.32mg/kg O
, O
equivalent O
to O
11.31mgAs/kg O
) O
alone O
or O
Niu O
Huang O
Jie O
Du O
Pian O
(a O
patent O
traditional O
Chinese O
medicine O
( O
TCM O
) O
, O
380mg/kg O
, O
equivalent O
to O
28.45mgAs/kg O
) O
, O
respectively O
. O

DMA O
was O
found O
to O
be O
the O
predominant O
species O
in O
the O
dog O
plasma O
after O
dosing O
, O
with O
As(V O
) O
appeared O
as O
the O
quickly O
eliminating O
one O
. O

No O
traces O
of O
MMA O
and O
As(III O
) O
were O
detected O
at O
any O
sampling O
time O
points O
. O

The O
main O
pharmacokinetic O
parameters O
found O
for O
DMA O
p.o O
. O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
were O
as O
follows O
: O
C(max O
) O
( O
14.7 O
4.2 O
) O
and O
( O
57 O
32.0)ng/mL O
, O
T(max O
) O
( O
2.4 O
0.5 O
) O
and O
( O
2.5 O
0.5)h O
, O
AUC(0-36 O
) O
( O
151.1 O
12.9 O
) O
and O
( O
635.9 O
418.2)ngh/mL O
, O
AUC(0- O
) O
( O
206 O
44.5 O
) O
and O
( O
687.2 O
425.1)ngh/mL O
, O
t(1/2 O
) O
( O
16.2 O
7.9 O
) O
and O
( O
9.4 O
2.2)h O
, O
respectively O
. O

The O
influence O
of O
compounding O
in O
Niu O
Huang O
Jie O
Du O
Pian O
on O
the O
pharmacokinetics O
of O
arsenics O
was O
shown O
with O
increased O
transformation O
of O
DMA O
and O
its O
faster O
elimination O
rate O
. O

-DOCSTART- O


To O
remove O
heat B-PHE
and O
damp B-PHE
, O
to O
counteract O
toxicity B-PHE
, O
and O
to O
cause O
subsidence B-PHE
of I-PHE
swelling I-PHE
. O

-DOCSTART- O


Treatment O
of O
headache B-PHE
and O
dizziness B-PHE
, O
costal B-PHE
and I-PHE
abdomina I-PHE
pain I-PHE
, O
spasmodic B-PHE
pain I-PHE
of O
the O
limbs O
, O
anemia B-PHE
, O
menstrual B-PHE
disorders I-PHE
, O
spontaneous O
sweating B-PHE
and O
night B-PHE
sweating I-PHE
. O

-DOCSTART- O


Mounting O
qi O
( O
hernia B-PHE
) O
, O
profuse B-PHE
menstruation I-PHE
. O

-DOCSTART- O


arrest O
cough B-PHE
and O
relieve O
asthms B-PHE

-DOCSTART- O


acute O
infantile B-PHE
convulsion I-PHE

-DOCSTART- O


cough B-PHE
due O
to O
wind-cold B-PHE

-DOCSTART- O


Cold B-PHE
pain I-PHE
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-PHE
, O
vomiting B-PHE
nausea B-PHE
, O
diarrhea B-PHE
, O
cold B-PHE
mounting O
, O
dysmenorrhea B-PHE
, O
urethral B-PHE
stone I-PHE
, O
swelling B-PHE
pain I-PHE
of O
sore O
and O
boil O
. O

-DOCSTART- O


To O
reduce O
swelling B-PHE
and O
promote O
healing B-PHE
. O

-DOCSTART- O


Acute B-PHE
Viral I-PHE
Bronchiolitis I-PHE

-DOCSTART- O


AIDS B-PHE
With O
Tuberculosis B-PHE

-DOCSTART- O


Red B-PHE
eyes I-PHE
with O
gall O
, O
pulmonary O
welling O
abscess B-PHE
, O
diarrhea B-PHE
, O
dysentery B-PHE
, O
leukorrhea B-PHE
, O
postpartum O
blood B-PHE
stasis I-PHE
abdominal B-PHE
pain I-PHE
, O
indigestion B-PHE
, O
nephritis B-PHE
with O
edema B-PHE
, O
cirrhosis B-PHE
with O
ascites B-PHE
, O
swelling B-PHE
toxin O
of O
welling B-PHE
abscess I-PHE
and O
sore B-PHE
. O

-DOCSTART- O


promote O
the O
intestine B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
cool O
blood B-PHE
; O

To O
benefit O
qi O
and O
contain O
blood B-PHE
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


For O
treatment O
and O
management O
of O
epilepsy B-PHE
and O
seizures B-PHE
associated O
with O
Lennox-Gastaut B-PHE
syndrome I-PHE
, O
a O
difficult-to-treat O
form O
of O
childhood B-PHE
epilepsy I-PHE
. O

-DOCSTART- O


Hemophilia B-PHE
A I-PHE

-DOCSTART- O


sore B-PHE

-DOCSTART- O


general O
swelling B-PHE
and O
small B-PHE
amount I-PHE
urine I-PHE

-DOCSTART- O


1 O
Since O
the O
prescription O
possesses O
a O
hemostatic O
action O
, O
it O
is O
also O
indicated O
for O
incised B-PHE
wounds I-PHE
with O
hemorrhage B-PHE
( O
topical O
use O
) O
. O

2 O
Applicable O
to O
cases O
of O
angina B-PHE
pectoris I-PHE
which O
are O
attributive O
to O
retention O
of O
blood B-PHE
stasis I-PHE
. O

3 O
Also O
applicable O
orally O
or O
topi O

-DOCSTART- O


Hypertension B-PHE
, O
kidney B-PHE
vacuity I-PHE
lumbago I-PHE
, O
weakness B-PHE
in O
sinews O
and O
bones O
, O
stirring O
fetus O
in O
pregnancy O
. O

-DOCSTART- O


ADHD B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


excessive B-PHE
thought I-PHE
; O
anxiety O

-DOCSTART- O


To O
calm O
the O
liver O
and O
suppress O
the O
asthenic B-PHE
yang O
, O
to O
promote O
the O
restoration O
of O
consciousness O
, O
decrease O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Liver B-PHE
health I-PHE
, O
Liver B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
chronic B-PHE
coughing I-PHE
and O
inflammation B-PHE
in O
urination O
. O

-DOCSTART- O


Intelligence B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective O
immunity B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


a O
symptom O
of O
having O
muscular B-PHE
flaccidity I-PHE
due O
to O
deficiency O
of O
Gi O
, O
and O
insufficiency B-PHE
of I-PHE
nourishment I-PHE
in O
organs O
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE

-DOCSTART- O


Decanoyl O
acetaldehyde O
is O
bacteriostatic O
and O
fungistatic O
. O

Its O
decoction O
retards O
the O
progress O
of O
tuberculosis B-PHE
experimentally O
. O

Synthetic O
product O
( O
compound O
of O
decanoyl O
acetaldehyde O
and O
NaHSO3 O
) O
promotes O
white B-PHE
cell I-PHE
phagocytosis I-PHE
. O

Anti-inflammation B-PHE
. O

Quercitrin O
, O
an O
active O
component O
, O
is O
a O
strong O
diuretic O
, O
and O
exerts O
such O
effect O
in O
a O
1 O
: O
10 O
, O
0 O
solution O
. O

-DOCSTART- O


To O
move O
qi O
, O
precipitate O
qi O
, O
relieve O
pain B-PHE
, O
disperse O
distention O
, O
free O
milk O
. O

-DOCSTART- O


Based O
on O
the O
behavior O
of O
protons O
when O
placed O
in O
a O
strong O
magnetic O
field O
, O
which O
is O
interpreted O
and O
transformed O
into O
images O
by O
magnetic O
resonance O
( O
MR O
) O
instruments O
. O

Paramagnetic O
agents O
have O
unpaired O
electrons O
that O
generate O
a O
magnetic O
field O
about O
700 O
times O
larger O
than O
the O
proton's O
field O
, O
thus O
disturbing O
the O
proton's O
local O
magnetic O
field O
. O

When O
the O
local O
magnetic O
field O
around O
a O
proton O
is O
disturbed O
, O
its O
relaxation O
process O
is O
altered O
. O

MR O
images O
are O
based O
on O
proton O
density O
and O
proton O
relaxation O
dynamics O
. O

MR O
instruments O
can O
record O
2 O
different O
relaxation O
processes O
, O
the O
T1 O
( O
spin-lattice O
or O
longitudinal O
relaxation O
time O
) O
and O
the O
T2 O
( O
spin-spin O
or O
transverse O
relaxation O
time O
) O
. O

In O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
visualization O
of O
normal O
and O
pathological O
brain O
tissue O
depends O
in O
part O
on O
variations O
in O
the O
radiofrequency O
signal O
intensity O
that O
occur O
with O
changes O
in O
proton O
density O
, O
alteration O
of O
the O
T1 O
, O
and O
variation O
in O
the O
T2 O
. O

When O
placed O
in O
a O
magnetic O
field O
, O
gadodiamide O
shortens O
both O
the O
T1 O
and O
the O
T2 O
relaxation O
times O
in O
tissues O
where O
it O
accumulates O
. O

At O
clinical O
doses O
, O
gadodiamide O
primarily O
affects O
the O
T1 O
relaxation O
time O
, O
thus O
producing O
an O
increase O
in O
signal O
intensity O
. O

Gadodiamide O
does O
not O
cross O
the O
intact O
blood-brain B-PHE
barrier I-PHE
; O
therefore O
, O
it O
does O
not O
accumulate O
in O
normal O
brain O
tissue O
or O
in O
central B-PHE
nervous I-PHE
system I-PHE
( O
CNS B-PHE
) O
lesions B-PHE
that O
have O
not O
caused O
an O
abnormal O
blood-brain B-PHE
barrier I-PHE
( O
e.g O
. O
, O
cysts B-PHE
, O
mature O
post-operative O
scars O
) O
. O

Abnormal B-PHE
vascularity I-PHE
or O
disruption B-PHE
of I-PHE
the I-PHE
blood-brain I-PHE
barrier I-PHE
allows O
accumulation O
of O
gadodiamide B-PHE
in I-PHE
lesions I-PHE
such O
as O
neoplasms B-PHE
, O
abscesses B-PHE
, O
and O
subacute B-PHE
infarcts I-PHE
. O

-DOCSTART- O


vomiting B-PHE
and O
regurgitation B-PHE

-DOCSTART- O


Inhibited O
urination B-PHE
, O
dribbling O
pain B-PHE
of O
urination O
, O
edema B-PHE
, O
bloody B-PHE
urine I-PHE
, O
damp-heat B-PHE
dysentery I-PHE
, O
asthma B-PHE
, O
sore B-PHE
swollen I-PHE
throat I-PHE
, O
toxin B-PHE
swelling I-PHE
of O
sores O
, O
wind-damp B-PHE
pain I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
bleeding B-PHE
knife O
wound O
. O

-DOCSTART- O


This O
is O
a O
syndrome B-PHE
with I-PHE
bloat I-PHE
and I-PHE
fullness I-PHE
in I-PHE
abdominal I-PHE
region I-PHE
. O

-DOCSTART- O


swelling B-PHE
and O
bearing-down B-PHE
pain I-PHE
of O
unilateral O
testis O
; O
unilateral O
swelling B-PHE
of I-PHE
the I-PHE
testis I-PHE

-DOCSTART- O


Boils B-PHE
and O
carbuncles B-PHE
. O

-DOCSTART- O


release O
the O
exterior O
and O
dispel O
wind B-PHE

-DOCSTART- O


Treatment O
of O
weakness B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
lung I-PHE
manifested O
by O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cough B-PHE
, O
palpitation B-PHE
, O
anorexia B-PHE
, O
loose B-PHE
stools I-PHE
, O
diabetes B-PHE
caused O
by O
internal O
heat B-PHE
. O

-DOCSTART- O


inflammation B-PHE
of O
the O
throat O
; O
sore B-PHE
throat I-PHE
; O
hoarse B-PHE
voice I-PHE
; O
aphonia B-PHE

-DOCSTART- O


Its O
aqueous O
infusion O
inhibits O
the O
growth B-PHE
of I-PHE
skin I-PHE
fungi I-PHE
such O
as O
Trichophyton B-PHE
violaceum I-PHE
. O

-DOCSTART- O


To O
enrich O
the O
blood B-PHE
, O
to O
activate O
blood B-PHE
circulation I-PHE
, O
and O
to O
remove O
obstruction O
of O
the O
channels O
and O
collaterals O
. O

-DOCSTART- O


Chronic B-PHE
Fatigue I-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
the O
following O
mild-to-moderate B-PHE
infections I-PHE
caused O
by O
susceptible O
strains O
of O
microorganisms O
: O
acute B-PHE
bacterial I-PHE
exacerbations I-PHE
of I-PHE
chronic I-PHE
bronchitis I-PHE
, O
secondary B-PHE
bacterial I-PHE
infection I-PHE
of O
acute B-PHE
bronchitis I-PHE
, O
community B-PHE
- I-PHE
acquired I-PHE
pneumonia I-PHE
, O
pharyngitis B-PHE
/ O
tonsilitis B-PHE
, O
and O
uncomplicated B-PHE
skin I-PHE
and O
skin B-PHE
structure I-PHE
infections I-PHE
. O

-DOCSTART- O


To O
remove O
heat B-PHE
from O
the O
lung O
and O
relieve O
sore B-PHE
throat I-PHE
, O
and O
to O
regulate O
the O
flow O
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
disinhibit O
water O
and O
disperse O
edema B-PHE
. O

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
. O

-DOCSTART- O


post B-PHE
delivery I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Woman O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE
, O
Others O
, O
Body B-PHE
weight I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Quality O
of O
life O
, O
Hemostatic B-PHE
function I-PHE
, O
Inflammation B-PHE

-DOCSTART- O


pull O
up O
toxicity B-PHE
and O
regenerate O
flesh B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
of O
a O
retarded B-PHE
child I-PHE
. O

There O
are O
five O
symptoms O
including O
slow B-PHE
stand I-PHE
, O
delayed O
development O
in O
walking O
, O
retardation O
in O
hair-growing O
, O
delayed B-PHE
development I-PHE
in O
growth O
of O
teeth O
, O
and O
delayed B-PHE
development I-PHE
of O
speech O
in O
an O
infant O
. O

-DOCSTART- O


Pulmonary O
Aspiration O

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
reinforce O
blood B-PHE

-DOCSTART- O


stop O
bleeding B-PHE
; O
hemostasis B-PHE

-DOCSTART- O


freckles B-PHE
on O
face O

-DOCSTART- O


Filgrastim O
binds O
to O
the O
G-CSF O
receptor O
and O
stimulates O
the O
production B-PHE
of I-PHE
neutrophils I-PHE
in O
the O
bone O
marrow O
. O

-DOCSTART- O


Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes O
in O
gene B-PHE
expression I-PHE
that O
lead O
to O
cell B-PHE
differentiation I-PHE
, O
decreased B-PHE
cell I-PHE
proliferation I-PHE
, O
and O
inhibition B-PHE
of I-PHE
tumorigenesis I-PHE
. O

-DOCSTART- O


Heart B-PHE
Failure I-PHE
. O

-DOCSTART- O


juvenile O
onset O
smallpox B-PHE
poison O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
Without O
Maturation B-PHE

-DOCSTART- O


pain B-PHE
in O
ear O

-DOCSTART- O


Numbness B-PHE
of I-PHE
the I-PHE
extremities I-PHE
, O
aching B-PHE
of O
the O
joints O
and O
menstrual B-PHE
disorders I-PHE
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
fullness B-PHE
and I-PHE
pain I-PHE
in I-PHE
the I-PHE
chest I-PHE
and I-PHE
abdomen I-PHE
. O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
rectify O
qi O
and O
regulate O
center O
. O

-DOCSTART- O


Treatment O
of O
hemoptysis B-PHE
, O
hematemesis B-PHE
, O
epistaxis B-PHE
, O
hematochezia B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
pricking O
pain B-PHE
in O
the O
chest O
and O
abdomen O
, O
traumatic B-PHE
swelling I-PHE
and O
pain B-PHE
. O

-DOCSTART- O


Coronary O
Artery O
Bypass O
Graft O
Redo O

-DOCSTART- O


deficiency B-PHE
and I-PHE
chills I-PHE
of I-PHE
uterus I-PHE

-DOCSTART- O


frequent B-PHE
vomiting I-PHE

-DOCSTART- O


epigastric O
twisting O
pain B-PHE
. O

-DOCSTART- O


Lopinavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
protease I-PHE
enzyme I-PHE
. O

-DOCSTART- O


Statin O
Therapy O

-DOCSTART- O


TBC3711 O
is O
a O
small O
molecule O
that O
blocks O
the O
action O
of O
endothelin O
, O
a O
potent O
mediator O
of O
blood O
vessel O
constriction O
and O
growth O
of O
smooth O
muscle O
in O
vascular B-PHE
walls I-PHE
. O
It O
is O
a O
next-generation O
endothelin O
A O
antagonist O
which O
possesses O
high O
oral O
bioavailability O
and O
is O
more O
selective O
and O
potent O
than O
THELIN(tm O
) O
( O
sitaxsentan O
sodium O
) O
Encysive's O
oral O
treatment O
for O
pulmonary B-PHE
arterial I-PHE
hypertension I-PHE
. O

TBC3711 O
is O
greater O
than O
100,000-fold O
selective O
in O
the O
targeting O
of O
the O
endothelin O
A O
receptor O
versus O
the O
endothelin O
B O
receptor O
. O

-DOCSTART- O


insulin O
sensitivity O
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Woman O
, O
Reproductive B-PHE
systems I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Quality O
of O
life O
, O
Menopausal B-PHE
woman O
, O
Eldery O
, O
Liver B-PHE
health I-PHE
, O
Metabolism B-PHE
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Bone B-PHE
metabolism/density B-PHE
, O
Memory O
, O
Liver O
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


swelling B-PHE
of O
the O
foot O
; O
edema B-PHE
of O
foot O

-DOCSTART- O


Obesity B-PHE
and O
Obesity-related B-PHE
Medical O
Conditions O

-DOCSTART- O


frost B-PHE
bite I-PHE
; O
chilblain B-PHE
; O
frostbite B-PHE

-DOCSTART- O


Migraine B-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
taxation O
damage O
in O
lumbar B-PHE
muscle I-PHE
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Stage O
IV O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
heparin-induced B-PHE
thrombocytopenia I-PHE

-DOCSTART- O


Protective B-PHE
immunity I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


For O
cooling O
blood B-PHE
and O
stopping O
bleeding B-PHE

-DOCSTART- O


Stage O
III O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


chest O
and O
hypochondriac O
pain O

-DOCSTART- O


This O
is O
bleeding B-PHE
due O
to O
an O
external B-PHE
wound I-PHE
. O

-DOCSTART- O


glad O
and O
misten B-PHE
complexion I-PHE

-DOCSTART- O


Treatment O
of O
taeniasis B-PHE
, O
ancylostomiasis B-PHE
, O
ascariasis B-PHE
, O
intestinal B-PHE
parasitosis I-PHE
with O
abdominal B-PHE
pain I-PHE
or O
with O
infantile B-PHE
malnutrition I-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
lung B-PHE
subcutaneous I-PHE
nodes I-PHE

-DOCSTART- O


For O
desolving O
phlegm B-PHE
, O
stopping O
cougth B-PHE
, O
and O
soothing O
breathing B-PHE

-DOCSTART- O


Roundworm B-PHE

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE
, O
Others O

-DOCSTART- O


fever B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
EGFR-expressing O
, O
metastatic B-PHE
colorectal I-PHE
carcinoma I-PHE
that O
is O
refractory O
to O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan- O
containing O
chemotherapy O
regimens O
. O

-DOCSTART- O


Rheumatism B-PHE
numbness I-PHE
, O
damp-heat B-PHE
itchy I-PHE
sore I-PHE
, O
clove B-PHE
sore I-PHE
, O
menstruant O
morbidity O
. O

-DOCSTART- O


To O
soothe O
the O
liver B-PHE
and O
regulate O
the O
circulation O
of O
qi O
, O
clear O
away O
heat B-PHE
and O
toxic O
materials O
. O

-DOCSTART- O


new O
and O
old O
cough B-PHE

-DOCSTART- O


To O
supplement O
blood B-PHE
and O
quicken O
blood B-PHE
, O
free O
channels B-PHE
and O
quicken O
network B-PHE
vessels I-PHE
. O

-DOCSTART- O


Untreated O
Adult B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Edema B-PHE
due O
to O
deficiency B-PHE
in I-PHE
the I-PHE
kidney I-PHE
, O
accompanied O
with O
heaviness O
sensation O
in O
the O
loins O
and O
knees O
and O
oliguria O
; O

retention O
of O
body O
fluid O
with O
dyspnea B-PHE
and O
cough B-PHE
. O

-DOCSTART- O


leukorrhea B-PHE
with O
pruritis B-PHE
vulva I-PHE

-DOCSTART- O


Liver O
Transplantation O

-DOCSTART- O


To O
regulate O
menstruation B-PHE
, O
replenish O
blood B-PHE
and O
regulate O
qi O
to O
relieve O
pain B-PHE
. O

-DOCSTART- O


To O
supplement O
blood B-PHE
, O
quicken B-PHE
blood I-PHE
, O
strengthen O
lumbus B-PHE
and O
knees B-PHE
. O

-DOCSTART- O


Treatment O
of O
mass B-PHE
in O
the O
abdomen O
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
abdominal B-PHE
distension I-PHE
and O
pain B-PHE
caused O
by O
retention O
of O
undigested O
food O
. O

-DOCSTART- O


To O
eliminate O
toxic B-PHE
material I-PHE
, O
promote O
pus B-PHE
drainage I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Papillary B-PHE
serous I-PHE
endometrial I-PHE
cancer I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE
Virus I-PHE
, O
Pediatric O

-DOCSTART- O


1 O
To O
remove O
blood B-PHE
stasis I-PHE
and O
alleviate O
pain B-PHE
. O

For O
stomachache B-PHE
, O
headache B-PHE
, O
toothache B-PHE
, O
trauma B-PHE
and O
rheumatism O
. O

2 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
. O

For O
sorethroat B-PHE
, O
aphthae B-PHE
, O
carbuncle B-PHE
, O
burn B-PHE
, O
snake B-PHE
bite I-PHE
, O
dysentery B-PHE
and O
diarrhea B-PHE
. O

3 O
To O
relax O
the O
muscles O
. O

As O
a O
muscle O
relaxant O
for O
restoration O
of O
fracture B-PHE
and O
surgical O
operation O
. O

-DOCSTART- O


Chloramphenicol O
reversibly O
binds O
to O
the O
L16 B-PHE
protein I-PHE
of O
the O
50S B-PHE
subunit I-PHE
of I-PHE
bacterial I-PHE
ribosomes I-PHE
, O
thus O
inhibits O
protein B-PHE
synthesis I-PHE
. O

Desoxyribonuclease O
is O
a O
biosynthetic O
form O
of O
human O
DNase B-PHE
I I-PHE
, O
which O
is O
involved O
in O
endonucleolytic O
cleavage O
of O
extracellular B-PHE
DNA I-PHE
to O
5-phosphodinucleotide O
and O
5-phosphooligonucleotide O
end O
products O
. O

Fibrinolysin O
attacks O
and O
inactivates O
fibrin B-PHE
molecules I-PHE
occurring O
in O
undesirable O
exudates O
on O
the O
surface O
of O
the O
human O
body O
and O
on O
human B-PHE
mucosa I-PHE
. O

-DOCSTART- O


pulmonary B-PHE
carbuncle I-PHE
; O
lung B-PHE
abscess I-PHE

-DOCSTART- O


a O
disease O
that O
tendons B-PHE
and O
bones B-PHE
become O
dry O

-DOCSTART- O


vomiting B-PHE

-DOCSTART- O


Yang O
poison B-PHE
; O
extreme O
heat B-PHE
; O
symptoms O
due O
to O
extreme O
heat B-PHE

-DOCSTART- O


the O
steaming B-PHE
of I-PHE
bone I-PHE
and O
tidal O
fever B-PHE

-DOCSTART- O


1 O
Byak-angelicin O
contained O
in O
its O
root O
can O
dilate O
the O
coronary B-PHE
arteries I-PHE
. O

2 O
Stimulating O
the O
respiratory B-PHE
center I-PHE
, O
vasomotor B-PHE
center I-PHE
and O
nervus B-PHE
vagus I-PHE
. O

3 O
Its O
decoction O
exerts O
bacteriostatic B-PHE
effect I-PHE
. O

4 O
Imperatorin O
, O
another O
active O
component O
, O
is O
effective O
for O
psoriasis B-PHE
. O

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Others O

-DOCSTART- O


Its O
volatile O
oil O
is O
an O
expectorant O
and O
antiasthmatic. O
. O

-DOCSTART- O


This O
is O
a O
symptom O
that O
the O
body O
becomes O
haggard B-PHE
because O
of O
exhaustion B-PHE
syndrome I-PHE
. O

-DOCSTART- O


To O
pacify O
the O
liver B-PHE
and O
subdue O
the O
yang O
; O

To O
conduct O
rebellious O
qi O
downward O
and O
stop O
vomiting B-PHE
; O

To O
stop O
bleeding B-PHE

-DOCSTART- O


gingivitis B-PHE
; O
epulis B-PHE

-DOCSTART- O


kill O
worms B-PHE

-DOCSTART- O


HER2-overexpressing O
breast B-PHE
cancer I-PHE

-DOCSTART- O


ischuria B-PHE
; O
dysuria B-PHE
; O
retention B-PHE
of I-PHE
urine I-PHE

-DOCSTART- O


Juzentaihoto O
Failed O
to O
Augment O
Antigen-Specific O
Immunity B-PHE
but O
Prevented O
Deterioration B-PHE
of O
Patients' O
Conditions O
in O
Advanced O
Pancreatic B-PHE
Cancer I-PHE
under O
Personalized O
Peptide O
Vaccine O
. O

-DOCSTART- O


To O
break O
blood B-PHE
and O
desolve O
stagnation B-PHE
; O
To O
benefit O
qi O

-DOCSTART- O


Huperzine O
B O
has O
been O
found O
to O
be O
an O
inhibitor O
of O
the O
enzyme B-PHE
acetylcholinesterase I-PHE
. O

This O
is O
the O
same O
mechanism O
of O
action O
of O
pharmaceutical O
drugs O
such O
as O
galantamine O
and O
donepezil O
used O
to O
treat O
Alzheimer's B-PHE
disease I-PHE
. O

-DOCSTART- O


Effects O
of O
Hachimijiogan O
on O
dopamine O
, O
serotonin O
and O
vasoactive O
intestinal O
peptide O
in O
plasma O
and O
hypothalamus O
in O
sulpiride-induced O
hyperprolactinemic O
rats O
. O

-DOCSTART- O


Chronic B-PHE
Heart I-PHE
Failure I-PHE

-DOCSTART- O


Treatment O
of O
carbuncle B-PHE
and O
boil B-PHE
at O
the O
early O
stage O
or O
formation B-PHE
of I-PHE
abscess I-PHE
difficult O
to O
burst B-PHE
, O
external O
use O
for O
scabies B-PHE
and O
leprosy B-PHE
. O

-DOCSTART- O


oppressed B-PHE
feeling I-PHE
and O
fullness B-PHE
in O
the O
chest O
and O
diaphragm O

-DOCSTART- O


Spontaneous O
external B-PHE
bleeding I-PHE
, O
hematochezia B-PHE
, O
headache B-PHE
, O
dizziness B-PHE
and O
dim B-PHE
vision I-PHE
, O
red B-PHE
eyes I-PHE
, O
night B-PHE
blindness I-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
fecal B-PHE
stoppage I-PHE
, O
hemorrhoids B-PHE
. O

-DOCSTART- O


warm B-PHE
malaria I-PHE
; O

pyrexial B-PHE
malaria I-PHE

-DOCSTART- O


Enduring O
cough B-PHE
and O
asthma B-PHE
, O
bronchitis B-PHE
, O
lumbago B-PHE
and O
limp O
leg B-PHE
, O
frequent O
urination B-PHE
, O
enuresis B-PHE
, O
impotence B-PHE
, O
emission B-PHE
, O
intestinal B-PHE
dry I-PHE
and O
constipation B-PHE
, O
stone B-PHE
strangury I-PHE
, O
sores B-PHE
and O
scrofula B-PHE
. O

-DOCSTART- O


Cancer B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
effuse O
sweat B-PHE
, O
dissipate O
cold B-PHE
and O
dry O
damp B-PHE
. O

-DOCSTART- O


snake-bite B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


To O
astringe O
intestines B-PHE
and O
check O
diarrhea B-PHE
, O
resolve O
toxin B-PHE
, O
relieve O
itch B-PHE
. O

-DOCSTART- O


Ritonavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
proteinase I-PHE
enzyme I-PHE
which O
prevents O
cleavage B-PHE
of I-PHE
the I-PHE
gag-pol I-PHE
polyprotein I-PHE
, O
resulting O
in O
noninfectious O
, O
immature O
viral B-PHE
particles I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
aching B-PHE
pain I-PHE
in O
joints O
, O
arthritis B-PHE
, O
dysmenorrhea B-PHE
, O
skin B-PHE
numbness I-PHE
, O
weakness B-PHE
in I-PHE
limbs I-PHE
, O
jaundice B-PHE
, O
cough B-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
sores B-PHE
, O
zoster B-PHE
, O
scalds B-PHE
. O

-DOCSTART- O


( O
1 O
) O
hemorrhoids B-PHE
( O
2 O
) O
polyp B-PHE

-DOCSTART- O


damp B-PHE
Pi O
arthritis B-PHE
due O
to O
dampness B-PHE
. O

damp B-PHE
stroke I-PHE
; O

attack O
of O
dampness B-PHE
syndrome I-PHE
due O
to O
attack O
of O
pathogenic B-PHE
factors I-PHE
. O

-DOCSTART- O


1 O
Inhibiting O
the O
growth O
of O
leukemia615 B-PHE
, O
sarcoma180 B-PHE
and O
cervial B-PHE
carcinoma14 I-PHE
in O
mice O
. O
2 O
Relieving O
iodine B-PHE
deficiency I-PHE
and O
goiter B-PHE
in O
experimental O
animals O
. O

-DOCSTART- O


swelling B-PHE
of O
the O
cheek O
; O
parotitis B-PHE

-DOCSTART- O


Bone B-PHE
Marrow I-PHE
Suppression I-PHE

-DOCSTART- O


Eum O
deficiency O
of O
liver O
and O
kidney O
; O
deficiency O
of O
Eum(vital O
essence O
) O
of O
the O
liver O
and O
kidney O

-DOCSTART- O


cough B-PHE
due O
to O
phlegm-damp B-PHE

-DOCSTART- O


Chronic B-PHE
Viral I-PHE
Hepatitis I-PHE
B I-PHE
Without I-PHE
Delta-agent I-PHE

-DOCSTART- O


prolapse B-PHE
of I-PHE
the I-PHE
rectum I-PHE

-DOCSTART- O


Hypertension B-PHE
. O

-DOCSTART- O


Menopausal B-PHE
syndrome I-PHE
marked O
by O
afternoon O
fever B-PHE
, O
excessive B-PHE
sweating I-PHE
, O
dizziness B-PHE
, O
tinnitus B-PHE
, O
insomnia B-PHE
and O
unsteady B-PHE
blood I-PHE
pressure I-PHE
. O

-DOCSTART- O


Uncaria O
Hook O
( O
UH O
) O
alkaloids O
are O
involved O
in O
the O
beneficial O
effects O
of O
Yokukansan O
. O

However O
, O
the O
pharmacokinetics O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
has O
not O
yet O
been O
sufficiently O
investigated O
. O

Therefore O
, O
we O
developed O
and O
validated O
a O
sensitive O
and O
specific O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
( O
LC/MS/MS O
) O
method O
for O
the O
simultaneous O
quantitation O
of O
seven O
UH O
alkaloids O
( O
corynoxeine O
, O
isocorynoxeine O
, O
rhynchophylline O
, O
isorhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
) O
in O
rat O
plasma O
and O
brain O
. O

After O
protein O
precipitation O
with O
acetonitrile O
, O
chromatographic O
separation O
was O
performed O
using O
an O
Ascentis O
Express O
RP-amide O
column O
, O
with O
gradient O
elution O
with O
0.002 O
formic O
acid O
and O
acetonitrile O
at O
0.3 O
mL/min O
. O

All O
analytes O
in O
the O
plasma O
and O
brain O
showed O
good O
linearity O
over O
a O
wide O
concentration O
range O
(r O
> O
0.995 O
) O
. O

Intra-day O
and O
inter-day O
variations O
of O
each O
constituent O
were O
8.6 O
and O
0.08 O
or O
less O
in O
the O
plasma O
, O
and O
14.9 O
and O
0.15 O
or O
less O
in O
the O
brain O
, O
respectively O
. O

The O
validated O
LC/MS/MS O
method O
was O
applied O
in O
the O
pharmacokinetic O
studies O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
to O
rats O
. O

In O
the O
plasma O
, O
rhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
were O
detected O
, O
but O
only O
geissoschizine O
methyl O
ether O
was O
detected O
in O
the O
brain O
. O

These O
results O
suggest O
that O
geissoschizine O
methyl O
ether O
is O
an O
important O
constituent O
of O
the O
pharmacological O
effects O
of O
Yokukansan O
. O

-DOCSTART- O


nausea B-PHE
without O
vomiting B-PHE
. O

-DOCSTART- O


1 O
Oral O
administration O
increases O
the O
level O
of O
cAMP B-PHE
and O
decrease O
the O
level B-PHE
of I-PHE
cGMP I-PHE
in O
plasma O
and O
in O
leukocytes O
. O
Protect O
the O
liver B-PHE
from O
damage O
. O
Hypotensive B-PHE
. O

-DOCSTART- O


Drug B-PHE
Induced I-PHE
Hepatotoxicity I-PHE

-DOCSTART- O


12-0-tetradecanoyl-phorbol-13-acetate O
isolated O
from O
its O
croton O
oil O
is O
a O
cancerigenic B-PHE
component I-PHE
. O

-DOCSTART- O


To O
desolve O
phlegm B-PHE
and O
soften O
hardness O
; O
To O
revitalize O
blood B-PHE

-DOCSTART- O


Some O
patients O
with O
major B-PHE
depressive I-PHE
disorder I-PHE
( O
MDD B-PHE
) O
do O
not O
show O
remission O
of O
their O
depressive O
symptomatology O
. O

We O
investigated O
the O
efficacy O
of O
Rokumigan O
( O
TJ-87 O
) O
and O
Hachimijiogan O
( O
TJ-7 O
) O
in O
20 O
patients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
associated O
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
. O

In O
these O
20 O
patients O
, O
TJ-7 O
or O
TJ-87 O
was O
added O
to O
the O
previous O
regimen O
for O
4 O
weeks O
. O

Six O
patients O
were O
'much O
improved' O
, O
six O
were O
'minimally O
improved' O
( O
responders O
) O
, O
and O
eight O
showed O
'no O
change' O
( O
non-responders O
) O
, O
on O
the O
Clinical O
Global O
Impression O
Global O
Improvement O
scale O
. O

All O
responders O
had O
Shofuku-fujin O
( O
tenderness B-PHE
or O
weakness B-PHE
of O
the O
lower O
abdomen O
) O
. O

In O
conclusion O
, O
we O
experienced O
12 O
outpatients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
, O
which O
was O
successfully O
treated O
with O
TJ-87 O
or O
TJ-7 O
. O

-DOCSTART- O


Treament O
of O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Kidney B-PHE
Diseases I-PHE

-DOCSTART- O


Efficacy O
of O
Keishibukuryogan O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
in O
treating O
cold B-PHE
sensation I-PHE
and O
numbness B-PHE
after O
stroke B-PHE
: O
clinical O
improvement O
and O
skin O
temperature O
normalization O
in O
22 O
stroke B-PHE
patients O
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
bladder B-PHE
cancer I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


distribution O
) O
, O
energy O
supply O
and O
recovery O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


Thoracic O
Surgery O

-DOCSTART- O


wind B-PHE
syndrome I-PHE

-DOCSTART- O


Carotid B-PHE
Artery I-PHE
Stenosis I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


Infant B-PHE
, I-PHE
Diabetic I-PHE
Mother I-PHE

-DOCSTART- O


Treament O
of O
heat B-PHE
in O
the O
lung O
with O
cough B-PHE
, O
sticky B-PHE
and I-PHE
bloody I-PHE
sputum I-PHE
, O
and O
distress B-PHE
in I-PHE
the I-PHE
chest I-PHE
. O

-DOCSTART- O


HGS-TR2J O
binds O
TRAIL O
Receptor O
2 O
with O
high O
affinity O
, O
induces O
apoptosis B-PHE
and O
has O
anti-tumor B-PHE
activity I-PHE
, O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
chemotherapy O
. O

HGS-TR2J O
mimics O
the O
activity O
of O
native O
TRAIL O
( O
tumor O
necrosis O
factor-related O
apoptosis-inducing O
ligand O
) O
and O
, O
thus O
, O
is O
considered O
an O
agonistic O
antibody B-PHE
. O

Numerous O
nonclinical O
studies O
have O
shown O
that O
cell O
lines O
derived O
from O
a O
broad O
array O
of O
solid O
and O
hematological B-PHE
human I-PHE
tumors I-PHE
, O
including O
lung O
, O
colon O
, O
breast O
, O
multiple O
myeloma B-PHE
, O
prostate O
and O
pancreas O
, O
are O
sensitive O
to O
killing O
by O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
induced O
by O
native O
TRAIL O
or O
by O
agonistic O
antibodies O
to O
TRAIL O
Receptors O
1 O
and O
2.2-24 O
. O

-DOCSTART- O


Tiagabine O
blocks O
GABA O
uptake O
into O
presynaptic O
neurons O
, O
permitting O
more O
GABA O
to O
be O
available O
for O
receptor O
binding O
on O
the O
surfaces O
of O
post-synaptic O
cells O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated O
N-type O
calcium O
ion O
channels O
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent O
calcium O
channel O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
. O

-DOCSTART- O


wind B-PHE
one O
of O
the O
five O
pathogenic O
factors O
, O
also O
one O
of O
the O
six O
exogenous O
pathogenic O
factors O
which O
often O
causes O
disease B-PHE
in O
association O
with O
other O
pathogenic O
agent O
. O

It O
is O
of O
Yang O
nature O
and O
apt O
to O
change O
, O
resulting O
symptoms O
are O
usually O
migratory O
and O
variable O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic O
material O
. O

2 O
To O
clear O
liver-heat B-PHE
to O
treat O
eye B-PHE
disease I-PHE
. O

3 O
To O
clear O
dampness-heat B-PHE
. O

-DOCSTART- O


Iohexol O
ia O
used O
in O
myelography O
, O
arthrography O
, O
nephroangiography O
, O
arteriography O
, O
and O
other O
radiographic O
procedures O
. O

-DOCSTART- O


exogenous O
exogenous B-PHE
febrile I-PHE
disease I-PHE
; O

syndrome B-PHE
of I-PHE
T'aeyang I-PHE
meridian I-PHE
affected O
by O
the O
wind B-PHE

affection O
by O
cold B-PHE
; O

common B-PHE
cold I-PHE

-DOCSTART- O


Glomerulonephritis O

-DOCSTART- O


blurred B-PHE
vision I-PHE

-DOCSTART- O


To O
strengthen O
spleen B-PHE
and O
benefit O
qi O
; O
To O
soothe O
liver B-PHE
and O
modulate O
qi O
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


Treament O
of O
abdomen B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
worms I-PHE
, O
sores B-PHE
, O
uterine B-PHE
bleeding I-PHE
( O
drug O
carbonizing O
) O
. O

-DOCSTART- O


irregular O
chills B-PHE
and I-PHE
fever I-PHE

-DOCSTART- O


unblock O
blood B-PHE

-DOCSTART- O


Treatment O
of O
chills B-PHE
, O
fever B-PHE
and O
headache B-PHE
in O
colds B-PHE
and O
influenza B-PHE
, O
vexation B-PHE
, O
oppressed B-PHE
feeling I-PHE
in O
the O
chest O
and O
insomnia B-PHE
. O

-DOCSTART- O


Kidney B-PHE
Failure I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


This O
is O
an O
external B-PHE
wound I-PHE
in I-PHE
muscle I-PHE
of I-PHE
waist I-PHE
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
is O
one O
of O
the O
most O
frequently O
used O
prescriptions O
in O
the O
long O
history O
of O
traditional O
Chinese O
medicine O
practice O
. O

The O
prescription O
contains O
three O
Chinese O
herbs O
, O
namely O
Artemisia O
capillaries O
Thunb O
. O

( O
Compositae O
) O
, O
Rheum O
officinale O
Baillon O
( O
Polygonaceae O
) O
, O
and O
Gardenia O
jasminoids O
Ellis O
( O
Rubiaceae O
) O
, O
and O
has O
been O
widely O
used O
to O
treat O
acute B-PHE
hepatitis I-PHE
with O
jaundice B-PHE
. O

In O
this O
study O
, O
the O
in O
vitro O
anti-HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
activities I-PHE
of O
the O
water O
extract O
of O
YCHT O
were O
investigated O
. O

Results O
showed O
that O
YCHT O
water O
extract O
inhibited O
both O
HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
infections I-PHE
. O

However O
, O
the O
inhibition O
was O
more O
effective O
against O
HSV-2 B-PHE
than O
against O
HSV-1 B-PHE
. O

The O
IC(50 O
) O
and O
IC(90 O
) O
values O
of O
YCHT O
water O
extract O
against O
HSV-1 B-PHE
infection I-PHE
were O
in O
the O
range O
of O
142.5-150.1 O
and O
191.3-393.9 O
microg/ml O
, O
and O
against O
HSV-2 B-PHE
infection I-PHE
they O
were O
in O
the O
range O
of O
19.6-29.4 O
and O
42.2-97.7 O
microg/ml O
, O
respectively O
. O

The O
water O
extract O
of O
YCHT O
showed O
no O
cytotoxic O
effect O
at O
a O
concentration O
of O
500 O
microg/ml O
or O
below O
, O
and O
had O
a O
CC(50 O
) O
value O
of O
850.7+/-1.7 O
microg/ml O
. O

The O
prescription O
was O
found O
to O
diminish O
HSV-2 B-PHE
infectivity I-PHE
in O
a O
dose-dependent O
manner O
, O
and O
the O
activity O
was O
influenced O
by O
the O
incubation O
periods O
and O
the O
incubation O
temperatures O
. O

Concurrent O
addition O
of O
virus O
with O
YCHT O
or O
pre-treatment O
of O
the O
virus O
with O
the O
prescription O
extract O
both O
protected O
the O
cells O
from O
infection B-PHE
. O

In O
summary O
, O
the O
water O
extract O
of O
YCHT O
was O
concluded O
to O
inhibit O
infections B-PHE
by O
HSV-1 B-PHE
and O
HSV-2 B-PHE
and O
this O
effect O
was O
likely O
mediated O
through O
direct O
inactivation O
of O
the O
virus B-PHE
infectivity I-PHE
. O

-DOCSTART- O


red-white O
dysentery B-PHE

-DOCSTART- O


To O
control O
the O
essence O
; O

To O
astringe O
the O
intestines B-PHE
and O
stop O
diarrhea B-PHE
; O

To O
decrease O
urination B-PHE

-DOCSTART- O


Treatment O
of O
edema B-PHE
with O
oliguria B-PHE
, O
dizziness B-PHE
and O
palpitation B-PHE
caused O
by O
retained O
fluid O
, O
diminished O
function O
of O
the O
spleen B-PHE
marked O
by O
anorexia B-PHE
, O
loose O
stools B-PHE
or O
diarrhea B-PHE
, O
restlessness B-PHE
and O
insomnia B-PHE
. O

-DOCSTART- O


disperse O
stasis B-PHE

-DOCSTART- O


clear O
( O
pathogenic O
) O
fire B-PHE
and O
invigorate O
blood B-PHE

-DOCSTART- O


Intravenous O
Anesthetic O
Interaction O
Unrecognized B-PHE
Condition I-PHE

-DOCSTART- O


Coronary B-PHE
heart I-PHE
disease I-PHE
, O
angina B-PHE
pectoris I-PHE
, O
hypercholesterolemia B-PHE
, O
Parkinson B-PHE
disease I-PHE
, O
peripheral B-PHE
arterial I-PHE
diseases I-PHE
, O
chest B-PHE
impediment I-PHE
and O
heart B-PHE
pain I-PHE
, O
cough B-PHE
of O
phlegm B-PHE
asthma B-PHE
, O
diarrhea B-PHE
and O
dysentery B-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
emission B-PHE
, O
retinal B-PHE
insufficiency I-PHE
syndrome I-PHE
. O

-DOCSTART- O


nine O
kinds O
of O
illness B-PHE
due O
to O
disturbance O
of O
Gi O

-DOCSTART- O


Endometriosis B-PHE

-DOCSTART- O


Treatment O
of O
scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
lower O
abdominal B-PHE
pain I-PHE
and O
cold B-PHE
sensation I-PHE
, O
distending B-PHE
pain I-PHE
in I-PHE
the I-PHE
epigastrium I-PHE
with O
anorexia B-PHE
, O
vomiting B-PHE
and O
diarrhea B-PHE
, O
hydrocele B-PHE
of O
tunica O
vaginalis O
. O

Fructus O
Foeniculi O
( O
processed O
with O
salt O
) O
: O
Scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
abdominal B-PHE
pain I-PHE
caused O
by O
cold B-PHE
. O

-DOCSTART- O


Woman O
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Small O
dosage O
of O
berberine O
enhances O
the O
action B-PHE
of I-PHE
acetylcholine I-PHE
on O
animals' O
hearts O
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

-DOCSTART- O


To O
contract O
uterus O
and O
stanch O
bleeding O
, O
relieve O
pain O
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Physical O
performance O
and O
fitness O
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Others O
, O
Body O
weight O
regulation O
, O
General O
woman O
, O
Strength O
and O
power O
, O
Digestion B-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE

-DOCSTART- O


Treatment O
of O
cough B-PHE
, O
itching B-PHE
of O
the O
throat O
and O
profuse O
expectoration B-PHE
in I-PHE
colds I-PHE
, O
nausea B-PHE
, O
vomiting B-PHE
and O
epigastric B-PHE
distension I-PHE
caused O
by O
improper O
diet O
or O
excessive O
drinking O
. O

-DOCSTART- O


Hepatocellular B-PHE
Carcinoma I-PHE

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
with O
chest B-PHE
congested I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver B-PHE
, O
spleen B-PHE
and O
stomach B-PHE
, O
and O
to O
resolve O
phlegm B-PHE
. O

-DOCSTART- O


Treatment O
of O
fever B-PHE
due O
to O
deficiency B-PHE
of O
yin O
, O
consumptive O
fever B-PHE
, O
fever B-PHE
in O
infantile O
malnutrition B-PHE
. O

-DOCSTART- O


The O
resin O
is O
a O
strong O
anion O
exchange O
resin O
, O
which O
means O
that O
it O
can O
exchange O
its O
chloride O
anions O
with O
anionic B-PHE
bile I-PHE
acids I-PHE
in O
the O
gastrointestinal B-PHE
tract I-PHE
and O
bind O
them O
strongly O
in O
the O
resin O
matrix O
. O

-DOCSTART- O


For O
the O
treatment O
of O
Tuberculosis B-PHE
and O
Tuberculosis-related O
mycobacterial B-PHE
infections I-PHE
. O

-DOCSTART- O


Breast B-PHE
Neoplasms I-PHE

-DOCSTART- O


a O
mass O
amount O
of O
phlegm B-PHE
, O
and O
dyspnea B-PHE
and O
cough B-PHE

-DOCSTART- O


damp B-PHE
Pi I-PHE
syndrome I-PHE
; O
arthritis B-PHE
due O
to O
dampness B-PHE
; O
damp B-PHE
impediment O
[ O
blockage B-PHE
] O

-DOCSTART- O


distension B-PHE
and O
fullness B-PHE

-DOCSTART- O


To O
arrest O
discharges O
, O
promote O
healing O
of O
wounds B-PHE
and O
tissue B-PHE
regeneration I-PHE
, O
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


In O
traditional O
Chinese O
medicine O
theory O
( O
TCM O
) O
, O
the O
affected O
parts O
of O
sprains B-PHE
, O
bruises B-PHE
and O
arthritis B-PHE
are O
considered O
to O
be O
under O
certain O
conditions O
of O
TCM O
concept O
. O

We O
administered O
two O
Kampo O
medicines O
with O
synergistic O
effects O
to O
promote O
quick O
recovery I-PHE
from O
these O
conditions O
. O

Jidabokuippo O
( O
Zhidapuyifang O
in O
Chinese O
) O
, O
which O
means O
'decoction O
for O
contusions' B-PHE
is O
expected O
to O
remove O
these O
conditions O
. O

Hachimijiogan O
( O
Baweidihuangwan O
in O
Chinese O
) O
, O
which O
translates O
as O
'eight-ingredient O
pill O
with O
Rehmannia' O
is O
expected O
to O
restore O
presumed O
minute O
bone B-PHE
injury I-PHE
and O
regulates O
bone B-PHE
metabolism I-PHE
by O
changing O
such O
conditions O
based O
on O
TCM O
theory O
. O

We O
administered O
the O
two O
prescriptions O
to O
10 O
patients O
( O
age O
range O
: O
40-85 O
years O
; O
1 O
male O
, O
9 O
females O
) O
suffering O
from O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
spinal B-PHE
compression I-PHE
fracture I-PHE
without O
changing O
their O
routine O
intake O
of O
other O
drugs O
. O

Patients O
reported O
on O
changes O
in O
the O
pain O
of O
affected O
body O
parts O
by O
using O
the O
visual O
analog O
scale O
( O
VAS O
) O
before O
and O
after O
administration O
of O
Kampo O
medicine O
. O

In O
almost O
all O
cases O
, O
recovery B-PHE
began O
promptly O
after O
administration O
and O
the O
pain B-PHE
disappeared O
within O
approximately O
2 O
weeks O
. O

Large O
doses O
for O
a O
short O
time O
brought O
about O
much O
quicker O
recovery B-PHE
than O
small O
doses O
. O

Administration O
of O
a O
combination O
of O
two O
Kampo O
medicines O
, O
Jidabokuippo O
and O
Hachimijiogan O
, O
quickly O
resolved O
the O
pain B-PHE
of O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
one O
spinal B-PHE
compression I-PHE
fracture I-PHE
. O

-DOCSTART- O


Treament O
of O
spitting B-PHE
of I-PHE
blood I-PHE
, O
epistaxis B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
amenorrhea B-PHE
with O
blood O
stasis O
, O
arthralgia B-PHE
, O
traumatic O
swelling B-PHE
and O
pain B-PHE
. O

-DOCSTART- O


1 O
To O
clear O
the O
lungs B-PHE
and O
tonify O
yin O
; O
2 O
To O
strengthen O
the O
stomach B-PHE
and O
promote O
the O
production B-PHE
of I-PHE
body I-PHE
fluids I-PHE

-DOCSTART- O


Sumatriptan O
is O
a O
serotonin O
agonist O
that O
acts O
selectively O
at O
5HT1 O
receptors O
. O

Naproxen O
inhibits O
the O
activity B-PHE
of I-PHE
the I-PHE
enzymes I-PHE
cyclo-oxygenase I-PHE
I I-PHE
and I-PHE
II I-PHE
, O
resulting O
in O
a O
decreased O
formation B-PHE
of I-PHE
precursors I-PHE
of I-PHE
prostaglandins I-PHE
and I-PHE
thromboxanes I-PHE
. O

-DOCSTART- O


Melphalan O
alkylates O
DNA B-PHE
at O
the O
N7 O
position O
of O
guanine O
and O
induces O
DNA B-PHE
inter-strand I-PHE
cross-linkages I-PHE
, O
resulting O
in O
the O
inhibition O
of O
DNA B-PHE
and I-PHE
RNA I-PHE
synthesis I-PHE
and O
cytotoxicity B-PHE
against O
both O
dividing O
and O
non-dividing O
tumor B-PHE
cells I-PHE
. O

-DOCSTART- O


1 O
Its O
alcoholic O
extract O
exerts O
antipyretic O
and O
analgesic O
effect O
. O

2 O
Its O
aqueous O
extract O
is O
a O
cardiotonic O
. O

-DOCSTART- O


Neuromyelitis B-PHE
Optica I-PHE
( O
NMO B-PHE
) O
and O
NMO B-PHE
Spectrum I-PHE
Disorder I-PHE
( O
NMOSD B-PHE
) O

-DOCSTART- O


restrain O
acid B-PHE

-DOCSTART- O


warm O
the O
lumbus B-PHE
and O
knees B-PHE

-DOCSTART- O


night O
fever B-PHE
and O
chilling B-PHE
in O
the O
morning O

-DOCSTART- O


strengthen O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

GSK2190915 O
, O
a O
potent O
5-lipoxygenase-activating O
protein O
inhibitor O
, O
prevents O
the O
synthesis B-PHE
of I-PHE
leukotrienes I-PHE
and O
5-oxo-6,8,11,14-eicosatetraenoic O
acid O
( O
5-oxo-ETE O
) O
. O

-DOCSTART- O


Others O

-DOCSTART- O


Quality O
of O
life O
, O
Others O

-DOCSTART- O


To O
diffuse O
lung O
qi O
, O
dispel O
wind-damp B-PHE
, O
disperse O
swelling B-PHE
toxin I-PHE
. O

-DOCSTART- O


Pneumonia B-PHE
, O
pyothorax B-PHE
, O
sore B-PHE
pharynx I-PHE
, O
oral B-PHE
ulcer I-PHE
, O
vesical B-PHE
calculus I-PHE
, O
swollen O
welling O
abscess B-PHE
. O

-DOCSTART- O


Doxorubicin O
forms O
complexes O
with O
DNA O
by O
intercalation O
between O
base O
pairs O
, O
and O
it O
inhibits O
topoisomerase B-PHE
II I-PHE
activity I-PHE
by O
stabilizing O
the O
DNA-topoisomerase B-PHE
II I-PHE
complex O
, O
preventing O
the O
religation O
portion O
of O
the O
ligation-religation O
reaction O
that O
topoisomerase B-PHE
II I-PHE
catalyzes I-PHE
. O

-DOCSTART- O


Gout B-PHE

-DOCSTART- O


Yokukansan O
( O
YKS O
) O
is O
a O
traditional O
Japanese O
medicine O
consisting O
of O
seven O
medicinal O
herbs O
that O
is O
used O
for O
the O
treatment O
of O
neurosis B-PHE
, O
insomnia B-PHE
, O
and O
the O
behavioral/psychological O
symptoms O
of O
dementia B-PHE
. O

This O
study O
examined O
the O
effects O
of O
YKS O
on O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
. O

Daily O
oral O
administration O
of O
YKS O
( O
0.5 O
or O
1 O
g/kg O
) O
for O
3 O
weeks O
significantly O
attenuated O
morphine O
tolerance O
and O
naloxone-precipitated O
morphine O
withdrawal O
signs O
( O
jumps O
and O
body O
weight O
loss O
) O
without O
affecting O
the O
analgesic O
effect O
of O
morphine O
. O

The O
inhibitory O
effect O
of O
YKS O
on O
withdrawal O
jumps O
in O
morphine-dependent O
mice O
was O
blocked O
by O
a O
single O
pretreatment O
with O
an O
a(2)-adrenoceptor O
antagonist O
, O
yohimbine O
, O
but O
not O
by O
an O
a(1)-adrenoceptor O
antagonist O
, O
prazosin O
. O

A O
similar O
inhibitory O
effect O
on O
withdrawal O
jumps O
was O
observed O
by O
repeated O
administration O
of O
yohimbine O
. O

The O
membrane O
expression O
of O
a(2A)-adrenoceptors O
in O
the O
pons/medulla O
was O
decreased O
in O
morphine O
withdrawn O
animals O
; O
this O
reduction O
was O
prevented O
by O
repeated O
administration O
of O
YKS O
or O
yohimbine O
. O

Competitive O
radioligand O
and O
[(35)S]guanosine-5'-O-(3-thiotriphosphate O
) O
binding O
assays O
revealed O
that O
YKS O
and O
its O
constituent O
herbs O
, O
Glycyrrhiza O
( O
GR O
) O
and O
Uncaria O
hook O
( O
UH O
) O
, O
had O
specific O
binding O
affinity O
for O
and O
antagonist O
activity O
against O
the O
a(2A)-adrenoceptor O
. O

Certain O
chemical O
constituents O
, O
including O
GR O
- O
derived O
glycyrrhizin O
and O
its O
metabolite O
, O
18b-glycyrrhetinic O
acid O
, O
and O
UH-derived O
geissoschizine O
methyl O
ether O
( O
GME O
) O
, O
shared O
such O
activities O
. O

Repeated O
administration O
of O
GR O
, O
UH O
, O
glycyrrhizin O
or O
GME O
significantly O
inhibited O
morphine O
withdrawal O
signs O
. O

These O
results O
suggest O
that O
YKS O
and O
its O
active O
constituents O
inhibit O
morphine O
tolerance O
and O
physical O
dependence O
, O
and O
that O
the O
latter O
is O
due O
at O
least O
in O
part O
to O
the O
prevention O
of O
the O
decreased O
membrane O
expression O
of O
the O
a(2A)-adrenoceptor O
in O
the O
brainstem O
by O
its O
prolonged O
blockade O
. O

-DOCSTART- O


Effects O
of O
Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
, O
on O
thiamine B-PHE
deficiency I-PHE
( O
TD B-PHE
) O
- O
induced O
decrease O
of O
glutamate O
uptake O
were O
examined O
in O
cultured O
rat O
cortical O
astrocytes O
. O

Yokukansan O
( O
100 O
- O
500 O
microg O
/ O
ml O
) O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
in O
glutamate O
uptake O
by O
astrocytes B-PHE
, O
implying O
that O
yokukansan O
may O
contain O
active O
herbs O
and O
compounds O
possessing O
this O
effect O
. O

Among O
the O
seven O
constituent O
herbs O
of O
yokukansan O
, O
significant O
effects O
were O
found O
for O
glycyrrhiza O
. O

Furthermore O
, O
glycyrrhizin O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
( O
10(-7)-10(-4)M O
) O
, O
among O
the O
eight O
components O
of O
glycyrrhiza O
, O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
of O
glutamate O
uptake O
in O
astrocytes O
in O
a O
concentration O
- O
dependent O
manner O
. O

These O
substances O
inhibited O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
activity O
under O
the O
in O
vitro O
conditions O
. O

These O
lines O
of O
evidence O
suggest O
that O
glycyrrhizin O
, O
a O
main O
component O
of O
glycyrrhiza O
, O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
are O
likely O
responsible O
for O
amelioration O
of O
dysfunction O
of O
glutamate O
transport O
in O
astrocytes O
. O

The O
inhibition O
of O
the O
PKC B-PHE
activity I-PHE
might O
be O
related O
to O
the O
pharmacological O
efficacy O
of O
these O
substances O
. O

-DOCSTART- O


Effects O
of O
tokishakuyakusan O
, O
Keishibukuryogan O
and O
Unkeito O
on O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
in O
uteri O
of O
pregnant O
mare's O
serum O
gonadotropin-treated O
immature O
rats O
. O

-DOCSTART- O


warm O
the O
lung B-PHE

-DOCSTART- O


This O
is O
a O
transmission O
of O
pathogenic O
factor O
of O
pyogenic B-PHE
febrile I-PHE
disease I-PHE
from O
Taeyanggyeong O
to O
Yangmyeonggyeong O
. O

-DOCSTART- O


support O
five O
viscera B-PHE

-DOCSTART- O


disperse O
accumulation B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Atrophy B-PHE

-DOCSTART- O


Taxation B-PHE
damage I-PHE
and O
sinew B-PHE
bone I-PHE
pain I-PHE
, O
impotence B-PHE
, O
stomachache B-PHE
, O
innominate B-PHE
toxin I-PHE
swelling I-PHE
, O
knife B-PHE
wound I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Kids O
, O
Others O
, O
Fetus O

-DOCSTART- O


Corylifolinin O
( O
isobavachalcone O
) O
dilates O
coronary B-PHE
artery I-PHE
significantly O
. O

-DOCSTART- O


A O
symptom O
that O
the O
chest O
is O
heavy O
and O
full O
. O

-DOCSTART- O


abdominal B-PHE
fullness I-PHE
; O
abdominal B-PHE
distension I-PHE

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
nourish O
blood B-PHE

-DOCSTART- O


Its O
alcoholic O
extract O
inhibits O
the O
heart B-PHE
and O
lowers O
blood B-PHE
pressure I-PHE
in O
anesthetized O
cats O
. O

-DOCSTART- O


fever B-PHE
with O
dysphoria B-PHE
; O
dysphoria B-PHE
with O
smothery O
sensation O
; O
smothery O
fever B-PHE

-DOCSTART- O


ceruminal B-PHE
impaction I-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE
is O
lumped O
at O
the O
neck O

-DOCSTART- O


dizziness B-PHE

-DOCSTART- O


Organophosphate B-PHE
Poisoning I-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
after O
phlegm B-PHE
due O
to O
Wind B-PHE
sidesae O
blocked O
Gi O
. O

-DOCSTART- O


Both O
acted O
at O
the O
same O
active O
site O
of O
penicillinbinding O
protein O
2A O
but O
at O
relatively O
high O
MICs O
of O
32 O
g/ml O
. O

The O
relatively O
high O
MICs O
make O
it O
less O
likely O
for O
both O
drugs O
to O
saturate O
target O
sites O
, O
thereby O
maintaining O
additive O
antibacterial B-PHE
effect I-PHE
. O

-DOCSTART- O


blood B-PHE
wind I-PHE
of O
female O

-DOCSTART- O


cool O
blood B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


Dim B-PHE
vision I-PHE
, O
flooding B-PHE
and O
spotting I-PHE
, O
bleeding I-PHE
due O
to O
external B-PHE
injury I-PHE
, O
sore B-PHE
toxin I-PHE
and O
intractable O
lichen B-PHE
. O

-DOCSTART- O


skin B-PHE
disease I-PHE
on O
palms O
. O

-DOCSTART- O


Ankylosing B-PHE
Spondylitis I-PHE

-DOCSTART- O


hoarseness B-PHE
due O
to O
singing O

-DOCSTART- O


dyspnea B-PHE
with O
coughing B-PHE

-DOCSTART- O


dry O
phlegm B-PHE
; O
dry-phlegm B-PHE
( O
syndrome O
) O

-DOCSTART- O


Delayed O
recovering O
of O
drug O
transport O
barrier O
by O
inhibiting O
the O
synthesis O
of O
barrier O
components O
. O

-DOCSTART- O


Water O
extract O
of O
Samultang O
reduces O
apoptotic B-PHE
cell I-PHE
death I-PHE
by O
h(2)o(2)-induced O
oxidative B-PHE
injury I-PHE
in O
sk-N-mc O
cells O
. O

-DOCSTART- O


carbuncle B-PHE
and O
cellulitis B-PHE
of O
the O
back O
; O

carbuncle B-PHE
on O
the O
back O

-DOCSTART- O


To O
eliminate O
fluid B-PHE
and O
relieve O
edema B-PHE
( O
sthenia-syndrome B-PHE
with O
edema B-PHE
and O
ascites B-PHE
) O
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE
; O
mass B-PHE
in I-PHE
the I-PHE
abdomen I-PHE

-DOCSTART- O


Wind-evil O
attacked O
meridian O
, O
facial B-PHE
paralysis I-PHE
, O
muscle B-PHE
numbness I-PHE
, O
pain B-PHE
of I-PHE
tendons I-PHE
and I-PHE
bone I-PHE
. O

-DOCSTART- O


For O
ascariasis B-PHE
and O
taeniasis B-PHE
. O

For O
constipation B-PHE
due O
to O
dryness B-PHE
of O
intestine O
. O

-DOCSTART- O


( O
1 O
) O
hematochezia B-PHE
( O
2 O
) O
viginal B-PHE
bleeding I-PHE

-DOCSTART- O


wind B-PHE
rash I-PHE
; O
German B-PHE
measles I-PHE
; O
rubella B-PHE
; O
urticaria B-PHE

-DOCSTART- O


traumatic B-PHE
cataract I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


eliminate O
vacuity O
and O
clod O
of O
the O
spleen O
and O
the O
stomach O

-DOCSTART- O


To O
dispel O
wind-damp B-PHE
, O
quicken O
blood B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Pregnancy B-PHE

-DOCSTART- O


To O
expel O
wind B-PHE
and O
heat B-PHE
, O
purge O
pathogenic O
fire O
and O
relax O
the O
bowels O
. O

-DOCSTART- O


cool O
blood B-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Memory B-PHE

-DOCSTART- O


Hepatoma B-PHE

-DOCSTART- O


bloody B-PHE
stool I-PHE
; O
hematochezia B-PHE

-DOCSTART- O


To O
invigorate O
blood B-PHE
and O
stop O
pain B-PHE
. O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Erythroid I-PHE
Leukemia I-PHE

-DOCSTART- O


Perennial B-PHE
Allergic I-PHE
Rhinitis I-PHE

-DOCSTART- O


Apical B-PHE
Ballooning I-PHE
Syndrome I-PHE

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility O
, O
Evacuation B-PHE

-DOCSTART- O


Overactive B-PHE
Bladder I-PHE
( O
OAB B-PHE
) O

-DOCSTART- O


For O
activating O
blood B-PHE
and O
modulating O
period O

-DOCSTART- O


To O
invigorate O
the O
function B-PHE
of I-PHE
the I-PHE
kidney I-PHE
, O
to O
alleviate O
asthma B-PHE
, O
and O
to O
relieve O
diarrhea B-PHE
. O

-DOCSTART- O


It O
may O
also O
bind O
to O
bacterial B-PHE
potassium I-PHE
transporters I-PHE
, O
thereby O
inhibiting O
their O
function O
. O

-DOCSTART- O


Deficiency O
of O
yin O
of O
the O
liver B-PHE
and O
the O
kidney B-PHE
marked O
by O
tinnitus B-PHE
, O
impairment B-PHE
of I-PHE
hearing I-PHE
, O
dizziness B-PHE
and O
blurred B-PHE
vision I-PHE
. O

-DOCSTART- O


sore B-PHE
of I-PHE
scrotum I-PHE

-DOCSTART- O


Pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-PHE
synthase I-PHE
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
DNA B-PHE
synthesis I-PHE
. O

Carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA B-PHE
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
DNA B-PHE
cross-links O
, O
as O
well O
as O
DNA-protein B-PHE
cross-links O
. O

By O
binding O
to O
the O
ATP-binding O
site O
, O
enzastaurin O
selectively O
inhibits O
protein B-PHE
kinase I-PHE
C I-PHE
beta I-PHE
, O
which O
appears O
to O
be O
cytotoxic O
in O
cells O
with O
DNA B-PHE
alterations O
or O
DNA O
damage O
which O
may O
decrease O
tumor B-PHE
blood I-PHE
supply I-PHE
, O
preventing O
growth B-PHE
. O

-DOCSTART- O


RK-0202 O
, O
an O
oral O
rinse O
for O
the O
prevention O
and O
treatment O
of O
mucositis B-PHE
, O
is O
based O
on O
the O
company's O
ProGelz O
technology O
and O
is O
comprised O
of O
the O
potent O
antioxidant O
N-acetylcysteine O
in O
a O
polymer O
matrix O
. O

-DOCSTART- O


deficiency O
of O
both O
Gi O
( O
vital O
energy O
) O
and O
blood B-PHE

-DOCSTART- O


Schizophrenia B-PHE
Prodrome I-PHE

-DOCSTART- O


For O
use O
in O
the O
treatment O
of O
symptomatic O
anaemia B-PHE
associated O
with O
chronic B-PHE
renal I-PHE
failure I-PHE
( O
CRF B-PHE
) O
in O
adult O
and O
paediatric O
patients O
. O

Also O
for O
use O
in O
the O
treatment O
of O
anaemia B-PHE
and O
reduction B-PHE
of I-PHE
transfusion I-PHE
requirements O
in O
adult O
patients O
receiving O
chemotherapy O
for O
solid B-PHE
tumours I-PHE
, O
malignant B-PHE
lymphoma I-PHE
or O
multiple B-PHE
myeloma I-PHE
, O
and O
at O
risk O
of O
transfusion O
as O
assessed O
by O
the O
patient's O
general O
status O
( O
e.g O
. O
cardiovascular O
status O
, O
pre-existing O
anaemia B-PHE
at O
the O
start O
of O
chemotherapy O
) O
. O

Also O
for O
used O
to O
increase O
the O
yield O
of O
autologous B-PHE
blood I-PHE
from O
patients O
in O
a O
predonation O
program O
. O

When O
administered O
subcutaneously O
, O
Epoetin O
Zeta O
is O
equivalent O
to O
Epoetin O
Alfa O
in O
terms O
of O
clinical O
effectiveness O
. O

-DOCSTART- O


Neoplasms B-PHE
, I-PHE
Breast I-PHE

-DOCSTART- O


dissipate O
depression B-PHE

-DOCSTART- O


vomiting B-PHE
and O
diarrhea B-PHE
due O
to O
visceral O
cold B-PHE

-DOCSTART- O


Motivation O
, O
Mood O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Others O
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


Its O
active O
component O
, O
triterpenic O
acid O
, O
increases O
cornary O
flow O
and O
improve O
systemic B-PHE
circulation. I-PHE
. O

-DOCSTART- O


disperse O
cold B-PHE

-DOCSTART- O


epiphora B-PHE
; O
lacrimation B-PHE

-DOCSTART- O


Cardiovascular B-PHE
Disorder I-PHE

-DOCSTART- O


terminate O
delivery O

-DOCSTART- O


To O
supplement O
qi O
and O
nourish O
yin O
, O
clear O
fire O
and O
engender O
liquid O
. O

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
promote O
eruption B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


To O
resolve O
phlegm B-PHE
and O
benefit O
throat B-PHE

-DOCSTART- O


1 O
Aloperine O
inhibits O
exudative B-PHE
inflammation I-PHE
and O
hemolysis B-PHE
of O
red O
blood B-PHE
cells O
2 O
. O

Its O
decoction O
or O
sophocarpine O
relieves O
asthma B-PHE
in O
guinea-pigs O
induced O
by O
acetylcholine O
and O
histamine O
. O

3 O
. O
Sophocarpine O
or O
matrine O
inhibits O
sarcoma180 B-PHE
in O
vitro O
. O

-DOCSTART- O


Shosaikoto O
, O
which O
is O
one O
of O
the O
Japanese O
and O
Chinese O
traditional O
herbal O
medicine O
mixtures O
, O
has O
several O
immunomodulating B-PHE
activities I-PHE
. O

Especially O
, O
Shosaikoto O
is O
a O
potent O
polyclonal O
B O
cell O
mitogen O
in O
vivo O
and O
in O
vitro O
. O

In O
order O
to O
characterize O
the O
active O
substances O
for O
mitogenic B-PHE
activity I-PHE
, O
Shosaikoto O
was O
fractionated O
by O
means O
of O
ethanol O
precipitation O
to O
give O
two O
fractions O
, O
called O
ethanol-precipitate O
( O
EP O
) O
fraction O
and O
ethanol-soluble O
( O
ES O
) O
fraction O
. O

The O
EP O
fraction O
consisted O
mainly O
of O
polysaccharides O
and O
showed O
significant O
mitogenic B-PHE
activity I-PHE
. O

The O
ES O
fraction O
consisted O
of O
low O
molecular O
compounds O
and O
did O
not O
show O
the O
activity O
in O
vitro O
. O

The O
EP O
fraction O
of O
hot O
water O
extracts O
of O
Glycyrrhizae O
Radix O
and O
Bupureuri O
Radix O
showed O
the O
activities O
, O
and O
the O
ES O
fraction O
of O
a O
hot O
water O
extract O
of O
Glycyrrhizae O
Radix O
and O
all O
fractions O
of O
hot O
water O
extract O
of O
Scutellariae O
Radix O
showed O
the O
cytotoxicity O
. O

These O
results O
suggested O
that O
the O
crude O
polysaccharide O
fractions O
could O
play O
an O
important O
role O
in O
the O
mitogenic B-PHE
activity I-PHE
by O
Shosaikoto O
. O

-DOCSTART- O


Decompensated B-PHE
Cirrhosis I-PHE

-DOCSTART- O


Cough B-PHE
and O
asthma B-PHE
, O
fright O
epilepsy B-PHE
, O
wind-cold-damp B-PHE
impediment I-PHE
, O
dysentery B-PHE
, O
prolapse B-PHE
of I-PHE
rectum I-PHE
, O
knocks B-PHE
and O
falls B-PHE
. O

-DOCSTART- O


Cardiovascular B-PHE
Diseases I-PHE

-DOCSTART- O


1 O
Its O
decoction O
enhances O
th O
intestinal B-PHE
contraction I-PHE
and O
tensity O
of O
rabbits O
in O
vitro O
, O
which O
can O
be O
counteracted O
by O
atropine O
. O

2 O
. O
Inhibiting O
the O
growth O
of O
sarcoma B-PHE
180 I-PHE
in O
mice O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
, O
deprive O
dampness B-PHE
and O
kill O
parasites B-PHE
. O

For O
sorethroat B-PHE
, O
dysentery B-PHE
, O
trichomonas B-PHE
enteritis I-PHE
, O
toothache B-PHE
, O
stomachache B-PHE
and O
leucorrhagia B-PHE
, O
external O
use O
for O
tinea B-PHE
and O
eczema B-PHE
. O

2 O
To O
relieve O
dyspnea B-PHE
and O
cough B-PHE
. O

3 O
Anticarcinogenic B-PHE
. O
For O
malignant B-PHE
hydatidiform I-PHE
mole I-PHE
, O
chorionic B-PHE
epithelioma I-PHE
and O
leukemia B-PHE
. O

-DOCSTART- O


Knee B-PHE
Osteoarthritis I-PHE

-DOCSTART- O


Malignancy B-PHE

-DOCSTART- O


Lysophospholipids O
have O
been O
found O
to O
mediate O
the O
activity O
of O
this O
drug O
. O

-DOCSTART- O


Crohn's B-PHE
Disease I-PHE

-DOCSTART- O


Swelling B-PHE
and O
pain B-PHE
due O
to O
blood B-PHE
stagnation I-PHE
caused O
by O
external B-PHE
injuries I-PHE
. O

-DOCSTART- O


Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl B-PHE
, O
APS B-PHE
, O
Shc B-PHE
and O
Gab B-PHE

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-PHE
of I-PHE
downstream I-PHE
signaling I-PHE
molecules I-PHE
including O
PI3 B-PHE
kinase I-PHE
and O
Akt B-PHE
. O

Akt O
regulates O
the O
activity B-PHE
of I-PHE
glucose I-PHE
transporter I-PHE
4 I-PHE
( O
GLUT4 B-PHE
) O
and O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
which O
play O
a O
critical O
role O
in O
metabolism O
. O

-DOCSTART- O


Treatment O
of O
rheumatic B-PHE
arthritis I-PHE
with O
muscular B-PHE
contracture I-PHE
, O
aching B-PHE
of O
the O
loins O
and O
knees O
, O
inflammation B-PHE
of O
the O
throat O
, O
carbuncle B-PHE
and O
boils O
, O
traumatic B-PHE
injuries I-PHE
. O

-DOCSTART- O


Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-PHE
kinases I-PHE
( O
TK B-PHE
) O
, O
thereby O
inhibiting O
ATP B-PHE
binding I-PHE
and O
preventing O
phosphorylation B-PHE
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-PHE
transduction I-PHE
pathways I-PHE
. O

Temozolomide O
is O
converted O
at O
physiologic O
pH O
to O
the O
short-lived O
active O
compound O
, O
monomethyl O
triazeno O
imidazole O
carboxamide O
( O
MTIC O
) O
. O

The O
cytotoxicity B-PHE
of I-PHE
MTIC I-PHE
is O
due O
primarily O
to O
methylation B-PHE
of I-PHE
DNA I-PHE
at O
the O
O6 O
and O
N7 O
positions O
of O
guanine O
, O
resulting O
in O
inhibition B-PHE
of I-PHE
DNA I-PHE
replication I-PHE
. O

-DOCSTART- O


Growth B-PHE

-DOCSTART- O


Treatment O
of O
: O
1 O
Hemorrhages B-PHE
due O
to O
external B-PHE
injuries I-PHE
. O
Dragon's O
blood O
( O
Xuejie O
) O
can O
be O
taken O
alone O
for O
external O
use O
, O
or O
it O
can O
be O
combined O
with O
Cattail O
pollen O
( O
Puhuang O
) O
. O

-DOCSTART- O


A O
74-year-old O
man O
was O
admitted O
to O
our O
hospital O
complaining O
of O
severe O
neck B-PHE
pain I-PHE
and O
general O
fatigue B-PHE
. O

He O
had O
been O
undergoing O
treatment O
for O
post-operative O
neck B-PHE
pain I-PHE
at O
the O
out-patient O
clinic O
of O
our O
hospital O
, O
but O
was O
now O
complaining O
of O
pain B-PHE
more O
intense O
than O
usual O
. O

Chest O
X-rays O
revealed O
diffuse O
ground O
glass O
shadows O
in O
bilateral O
lung O
fields O
, O
and O
computed O
tomography O
revealed O
diffuse O
intestinal O
shadows O
. O

A O
drug O
lymphocyte O
stimulation O
test O
( O
DLST O
) O
was O
also O
performed O
at O
that O
time O
. O

Steroid O
pulse O
therapy O
improved O
the O
clinical O
symptoms O
, O
hypoxemia B-PHE
and O
chest O
X-ray O
findings O
. O

DLST O
performed O
again O
with O
Yokukansan O
and O
Hachimijiogan O
133 O
days O
after O
the O
initial O
diagnosis O
of O
pneumonitis O
showed O
Yokukansan O
was O
positive O
. O

This O
result O
showed O
Yukukansan O
may O
be O
a O
causative O
drug O
for O
allergic O
drug-induced B-PHE
pneumonitis I-PHE
. O

Any O
drugs O
including O
kanpo O
may O
be O
possible O
to O
induce O
allergic B-PHE
pneumonitis I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE

-DOCSTART- O


Alzheimer B-PHE
Disease I-PHE

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
subdue O
hyperactivity B-PHE
of I-PHE
the I-PHE
liver I-PHE
, O
and O
improve O
eyesight B-PHE
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
depression B-PHE
. O

-DOCSTART- O


To O
stop O
bleeding B-PHE
and O
promote O
the O
healing B-PHE
of I-PHE
wounds I-PHE
. O

-DOCSTART- O


seven O
injuries B-PHE
; O
seven O
kinds O
of O
impairments B-PHE

-DOCSTART- O


Regulation O
of O
qi O

-DOCSTART- O


Eye B-PHE
pain I-PHE
, O
eye B-PHE
swelling I-PHE
, O
red B-PHE
eyes I-PHE
and O
tearing B-PHE
. O

-DOCSTART- O


Its O
leaf O
infusion O
from O
NaCl O
solution O
inhibits O
the O
growth O
of O
Bacillus B-PHE
coli I-PHE
. O

-DOCSTART- O


phthisical B-PHE
cough I-PHE
due O
to O
Eum O
deficiency O

-DOCSTART- O


swollen O
check O
, O
mumps B-PHE
; O
epidemic B-PHE
parotitis I-PHE

-DOCSTART- O


Infection B-PHE

-DOCSTART- O


Behavioral B-PHE
and I-PHE
psychological I-PHE
symptoms I-PHE
of I-PHE
dementia I-PHE
( O
BPSD B-PHE
) O
are O
commonly O
seen O
in O
patients O
with O
Alzheimer's B-PHE
disease I-PHE
( O
AD B-PHE
) O
and O
other O
forms O
of O
senile B-PHE
dementia I-PHE
. O

BPSD B-PHE
have O
a O
serious O
impact O
on O
the O
quality O
of O
life O
of O
dementia B-PHE
patients O
, O
as O
well O
as O
their O
caregivers O
. O

However O
, O
an O
effective O
drug O
therapy O
for O
BPSD B-PHE
has O
not O
been O
established O
. O

Recently O
, O
the O
traditional O
Japanese O
medicine O
Yokukansan O
( O
YKS O
, O
Yi-gan O
san O
in O
Chinese O
) O
has O
been O
reported O
to O
improve O
BPSD B-PHE
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
study O
. O

Moreover O
, O
abnormalities B-PHE
of I-PHE
the I-PHE
serotonin I-PHE
( O
5-HT B-PHE
) O
system O
such O
as O
5-HT2A O
receptors O
have O
been O
reported O
to O
be O
associated O
with O
BPSD B-PHE
of O
AD B-PHE
patients O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
YKS O
on O
head-twitch O
response O
induced O
by O
2,5-dimethoxy-4-iodoamphetamine O
( O
DOI O
, O
5 O
mg/kg O
, O
i.p O
. O
) O
in O
mice O
, O
a O
behavioral O
response O
that O
is O
mediated O
, O
in O
part O
, O
by O
5-HT2A O
receptors O
. O

Acute O
treatment O
with O
YKS O
( O
100 O
and O
300 O
mg/kg O
, O
p.o O
. O
) O
had O
no O
effect O
on O
the O
DOI-induced B-PHE
head-twitch I-PHE
response I-PHE
, O
whilst O
14 O
days O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
significantly O
inhibited O
this O
response O
. O

Moreover O
, O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
decreased O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
is O
part O
of O
the O
circuitry O
mediating O
the O
head-twitch B-PHE
response I-PHE
. O

These O
findings O
suggest O
that O
the O
inhibition O
of O
DOI-induced B-PHE
head-twitch I-PHE
response O
by O
YKS O
may O
be O
mediated O
, O
in O
part O
, O
by O
altered O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
suggests O
the O
involvement O
of O
the O
5-HT B-PHE
system I-PHE
in O
psychopharmacological O
effects O
of O
YKS O
. O

-DOCSTART- O


Obesity B-PHE

-DOCSTART- O


relieve O
pain B-PHE

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
and O
relieve O
cough B-PHE
. O

For O
acute O
and O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Non-Small B-PHE
Cell I-PHE
Lung I-PHE
Cancer I-PHE

-DOCSTART- O


To O
regulate O
the O
qi O
of O
the O
liver B-PHE
and O
stomach B-PHE
, O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Bacterial B-PHE
infections I-PHE
of O
the O
ear O

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
, I-PHE
Neurogenic I-PHE

-DOCSTART- O


Retention B-PHE
of I-PHE
milk I-PHE
in O
babies O
, O
profuse O
sputum B-PHE
and O
infantile B-PHE
convulsions I-PHE
. O

-DOCSTART- O


To O
stablize O
liver B-PHE
and O
suppress O
dizziness B-PHE
; O
To O
soothe O
neck B-PHE
and O
wake-up O
brain B-PHE

-DOCSTART- O


burn B-PHE

-DOCSTART- O


Melanoma B-PHE

-DOCSTART- O


reddish B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


night B-PHE
sweat I-PHE
and O
nocturnal B-PHE
emission I-PHE

-DOCSTART- O


urinary B-PHE
incontinence I-PHE
; O
galacturia B-PHE
; O
stranguria B-PHE
with O
chyluria B-PHE
; O
stranguria B-PHE
marked O
by O
chyluria B-PHE

-DOCSTART- O


To O
dissipate O
stasis B-PHE
and O
quicken O
blood B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


replenish O
essence-marrow O

-DOCSTART- O


( O
1 O
) O
diarrhea B-PHE
( O
2 O
) O
diarrhea B-PHE
and O
urination B-PHE
( O
3 O
) O
diarrhea B-PHE
and O
dysentery B-PHE

-DOCSTART- O


A O
UPLC/Q-TOF-MS/MS O
method O
for O
analyzing O
the O
constituents O
in O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
traditional O
Chinese O
medical O
formula O
, O
has O
been O
established O
. O

The O
UPLC/MS O
fingerprints O
of O
the O
samples O
were O
established O
first O
in O
vitro O
and O
in O
vivo O
, O
with O
45 O
compounds O
in O
YCHT O
and O
21 O
compounds O
in O
rat O
plasma O
after O
oral O
administration O
of O
YCHT O
were O
detected O
. O

Of O
the O
45 O
detected O
compounds O
in O
vitro O
, O
30 O
were O
identified O
, O
and O
all O
of O
the O
21 O
compounds O
detected O
in O
rat O
plasma O
were O
identified O
either O
by O
comparing O
the O
retention O
time O
and O
mass O
spectrometry O
data O
with O
that O
of O
reference O
compounds O
or O
by O
mass O
spectrometry O
analysis O
and O
retrieving O
the O
reference O
literatures O
. O

Of O
the O
identified O
21 O
compounds O
in O
rat O
plasma O
, O
19 O
were O
the O
original O
form O
of O
compounds O
absorbed O
from O
the O
45 O
detected O
compounds O
in O
vitro O
, O
2 O
were O
the O
metabolites O
of O
the O
compounds O
existed O
in O
YCHT O
. O

It O
is O
concluded O
that O
a O
rapid O
and O
validated O
method O
has O
been O
developed O
based O
on O
UPLC-MS/MS O
, O
which O
shows O
high O
sensitivity O
and O
resolution O
that O
is O
more O
suitable O
for O
identifying O
the O
bioactive O
constituents O
in O
plasma O
after O
oral O
administration O
of O
Chinese O
herbal O
medicines O
, O
and O
provides O
helpful O
chemical O
information O
for O
further O
pharmacology O
and O
active O
mechanism O
research O
on O
the O
Chinese O
medical O
formula O
. O

-DOCSTART- O


Ureteral B-PHE
Stent I-PHE
Occlusion I-PHE

-DOCSTART- O


De O
Novo O
Kidney O
Transplant O
Patients O

-DOCSTART- O


Glaucoma B-PHE

-DOCSTART- O


excessive O
drinking O
of O
water O
due O
to O
thirst B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
soothe O
sinews B-PHE
and O
free O
network O
vessels B-PHE
. O

-DOCSTART- O


Ovarian B-PHE
Hyperstimulation I-PHE
Syndrome I-PHE

-DOCSTART- O


Rosuvastatin O
is O
a O
competitive O
inhibitor O
of O
HMG-CoA O
reductase O
, O
which O
reductase O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
an O
early O
rate-limiting O
step O
in O
cholesterol O
biosynthesis O
. O

Lapaquistat O
acetate O
is O
a O
squalene O
synthase O
inhibitor O
investigated O
for O
the O
treatment O
of O
hypercholesterolemia B-PHE
. O

-DOCSTART- O


moisten O
the O
liver B-PHE

-DOCSTART- O


vomiting B-PHE
of O
milk O

-DOCSTART- O


Oxcarbazepine O
produces O
blockade B-PHE
of I-PHE
voltage-sensitive I-PHE
sodium I-PHE
channels I-PHE
, O
resulting O
in O
stabilization O
of O
hyperexcited O
neural B-PHE
membranes I-PHE
, O
inhibition O
of O
repetitive B-PHE
neuronal I-PHE
firing I-PHE
, O
and O
diminution O
of O
propagation B-PHE
of I-PHE
synaptic I-PHE
impulses I-PHE
. O

These O
actions O
are O
thought O
to O
be O
important O
in O
the O
prevention O
of O
seizure B-PHE
spread I-PHE
in O
the O
intact O
brain O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated B-PHE
N-type I-PHE
calcium I-PHE
ion I-PHE
channels I-PHE
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent B-PHE
calcium I-PHE
channel I-PHE
in O
the O
central O
nervous O
system O
. O

-DOCSTART- O


Toxoplasmosis B-PHE

-DOCSTART- O


white B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


nourish O
essence-marrow B-PHE

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myelomonocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


warm O
the O
menses B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
resolve O
phlegm B-PHE
and O
promote O
blood B-PHE
circulation I-PHE
to O
remove O
obstruction B-PHE
in I-PHE
the I-PHE
channels I-PHE
. O

-DOCSTART- O


Atrophic B-PHE
Vaginitis I-PHE

-DOCSTART- O


Treatment O
of O
stagnation B-PHE
of I-PHE
undigested I-PHE
meat I-PHE
with O
epigastric B-PHE
distension I-PHE
, O
diarrhea B-PHE
and O
abdominal B-PHE
pain I-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
epigastric B-PHE
pain I-PHE
or O
abdominal B-PHE
colic I-PHE
, O
after O
childbirth O
, O
heraial O
pain B-PHE
, O
hyperlipemia B-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
dryness B-PHE
of I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


profuse B-PHE
bleeding I-PHE
after O
delivery B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Inv(16)(p13.1q22 O
) O
; O
CBFB-MYH11 O

-DOCSTART- O


secure O
the O
essence O

-DOCSTART- O


Septic B-PHE
Shock I-PHE

-DOCSTART- O


Sore B-PHE
Throat I-PHE
Due O
to O
a O
Common O
Cold B-PHE

-DOCSTART- O


Neuropathic B-PHE
pain I-PHE

-DOCSTART- O


cool O
blood B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


close O
sores B-PHE

-DOCSTART- O


Kids O
, O
Protective B-PHE
immunity I-PHE
, O
Metabolism B-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
motility B-PHE
, O
Others O

-DOCSTART- O


Parasite O
worms B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
chronic B-PHE
hepatitis I-PHE
B O
in O
adult O
and O
adolescent O
patients O
??6 O
years O
of O
age O
with O
evidence O
of O
viral O
replication O
and O
either O
evidence O
of O
persistent O
elevations O
in O
serum O
aminotransferases O
( O
ALT O
or O
AST O
) O
or O
histologically O
active O
disease O
. O

-DOCSTART- O


Unspecified O
Adult O
Solid B-PHE
Tumor I-PHE
, O
Protocol O
Specific O

-DOCSTART- O


fever B-PHE
of O
juvenile O
Gamjeck O

-DOCSTART- O


Its O
solution O
may O
kill O
the O
oncomelania O
. O

-DOCSTART- O


Photoaging B-PHE

-DOCSTART- O


Myelomeningocele B-PHE

-DOCSTART- O


Treatment O
of O
attack O
of O
damp-heat B-PHE
manifested O
by O
stuffiness B-PHE
and O
fullness B-PHE
sensation O
in O
the O
abdomen O
, O
or O
causing O
acute O
dysentery B-PHE
of I-PHE
jaundice I-PHE
, O
high B-PHE
fever I-PHE
accompained O
by O
impairment B-PHE
of I-PHE
conciousness I-PHE
, O
fidgetness B-PHE
and O
insomnia B-PHE
due O
to O
exuberant B-PHE
fire I-PHE
, O
spitting B-PHE
of I-PHE
blood I-PHE
and O
epistaxis B-PHE
caused O
by O
heat B-PHE
in I-PHE
the I-PHE
blood I-PHE
, O
inflammation B-PHE
of O
the O
eye O
, O
acid B-PHE
regurgitation I-PHE
, O
toothache B-PHE
, O
diabetes B-PHE
, O
carbuncles B-PHE
and O
sores B-PHE
, O
external O
use O
for O
eczema B-PHE
and O
other O
skin B-PHE
diseases I-PHE
with O
exudation B-PHE
, O
purulent B-PHE
discharge I-PHE
from O
the O
ear O
. O

-DOCSTART- O


Dimethindene O
can O
also O
be O
used O
as O
an O
adjuvant O
in O
eczema B-PHE
and O
other O
pruriginous B-PHE
dermatoses I-PHE
of O
allergic O
origin O
. O

-DOCSTART- O


For O
the O
treatment O
of O
mild O
to O
moderate O
infections B-PHE
in O
adults O
and O
adolescents O
( O
12 O
years O
of O
age O
or O
older O
) O
which O
are O
caused O
by O
susceptible O
strains B-PHE
of O
microorganisms O
in O
acute B-PHE
bacterial I-PHE
exacerbation I-PHE
of O
chronic B-PHE
bronchitis I-PHE
, O
community-acquired B-PHE
pneumonia I-PHE
, O
pharyngitis/tonsillitis B-PHE
, O
and O
uncomplicated O
skin O
and O
skin-structure B-PHE
infections I-PHE
. O

-DOCSTART- O


sweating O
head O
; O
perspiration B-PHE
on O
forehead O
; O
morbid O
perspiration B-PHE
on O
the O
head O

-DOCSTART- O


This O
is O
bursting O
a O
carbuncle B-PHE
and O
cellulites B-PHE
after O
decaying O
. O

It O
is O
occurred O
in O
thick O
skin O
and O
region O
which O
have O
a O
lot O
of O
glandulae B-PHE
sebaceae I-PHE
and O
follicular B-PHE
. O

-DOCSTART- O


To O
replenish O
the O
kidney B-PHE
, O
to O
strengthen O
the O
bones B-PHE
, O
to O
promote O
the O
healing B-PHE
of I-PHE
fracture I-PHE
, O
and O
to O
relieve O
pain B-PHE
. O

-DOCSTART- O


blood B-PHE
stagnation I-PHE
caused O
by O
falling B-PHE
or O
strike B-PHE

-DOCSTART- O


Fatigue B-PHE

-DOCSTART- O


flaccidity B-PHE
and O
limping B-PHE

-DOCSTART- O


black B-PHE
hair I-PHE

-DOCSTART- O


Denosumab O
is O
designed O
to O
target O
RANKL B-PHE
( O
RANK B-PHE
ligand I-PHE
) O
, O
a O
protein O
that O
acts O
as O
the O
primary O
signal O
to O
promote O
bone B-PHE
removal/resorption I-PHE
. O

In O
many O
bone B-PHE
loss I-PHE
conditions O
, O
RANKL B-PHE
overwhelms O
the O
body's O
natural O
defense O
against O
bone B-PHE
destruction I-PHE
. O

Denosumab O
prevents O
RANKL B-PHE
from O
activating O
its O
receptor O
, O
RANK B-PHE
, O
on O
the O
surface O
of O
osteoclasts B-PHE
and O
their O
precursors O
. O

Prevention O
of O
the O
RANKL/RANK B-PHE
interaction O
inhibits O
osteoclast B-PHE
formation I-PHE
, O
function O
, O
and O
survival O
, O
thereby O
decreasing O
bone B-PHE
resorption I-PHE
and O
increasing O
bone B-PHE
mass I-PHE
and O
strength O
in O
both O
cortical B-PHE
and I-PHE
trabecular I-PHE
bone I-PHE
. O

-DOCSTART- O


mental B-PHE
confusion I-PHE

-DOCSTART- O


Counteracting O
the O
arrhythmias B-PHE
induced O
pituitrin B-PHE
in O
rabbits. O
. O

-DOCSTART- O


To O
relieve O
rheumatic B-PHE
conditions I-PHE
, O
and O
to O
remove O
damp-heat B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
flooding B-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
pharyngolaryngitis B-PHE
, O
mammary B-PHE
welling I-PHE
abscess I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
poisonous B-PHE
snake I-PHE
bite I-PHE
. O

-DOCSTART- O


move O
Gi(Qi O
) O
and O
blood B-PHE

-DOCSTART- O


Omeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-PHE
acid I-PHE
secretion I-PHE
by O
specific O
inhibition O
of O
the O
H<sup>+</sup>/K<sup>+</sup>-ATPase O
in O
the O
gastric O
parietal O
cell O
. O

By O
acting O
specifically O
on O
the O
proton O
pump O
, O
omeprazole O
blocks O
the O
final O
step O
in O
acid O
production O
, O
thus O
reducing O
gastric B-PHE
acidity I-PHE
. O

-DOCSTART- O


Tuberculosis B-PHE

-DOCSTART- O


diarrhea B-PHE
due O
to O
damp-heat B-PHE

-DOCSTART- O


Amenorrhea B-PHE
, O
concretion O
and O
conglomeration O
, O
knocks O
and O
falls O
, O
abdominal B-PHE
pain I-PHE
, O
asthma B-PHE
( O
raw O
) O
, O
blood B-PHE
ejection I-PHE
, O
hematuria B-PHE
, O
hematochezia B-PHE
, O
prolapse B-PHE
of O
rectum O
( O
scorch-fry O
) O
. O

-DOCSTART- O


Carcinoma B-PHE
, I-PHE
Renal I-PHE
Cell I-PHE

-DOCSTART- O


somnolence B-PHE

-DOCSTART- O


Neck B-PHE
bone I-PHE
problems I-PHE
and O
inflammation B-PHE

-DOCSTART- O


To O
remove O
heat B-PHE
and O
counteract O
toxicity B-PHE
, O
to O
nourish O
liver B-PHE
and O
stomach B-PHE
, O
curing O
sore B-PHE
, O
to O
improve O
consciousness B-PHE
, O
to O
tonify B-PHE
the I-PHE
body I-PHE
. O

-DOCSTART- O


Other O
Nutritional B-PHE
Deficiencies I-PHE

-DOCSTART- O


expel O
pus B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Stagnation O
of O
qi O
and O
blood B-PHE
marked O
by O
chest B-PHE
pain I-PHE
; O
dry B-PHE
cough I-PHE
with O
shortness B-PHE
of I-PHE
breath I-PHE
; O
insomnia B-PHE
. O

-DOCSTART- O


An O
active O
component O
pachyman O
promotes O
macrophage B-PHE
phagocytosis I-PHE
in O
mice O
, O
and O
enhances O
lymphocyte-blastogensis B-PHE
rate O
in O
vitro O
. O

Preventing O
the O
formation O
of O
gastric B-PHE
ulcer I-PHE
under O
stress B-PHE
in O
rats O
. O

Diuretic B-PHE
and O
liver-protective B-PHE
. O

-DOCSTART- O


toothache B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
motility B-PHE
, O
Evacuation B-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


For O
dispersing O
wind-coldness B-PHE

-DOCSTART- O


Chlorpheniramine O
binds O
to O
the O
histamine O
H1 O
receptor O
, O
which O
blocks O
the O
action B-PHE
of I-PHE
endogenous I-PHE
histamine I-PHE
, O
which O
subsequently O
leads O
to O
temporary O
relief O
of O
the O
negative B-PHE
symptoms I-PHE
brought O
on O
by O
histamine O
. O

-DOCSTART- O


cosolidate O
bones B-PHE

-DOCSTART- O


Ipilimumab O
blocks O
the O
CTLA-4 B-PHE
inhibitory I-PHE
signal I-PHE
, O
and O
allows O
the O
Cytotoxic B-PHE
T I-PHE
lymphocytes I-PHE
to O
destroy O
the O
cancer B-PHE
cells I-PHE
. O

Fotemustine O
alkylates O
guanine O
by O
forming O
chloroethyl O
adducts O
at O
the O
6 O
position O
of O
guanine O
, O
resulting O
in O
N1-guanine O
and O
N3-cytosine O
cross O
linkages O
, O
inhibition O
of O
DNA B-PHE
synthesis I-PHE
, O
cell B-PHE
cycle I-PHE
arrest I-PHE
, O
and O
finally O
apoptosis B-PHE
. O

-DOCSTART- O


malaria B-PHE
with O
mass O
under O
left O
hypochondrium O

-DOCSTART- O


phlegm-retention B-PHE
syndrome I-PHE
; O
congested O
fluids O
; O
retention O
of O
phlegm B-PHE
and O
fluid O
( O
1 O
) O
morbid O
conditions O
characterized O
by O
accumulation O
of O
dampness O
as O
a O
pathological O
product O
resulting O
from O
dysfunction B-PHE
of I-PHE
the I-PHE
lung I-PHE
, I-PHE
spleen I-PHE
md I-PHE
kidney I-PHE
or O
from O
disturbance O
of O
water O
circulation O
in O
the O
passage O
of O
Triple O
Ch'o(? O
. O

The O
thicker O
dampness O
is O
called O
phlegm B-PHE
, O
while O
the O
thinner O
fluid O
. O

Retention O
of O
phlegm B-PHE
and O
fluid O
can O
give O
rise O
to O
various O
diseases B-PHE
, O
one O
of O
the O
four O
kinds O
of O
fluid O
retention O
. O

( O
2 O
) O
a O
morbid O
condition O
due O
to O
fluid O
retention O
in O
the O
stomach B-PHE
and O
intestines B-PHE
. O

-DOCSTART- O


white-haired B-PHE

-DOCSTART- O


bluish B-PHE
blindness I-PHE
; O
optic B-PHE
atrophy I-PHE
; O
glaucoma B-PHE

-DOCSTART- O


deficiency O
of O
Gi O
( O
vital O
energy O
) O
of O
the O
stomach O

-DOCSTART- O


To O
nourish O
yin O
and O
clear O
away O
heat B-PHE
, O
relieve O
restlessness B-PHE
and O
tranquilize O
the O
mind B-PHE
, O
regulate O
the O
equilibrium O
of O
the O
human B-PHE
body I-PHE
, O
improve O
health B-PHE
and O
prolong B-PHE
life I-PHE
. O

-DOCSTART- O


Simultaneous O
quantitative O
analyses O
of O
indole O
and O
oxindole O
alkaloids O
of O
Uncaria O
Hook O
in O
rat O
plasma O
and O
brain O
after O
oral O
administration O
of O
the O
traditional O
Japanese O
medicine O
Yokukansan O
using O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
. O

-DOCSTART- O


A O
symptom O
that O
the O
chest B-PHE
and O
a O
middle O
part O
of O
the O
stomach B-PHE
are O
full O
and O
uncomfortable O
. O

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
and O
blood B-PHE
, O
to O
relieve O
cough B-PHE
, O
and O
to O
induce O
tranquilization B-PHE
. O

-DOCSTART- O


Haemorrhage B-PHE

-DOCSTART- O


move O
stasis B-PHE

-DOCSTART- O


To O
arrest O
spontaneous O
emission O
, O
to O
reduce O
excessive B-PHE
urination I-PHE
, O
and O
to O
cure O
turbid B-PHE
discharge I-PHE
from O
the O
urethra O
. O
cturnal B-PHE
emission I-PHE
, O
spermatorrhea B-PHE
, O
enuresis B-PHE
, O
frequent B-PHE
urination I-PHE
, O
turbid B-PHE
discharge I-PHE
with O
urine O
. O

-DOCSTART- O


Pregnancy B-PHE
in I-PHE
Diabetics I-PHE

-DOCSTART- O


the O
heat B-PHE
from O
bones O
without O
sweating B-PHE

-DOCSTART- O


Eum O
in O
its O
extreme O
rise O
to O
agitation B-PHE

-DOCSTART- O


wind-cold B-PHE
; O

wind-cold B-PHE
pathogen I-PHE
wind B-PHE
and O
cold B-PHE
blended O
as O
a O
pathogenic O
facto O

-DOCSTART- O


Hemostatic O
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
transform O
damp B-PHE
, O
disperse O
accumulation O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Metformin O
acts O
by O
the O
initial O
activation B-PHE
of I-PHE
AMP-activated I-PHE
protein I-PHE
kinase I-PHE
( O
AMPK B-PHE
) O
, O
a O
liver B-PHE
enzyme I-PHE
that O
plays O
an O
important O
role O
in O
insulin B-PHE
signaling I-PHE
, O
whole O
body B-PHE
energy I-PHE
balance I-PHE
, O
and O
the O
metabolism B-PHE
of I-PHE
glucose I-PHE
and O
fats O
. O

Rosiglitazone O
acts O
as O
a O
highly O
selective O
and O
potent O
agonist O
at O
peroxisome O
proliferator O
activated O
receptors O
( O
PPAR O
) O
in O
target O
tissues O
for O
insulin B-PHE
action I-PHE
such O
as O
adipose O
tissue O
, O
skeletal O
muscle O
, O
and O
liver O
and O
enhances O
tissue B-PHE
sensitivity I-PHE
to O
insulin O
. O

-DOCSTART- O


Pi B-PHE
syndrome I-PHE
due O
to O
pathogenic B-PHE
wind I-PHE
, O
cold B-PHE
and O
damp B-PHE

-DOCSTART- O


diabetes B-PHE
; O
wasting B-PHE
( O
emaciation B-PHE
) O
and O
thirsting B-PHE
syndrome I-PHE

-DOCSTART- O


The O
functional O
group O
of O
the O
anion O
exchange O
resin O
is O
a O
quaternary O
ammonium O
group O
attached O
to O
an O
inert O
styrene-divinylbenzene O
copolymer O
. O

-DOCSTART- O


Used O
to O
numb B-PHE
the I-PHE
skin I-PHE
, O
or O
surfaces O
of O
the O
penis O
or O
vagina O
, O
in O
preparation O
for O
a O
medical O
procedure O
or O
to O
lessen O
the O
pain B-PHE
of O
inserting O
a O
medical O
instrument O
such O
as O
a O
tube O
or O
speculum O
. O

-DOCSTART- O


fever B-PHE
; O
feverishness B-PHE

-DOCSTART- O


Heat B-PHE
in O
the O
heart O
, O
insufficient O
yin O
in O
kidney B-PHE
, O
frightening B-PHE
and O
madness B-PHE
, O
frequent O
talk O
and O
smile O
, O
driness B-PHE
in O
the O
mouth O
, O
red B-PHE
tong I-PHE
, O
loss B-PHE
of I-PHE
blood I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
yellow B-PHE
body I-PHE
due O
to O
blood B-PHE
deficiency I-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
dry O
damp B-PHE
and O
kill O
worms B-PHE
. O

-DOCSTART- O


invigorate O
blood B-PHE
and O
unblock O
the O
network B-PHE
vessels B-PHE

-DOCSTART- O


cough B-PHE

-DOCSTART- O


Ureterostomy O
; O
Functional B-PHE
Disturbance I-PHE

-DOCSTART- O


anal B-PHE
fistula I-PHE
hemorrhoids I-PHE
complicated O
by O
anal B-PHE
fistula I-PHE
. O

-DOCSTART- O


Hypercholesterolemia B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
cancer B-PHE
patients O
with O
severe O
pain B-PHE
that O
breaks O
through O
their O
regular O
narcotic O
therapy O
. O

-DOCSTART- O


1 O
flaccidity B-PHE
of I-PHE
lower I-PHE
limbs I-PHE
2 O
leg O
Gi O
; O
beriberi B-PHE

-DOCSTART- O


Treatment O
of O
amenorrhea B-PHE
with O
mass B-PHE
in I-PHE
the I-PHE
abdomen I-PHE
, O
swelling B-PHE
of I-PHE
breast I-PHE
after O
childbirth O
, O
rubella B-PHE
red O
in O
colour O
, O
itching B-PHE
, O
acne B-PHE
. O

-DOCSTART- O


diarrhea B-PHE

-DOCSTART- O


irritability B-PHE
and O
restlessness B-PHE
; O

dysphoria B-PHE

-DOCSTART- O


Lupus B-PHE
Nephritis I-PHE

-DOCSTART- O


Second-degree B-PHE
Burn I-PHE

-DOCSTART- O


Heartburn B-PHE

-DOCSTART- O


In O
addition O
to O
binding O
to O
specific O
nuclear O
steroid O
receptors O
, O
dexamethasone O
also O
interferes O
with O
NF-kB B-PHE
activation I-PHE
and O
apoptotic B-PHE
pathways I-PHE
. O

-DOCSTART- O


difficult B-PHE
delivery I-PHE
; O

dystocia B-PHE

-DOCSTART- O


nourish O
Eum(Yin O
) O
blood B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
diabetes B-PHE
mellitus I-PHE
( O
type O
2 O
) O
. O

-DOCSTART- O


( O
1 O
) O
cold-type B-PHE
hernia I-PHE
; O
periumbilical B-PHE
colic I-PHE
due O
to O
invasion B-PHE
of I-PHE
cold I-PHE
( O
2 O
) O
testalgia B-PHE
due O
to O
pathogenic B-PHE
cold I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Body B-PHE
fat I-PHE
deposition I-PHE
( O
total O
amount O

-DOCSTART- O


diabetics B-PHE
; O
emaciation-thirst B-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
edema B-PHE
, O
toxin B-PHE
swelling B-PHE
of O
sores O
. O

-DOCSTART- O


Stage O
II O
Non-Contiguous O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Memory O

-DOCSTART- O


For O
prophylaxis O
of O
respiratory B-PHE
diseases I-PHE
casued O
by O
respiratory B-PHE
syncytial I-PHE
virus I-PHE
. O

-DOCSTART- O


wind-heat B-PHE
; O
wind B-PHE
and O
heat B-PHE
; O
wind-heat B-PHE
pathogene I-PHE
wind I-PHE
and O
heat B-PHE
blended O
as O
a O
pathogenic O
factor O
. O

-DOCSTART- O


a O
disease O
of O
periumbilical B-PHE
sharp I-PHE
pain I-PHE
and O
cold B-PHE
hand I-PHE
and I-PHE
foot I-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Maturation O

-DOCSTART- O


unconsciousness B-PHE

-DOCSTART- O


Conservative O
treatment O
of O
benign B-PHE
prostatic I-PHE
hypertrophy I-PHE
- O
clinical O
effects O
of O
increased O
administration O
of O
Hachimijiogan O
and O
the O
relation O
between O
these O
effects O
and O
the O
Sho O
of O
Chinese O
medicine O
. O

-DOCSTART- O


OBJECTIVE O
: O
The O
purpose O
of O
this O
clinical O
trial O
was O
to O
assess O
the O
efficacy O
of O
Goshuyuto O
, O
a O
typical O
Kampo O
formula O
, O
in O
preventing O
episodes O
of O
headache B-PHE
in O
chronic B-PHE
headache I-PHE
patients O
. O

RESEARCH O
DESIGN O
AND O
METHODS O
: O
Because O
the O
treatment O
target O
of O
a O
Kampo O
formula O
is O
decided O
on O
a O
basis O
different O
to O
that O
of O
Western O
medicine O
, O
we O
first O
selected O
patients O
belonging O
to O
a O
subgroup O
that O
responded O
to O
goshuyuto O
before O
conducting O
the O
usual O
randomized O
controlled O
trial O
. O

During O
stage O
1, O
the O
subjects O
were O
instructed O
to O
orally O
consume O
goshuyuto O
for O
4 O
weeks O
. O

Only O
those O
subjects O
judged O
as O
responders O
advanced O
to O
stage O
2, O
during O
which O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
was O
conducted O
. O

The O
subjects O
consumed O
the O
same O
dose O
of O
goshuyuto O
or O
placebo O
for O
12 O
weeks O
. O

RESULTS O
: O
Of O
the O
91 O
subjects O
enrolled O
in O
stage O
1, O
60 O
were O
judged O
as O
responders O
. O

Of O
these O
, O
53 O
advanced O
to O
stage O
2; O
28 O
were O
assigned O
to O
the O
goshuyuto O
group O
and O
25 O
to O
the O
placebo O
group O
. O

The O
decrease O
in O
the O
number O
of O
days O
on O
which O
headache B-PHE
episodes O
occurred O
was O
greater O
in O
the O
goshuyuto O
group O
than O
in O
the O
placebo O
group O
( O
2.6 O
+/- O
3.7 O
vs O
. O
0.3 O
+/- O
4 O
days O
, O
p O
= O
0.034 O
) O
; O
no O
difference O
was O
observed O
with O
regard O
to O
the O
reduction O
in O
the O
frequency O
of O
consuming O
reliever O
medications O
( O
2.2 O
+/- O
4 O
vs O
. O
1.4 O
+/- O
8.2 O
, O
p O
= O
0.672 O
) O
. O

Improvement O
in O
the O
associated O
symptoms O
was O
observed O
in O
more O
than O
0.5 O
of O
the O
subjects O
in O
the O
goshuyuto O
group O
. O

CONCLUSION O
: O
Goshuyuto O
is O
useful O
in O
preventing O
episodes O
of O
headache B-PHE
in O
chronic B-PHE
headache I-PHE
patients O
. O

Responder-limited O
design O
is O
a O
candidate O
for O
evaluating O
Kampo O
medicine O
. O

-DOCSTART- O


Essential B-PHE
Hypertension I-PHE

-DOCSTART- O


DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Liver B-PHE
health I-PHE
, O
Liver B-PHE
, O
Blood B-PHE
pressure I-PHE

-DOCSTART- O


In O
addition O
, O
dalbavancin O
alters O
bacterial O
- O
cell O
- O
membrane O
permeability O
and O
RNA B-PHE
synthesis I-PHE
. O

-DOCSTART- O


NMO B-PHE
Spectrum I-PHE
Disorder I-PHE
( O
NMOSD B-PHE
) O

-DOCSTART- O


For O
the O
symptomatic B-PHE
relief I-PHE
of O
pain B-PHE
, O
burning B-PHE
, O
urgency B-PHE
, O
frequency O
, O
and O
other O
discomforts B-PHE
arising O
from O
irritation B-PHE
of O
the O
lower B-PHE
urinary I-PHE
tract I-PHE
mucosa I-PHE
caused O
by O
infection B-PHE
, O
trauma B-PHE
, O
surgery O
, O
endoscopic O
procedures O
, O
or O
the O
passage O
of O
sounds O
or O
catheters O
. O

-DOCSTART- O


Lenalidomide O
inhibits O
TNF-alpha B-PHE
production I-PHE
, O
stimulates O
T B-PHE
cells I-PHE
, O
reduces O
serum O
levels O
of O
the O
cytokines O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
and O
basic O
fibroblast O
growth O
factor O
( O
bFGF O
) O
, O
and O
inhibits O
angiogenesis B-PHE
. O

Acetylsalicylic O
acid O
binds O
to O
and O
acetylates O
serine O
residues O
in O
cyclooxygenases O
, O
resulting O
in O
decreased O
synthesis B-PHE
of I-PHE
prostaglandin I-PHE
, O
platelet O
aggregation O
, O
and O
inflammation B-PHE
. O

Dexamethasone O
is O
a O
glucocorticoid O
agonist O
. O

In O
addition O
to O
binding O
to O
specific O
nuclear O
steroid O
receptors O
, O
dexamethasone O
also O
interferes O
with O
NF-kB B-PHE
activation I-PHE
and O
apoptotic O
pathways O
. O

Bendamustine O
acts O
as O
an O
alkylating O
agent O
causing O
intra-strand O
and O
inter-strand O
cross-links O
between O
DNA O
bases O
. O

-DOCSTART- O


erysipelas B-PHE
acute I-PHE
infection I-PHE
of I-PHE
the I-PHE
skin I-PHE
characterized O
by O
sudden O
onset O
of O
local O
bright O
red O
coloration O
and O
swelling B-PHE
with O
rapid O
spreading O
. O

-DOCSTART- O


1 O
Analgeic O
. O
2 O
Sedative O
. O
3 O
Antispasmodic O

-DOCSTART- O


Gastroesophageal B-PHE
Reflux I-PHE
Disease I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD B-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O
, O
Reproductive B-PHE
systems I-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


Stage O
II O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


1 O
For O
cases O
of O
apoplexy B-PHE
with O
sudden O
onset O
of O
face B-PHE
distortion I-PHE
, O
dysphasia B-PHE
, O
numbness B-PHE
of I-PHE
the I-PHE
limbs I-PHE
, O
or O
even O
hemiplegia B-PHE
, O
rigidity B-PHE
of I-PHE
the I-PHE
extremities I-PHE
, O
white B-PHE
and I-PHE
greasy I-PHE
fur I-PHE
on O
the O
tongue O
, O
floating O
and O
smooth O
pulse B-PHE
, O
which O
are O
attributive O
to O
attack O
of O
wind-phlegm B-PHE
to O
the O

-DOCSTART- O


distribution O
) O
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE

-DOCSTART- O


Sleep B-PHE
Disturbance I-PHE

-DOCSTART- O


furuncle B-PHE
and O
swelling B-PHE
of I-PHE
carbuncle I-PHE

-DOCSTART- O


dirty B-PHE
face I-PHE
; O

dirty B-PHE
complexion I-PHE
; O

grimy B-PHE
facial I-PHE
complexion I-PHE
a O
face O
appearing O
as O
if O
covered O
with O
dirt O
, O
as O
often O
seen O
in O
hepatic B-PHE
disease I-PHE
, O
disease O
due O
to O
damp-heat B-PHE
. O

-DOCSTART- O


Eye B-PHE
health I-PHE
, O
Eye B-PHE

-DOCSTART- O


For O
desolving O
stasis B-PHE
and O
stopping O
bleeding B-PHE

-DOCSTART- O


Genz-112638 O
, O
a O
novel O
ceramide O
analog O
given O
orally O
, O
is O
designed O
to O
inhibit O
the O
enzyme B-PHE
glucosylceramide I-PHE
synthase I-PHE
, O
which O
results O
in O
reduced O
production O
of O
glucocerebroside B-PHE
. O

This O
is O
the O
substance O
that O
builds O
up O
in O
the O
cells O
and O
tissues O
of O
people O
with O
Gaucher B-PHE
disease I-PHE
. O

In O
preclinical O
studies O
, O
the O
molecule O
has O
shown O
high O
potency O
and O
specificity O
. O

-DOCSTART- O


Metformin O
acts O
by O
the O
initial O
activation O
of O
AMP-activated B-PHE
protein I-PHE
kinase I-PHE
( O
AMPK B-PHE
) O
, O
a O
liver B-PHE
enzyme I-PHE
that O
plays O
an O
important O
role O
in O
insulin O
signaling O
, O
whole O
body B-PHE
energy I-PHE
balance I-PHE
, O
and O
the O
metabolism B-PHE
of I-PHE
glucose I-PHE
and O
fats B-PHE
. O

Sulfonylureas O
such O
as O
glyburide O
bind O
to O
ATP-sensitive B-PHE
potassium I-PHE
channels I-PHE
on O
the O
pancreatic O
cell O
surface O
, O
raising O
intracellular O
concentrations B-PHE
of I-PHE
calcium I-PHE
ions O
, O
which O
induces O
the O
secretion B-PHE
, O
or O
exocytosis B-PHE
, O
of O
insulin B-PHE
. O

-DOCSTART- O


( O
1 O
) O
tangling O
up O
of O
intestine O
; O
accumulation O
of O
pathogenic O
factor O
in O
viscera O
( O
2 O
) O
Accumulation O
of O
Eum O
Cold B-PHE
in O
Viscera O
one O
of O
the O
symptoms O
in O
Soeumin O
( O
marked O
by O
hard O
mass O
on O
the O
right O
side O
of O
the O
epigastrium O
. O
The O
prognosis O
is O
not O
hopeful O
. O

-DOCSTART- O


having O
a O
yellow B-PHE
or I-PHE
reddish I-PHE
urine I-PHE
due O
to O
blocking O
the O
circulation B-PHE
of I-PHE
bile I-PHE
by O
epidemic B-PHE
toxin I-PHE
, O
fail O
to O
control O
food O
, O
and O
damp-heat B-PHE
and O
cold-damp B-PHE
blocked O
in O
the O
middle O
heater O

-DOCSTART- O


Nervous B-PHE
System I-PHE
Diseases I-PHE
, O
Sympathetic O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
cancer/tumors B-PHE
( O
unspecified O
) O
. O

-DOCSTART- O


To O
provide O
some O
insights O
how O
herbal O
medicines O
affect O
deoxyribonucleic B-PHE
acid I-PHE
( I-PHE
DNA I-PHE
) I-PHE
synthesis I-PHE
in O
the O
uterus O
, O
the O
DNA B-PHE
polymerase I-PHE
activities I-PHE
( O
alpha O
and O
beta O
) O
in O
uterine O
samples O
taken O
from O
rats O
were O
measured O
. O

DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
with O
respect O
to O
DNA O
content O
revealed O
alpha O
cyclic O
change O
with O
the O
highest O
level O
on O
proestrus O
, O
while O
DNA B-PHE
polymerase I-PHE
beta I-PHE
activity I-PHE
showed O
no O
significant O
changes O
during O
the O
estrous O
cycle O
. O

The O
increased O
period O
of O
the O
activity O
coincided O
with O
that O
of O
17 B-PHE
beta-estradiol I-PHE
( O
E2 B-PHE
) O
but O
not O
progesterone B-PHE
( O
P4 B-PHE
) O
in O
the O
blood O
. O

Injection O
of O
10 O
IU O
pregnant B-PHE
mare I-PHE
serum I-PHE
gonadotropin I-PHE
( O
PMS B-PHE
) O
on O
day O
27 O
of O
age O
gradually O
increased O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
in O
uteri O
, O
while O
concomitant O
treatment O
with O
PMS B-PHE
and O
200 O
micrograms O
Tokishakuyakusan O
( O
TS O
) O
, O
Keishibukuryogan O
( O
KB O
) O
or O
Unkeito O
( O
UT O
) O
suppressed O
the O
enzyme B-PHE
activity I-PHE
, O
with O
a O
most O
remarkable O
effect O
of O
KB O
. O

These O
results O
suggest O
that O
TS O
, O
KB O
or O
UT O
suppresses O
in O
vivo O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
induced O
by O
PMS B-PHE
in O
the O
rat O
uterus O
. O

-DOCSTART- O


Angina B-PHE
pectoris I-PHE
, O
cerebral B-PHE
atherosclerosis I-PHE
, O
diffusive O
intravascular B-PHE
clotting I-PHE
, O
thrombophlebitis B-PHE
, O
hepatitis B-PHE
, O
acute B-PHE
surgical I-PHE
infection I-PHE
, O
mastitis B-PHE
, O
erysipelas B-PHE
, O
otitis B-PHE
media I-PHE
, O
tonsillitis B-PHE
, O
bone B-PHE
marrow I-PHE
infection I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
dysmenorrhea O
, O
amenorrhea B-PHE
, O
postpartum B-PHE
stasis I-PHE
stagnation I-PHE
abdominal I-PHE
pain I-PHE
, O
pain B-PHE
in I-PHE
heart I-PHE
and I-PHE
abdomen I-PHE
, O
concretion B-PHE
conglomeration I-PHE
accumulation I-PHE
and O
gathering O
, O
heat B-PHE
impediment O
swelling B-PHE
and O
pain B-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
heat B-PHE
entering O
construction-blood B-PHE
, O
vexation B-PHE
and O
agitation B-PHE
, O
insomnia B-PHE
and O
vexation B-PHE
, O
swelling B-PHE
toxin O
of O
welling O
abscess B-PHE
and O
sore B-PHE
, O
zoster B-PHE
, O
neurodermatitis B-PHE
, O
psoriasis B-PHE
. O

-DOCSTART- O


Treatment O
of O
cough B-PHE
with O
profuse O
expectoration B-PHE
, O
indigestion B-PHE
, O
stagnancy B-PHE
of I-PHE
food I-PHE
with O
abdominal O
pain B-PHE
, O
traumatic O
swelling B-PHE
and O
ecchymoses B-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


stabilize O
pain B-PHE

-DOCSTART- O


Ipilimumab O
is O
a O
fully O
human O
IgG1 B-PHE
antibody I-PHE
that O
binds O
to O
CTLA-4 B-PHE
( O
cytotoxic B-PHE
T I-PHE
lymphocyte-associated I-PHE
antigen I-PHE
4 I-PHE
) O
, O
a O
molecule O
on O
T-cells O
that O
is O
indicated O
for O
unresectable B-PHE
or I-PHE
metastatic I-PHE
melanoma I-PHE
. O

The O
absence O
or O
presence O
of O
CTLA-4 O
can O
augment O
or O
suppress O
the O
immune B-PHE
system's I-PHE
T-cell O
response O
in O
fighting O
disease B-PHE
. O

Ipilimumab O
is O
designed O
to O
block O
the O
activity O
of O
CTLA-4 O
, O
thereby O
sustaining O
an O
active B-PHE
immune I-PHE
response I-PHE
in O
its O
attack O
on O
cancer B-PHE
cells I-PHE
. O

The O
proposed O
mechanism O
of O
action O
is O
indirect O
, O
and O
may O
be O
through O
T-cell O
- O
mediated O
anti-tumor B-PHE
immune I-PHE
responses I-PHE
. O

-DOCSTART- O


This O
is O
a O
syndrome O
that O
children O
wet O
their O
pants O
regardless O
of O
time O
. O

-DOCSTART- O


1 O
Applicable O
to O
cases O
of O
diarrhea B-PHE
in O
summer O
time O
, O
manifested O
as O
watery B-PHE
diarrhea I-PHE
, O
abdominal B-PHE
fullness I-PHE
, O
increased O
borborygmus B-PHE
, O
nausea B-PHE
, O
feeling O
of O
oppression O
over O
the O
chest O
, O
fatigue B-PHE
, O
white O
and O
smooth O
fur O
on O
the O
tongue O
, O
soft O
and O
floating O
, O
slow B-PHE
pulse I-PHE
, O
which O
are O
attribut O

-DOCSTART- O


For O
the O
treatment O
of O
moderate O
and O
severe O
hypertension B-PHE
, O
either O
alone O
or O
as O
an O
adjunct O
, O
and O
for O
the O
treatment O
of O
renal B-PHE
hypertension I-PHE
. O

-DOCSTART- O


wind B-PHE
invaded O
Chang O
organ O

-DOCSTART- O


cough B-PHE
due O
to O
lung B-PHE
exhaustion I-PHE
syndrome I-PHE

-DOCSTART- O


Hydrochlorothiazide O
allows O
the O
blood B-PHE
vessels I-PHE
to O
relax O
and O
causes O
kidneys B-PHE
to O
remove O
more O
salt B-PHE
and I-PHE
water I-PHE
from I-PHE
the I-PHE
blood I-PHE
in O
order O
to O
reduce O
blood B-PHE
volume I-PHE
. O

Valsartan O
is O
in O
a O
group O
of O
drugs O
called O
angiotensin O
II O
receptor O
antagonists O
. O

Valsartan O
keeps O
blood B-PHE
vessels I-PHE
from O
narrowing O
, O
which O
lowers O
blood B-PHE
pressure I-PHE
and O
improves O
blood B-PHE
flow I-PHE
. O

-DOCSTART- O


Relief O
of O
mild O
to O
moderate O
pain B-PHE
of O
acte B-PHE
musculoskeletal I-PHE
disorders I-PHE
. O

-DOCSTART- O


nourish O
blood B-PHE

-DOCSTART- O


The O
exact O
mechanism O
of O
action O
of O
ingenol O
mebutate O
in O
actinic B-PHE
keratosis I-PHE
is O
unknown O
. O

It O
is O
presumed O
to O
involve O
primary O
necrosis B-PHE
then O
neutrophil-mediated B-PHE
inflammation I-PHE
and O
antibody-dependent B-PHE
cell I-PHE
death I-PHE
of O
residual O
disease B-PHE
cells I-PHE
. O

Additionally O
in O
early O
studies O
, O
PEP005 O
was O
shown O
to O
be O
an O
effective O
activator O
of O
PKC-delta O
and O
PKC-delta O
translocation O
into O
nucleus B-PHE
and O
membranes B-PHE
. O

PEP005 O
also O
downregulates O
the O
expression B-PHE
and I-PHE
activity I-PHE
of I-PHE
PKC-alpha I-PHE
. O

PEP005 O
induced O
modulation O
of O
PKCs O
leads O
to O
Ras B-PHE
/ O
Raf B-PHE
/ O
MAPK B-PHE
and O
p38 B-PHE
activation O
and O
AKT B-PHE
/ O
PKB B-PHE
inhibition O
. O

-DOCSTART- O


Treatment O
of O
measles B-PHE
without O
adequate O
eruption B-PHE
, O
urticaria B-PHE
with O
itching B-PHE
, O
edema B-PHE
with O
oliguria B-PHE
. O

-DOCSTART- O


Amenorrhea B-PHE
, O
menstrual B-PHE
disorders I-PHE
, O
difficult O
labour O
, O
retention B-PHE
of I-PHE
placenta I-PHE
, O
postpartum O
abdominal B-PHE
pain I-PHE
due O
to O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Organic O
iodine O
compounds O
attenuate O
x-rays O
as O
they O
pass O
through O
the O
body O
, O
thereby O
allowing O
the O
body O
structures O
containing O
iodine O
to O
be O
delineated O
in O
contrast O
to O
those O
structures O
that O
do O
not O
contain O
iodine O
. O

The O
degree O
of O
opacity O
produced O
by O
these O
compounds O
is O
directly O
proportional O
to O
the O
total O
amount O
( O
concentration O
and O
volume O
) O
of O
the O
iodinated O
contrast O
agent O
in O
the O
path O
of O
the O
x-rays O
. O

After O
intravascular O
administration O
, O
iodixanol O
makes O
opaque O
those O
internal O
structures O
in O
its O
path O
of O
flow O
, O
allowing O
their O
visualization O
until O
significant O
hemodilution B-PHE
and O
elimination O
occur O
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Others O

-DOCSTART- O


Muscle B-PHE
Spasticity I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
C I-PHE

-DOCSTART- O


clear O
the O
head B-PHE
and O
eyes B-PHE

-DOCSTART- O


Prevent O
pregnancy B-PHE

-DOCSTART- O


[ O
Treatment O
of O
breast B-PHE
proliferation I-PHE
disease I-PHE
with O
modified O
Xiao O
Yao O
San O
and O
er O
chen O
decoction O
] O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


regenerate O
blood B-PHE

-DOCSTART- O


We O
reported O
previously O
that O
cholesterol O
feeding O
induced O
an O
increase O
in O
hepatic B-PHE
secretion I-PHE
of O
VLDL B-PHE
and O
a O
decrease O
in O
that O
of O
LDL B-PHE
, O
especially O
LDL-apo B-PHE
B100 I-PHE
, O
using O
monkey O
liver O
perfusion O
. O

In O
the O
present O
study O
we O
conducted O
rat O
liver O
perfusion O
using O
the O
HMG O
Co O
A O
reductase O
inhibitor O
( O
CS-514 O
) O
and O
Kampo O
medicine O
( O
Daisaikoto O
) O
to O
elucidate O
the O
mechanism O
of O
the O
effect O
of O
dietary O
cholesterol O
on O
hepatic B-PHE
lipoprotein I-PHE
and O
apolipoprotein B-PHE
synthesis I-PHE
. O

Although O
the O
secretion B-PHE
of I-PHE
VLDL I-PHE
was O
increased O
by O
cholesterol O
feeding O
, O
that O
of O
LDL B-PHE
and O
especially O
of O
apo B-PHE
B100 I-PHE
of I-PHE
LDL I-PHE
were O
markedly O
decreased O
, O
and O
apo B-PHE
E I-PHE
of I-PHE
the I-PHE
LDL I-PHE
was O
increased O
as O
observed O
in O
the O
monkey O
liver O
perfusion O
experiments O
. O

The O
effect O
of O
CS-514 O
was O
clearly O
different O
from O
the O
effect O
of O
dietary B-PHE
cholesterol I-PHE
in O
spite O
of O
the O
suppression O
of O
hepatic O
cholesterogenesis O
which O
was O
comparable O
to O
that O
induced O
by O
cholesterol O
feeding O
, O
suggesting O
that O
the O
decrease O
in O
secretion B-PHE
of I-PHE
LDL-apo I-PHE
B100 I-PHE
induced O
by O
the O
dietary O
cholesterol O
is O
not O
due O
to O
suppressed O
cholesterogenesis O
. O

Daisaikoto O
, O
which O
was O
added O
to O
the O
diet O
together O
with O
cholesterol B-PHE
, O
diminished O
the O
effects O
of O
dietary B-PHE
cholesterol I-PHE
on O
the O
plasma B-PHE
and I-PHE
hepatic I-PHE
cholesterol I-PHE
levels I-PHE
. O

When O
the O
liver O
treated O
with O
Daisaikoto O
was O
perfused O
, O
the O
effect O
of O
dietary B-PHE
cholesterol I-PHE
on O
the O
production O
of O
lipoprotein B-PHE
and O
apolipoprotein B-PHE
was O
markedly O
diminished O
. O

This O
evidence O
indicates O
that O
the O
decrease O
in O
LDL-apo B-PHE
B100 I-PHE
and O
the O
increase O
in O
apo B-PHE
E I-PHE
were O
mediated O
by O
the O
hepatic B-PHE
cholesterol I-PHE
level I-PHE
. O

-DOCSTART- O


dispel O
wind-damp B-PHE

-DOCSTART- O


Diabetes B-PHE

-DOCSTART- O


a O
lumbago B-PHE
pain I-PHE
. O

Occur O
by O
invasion B-PHE
of I-PHE
wind-heat I-PHE
in O
kidney O
meridian O
. O

-DOCSTART- O


Methotrexate B-PHE
anti-tumor I-PHE
activity I-PHE
is O
a O
result O
of O
the O
inhibition O
of O
folic B-PHE
acid I-PHE
reductase I-PHE
, O
leading O
to O
inhibition O
of O
DNA B-PHE
synthesis I-PHE
and O
inhibition O
of O
cellular B-PHE
replication I-PHE
. O

Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes B-PHE
in I-PHE
gene I-PHE
expression I-PHE
that O
lead O
to O
cell B-PHE
differentiation I-PHE
, O
decreased O
cell B-PHE
proliferation I-PHE
, O
and O
inhibition O
of O
tumorigenesis B-PHE
. O

Mercaptopurine O
inhibits O
nucleotide B-PHE
interconversions I-PHE
and O
de O
novo O
purine B-PHE
synthesis I-PHE
, O
thereby O
blocking O
the O
formation B-PHE
of I-PHE
purine I-PHE
nucleotides I-PHE
and O
inhibiting O
DNA B-PHE
synthesis I-PHE
. O

Idarubicin O
intercalates O
into O
DNA B-PHE
and O
interferes O
with O
the O
activity B-PHE
of I-PHE
topoisomerase I-PHE
II I-PHE
, O
thereby O
inhibiting O
DNA B-PHE
replication I-PHE
, O
RNA B-PHE
transcription I-PHE
and O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


Rifampin O
acts O
via O
the O
inhibition O
of O
DNA-dependent O
RNA B-PHE
polymerase I-PHE
, O
leading O
to O
a O
suppression O
of O
RNA B-PHE
synthesis I-PHE
and O
cell O
death O
. O

-DOCSTART- O


profuse B-PHE
nasal I-PHE
bleeding I-PHE
; O
brandy B-PHE
nose I-PHE
; O
rosacea B-PHE

-DOCSTART- O


Gumiganghwaltang O
( O
GMGHT O
) O
is O
an O
Oriental O
herbal O
prescription O
, O
which O
has O
been O
commonly O
used O
to O
treat O
a O
cold B-PHE
and O
inflammatory B-PHE
diseases I-PHE
in O
Korea O
. O

However O
, O
the O
mechanism O
of O
GMGHT O
is O
not O
clear O
. O

In O
this O
study O
, O
we O
investigated O
the O
anti-inflammatory B-PHE
mechanism I-PHE
of O
GMGHT O
in O
mouse O
peritoneal O
macrophages O
. O

GMGHT O
exerted O
an O
anti-inflammatory B-PHE
action I-PHE
through O
inhibiting O
lipopolysaccaride O
( O
LPS)-induced O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
and O
interleukin O
( O
IL)-6 O
production O
in O
mouse O
peritoneal O
macrophages O
. O

The O
maximal O
inhibition O
rate O
of O
TNF-alpha O
, O
and O
IL-6 O
production O
by O
GMGHT O
(1 O
mg/ml O
) O
was O
52.31+/-2.8% O
and O
56.31+/-3.1% O
, O
respectively O
. O

In O
the O
inflammatory B-PHE
process I-PHE
, O
cyclooxygenase B-PHE
2 I-PHE
( O
COX-2 B-PHE
) O
and O
inducible O
nitric B-PHE
oxide I-PHE
synthase I-PHE
( O
iNOS B-PHE
) O
increased O
in O
peritoneal O
macrophages O
. O

GMGHT O
decreased O
the O
protein O
level O
of O
COX-2 B-PHE
and O
iNOS B-PHE
in O
LPS-stimulated O
mouse O
peritoneal O
macrophages O
. O

In O
addition O
, O
GMGHT O
inhibited O
nuclear B-PHE
factor-kappaB I-PHE
activation I-PHE
and O
IkappaB-alpha B-PHE
degradation I-PHE
. O

Our O
study O
suggests O
that O
an O
important O
molecular O
mechanism O
by O
GMKHT O
reduce O
inflammation B-PHE
, O
which O
might O
explain O
its O
beneficial O
effect O
in O
the O
regulation O
of O
inflammatory B-PHE
reactions I-PHE
. O

-DOCSTART- O


Ulcer B-PHE

-DOCSTART- O


These O
cross-links O
result O
in O
apoptosis B-PHE
and O
cell B-PHE
growth I-PHE
inhibition I-PHE
. O

-DOCSTART- O


disperse O
cold B-PHE
and O
eliminate O
dampness B-PHE

-DOCSTART- O


Lymphoma B-PHE

-DOCSTART- O


loosen O
the O
chest B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
felling B-PHE
of I-PHE
cold I-PHE
and O
a O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE
. O

-DOCSTART- O


astringe O
and O
stop O
bleeding B-PHE

-DOCSTART- O


To O
benefit O
vital O
energy O
, O
lift O
yang O
and O
activate O
vital O
energy O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Mood O
, O
Quality O
of O
life O
, O
Endocrine B-PHE
system I-PHE
, O
activation O
, O
attention O
, O
sleep B-PHE
, O
Arousal B-PHE
, O
vigilance B-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Lipid O
profile O
, O
motility B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


To O
replenish O
the O
kidney B-PHE
and O
subdue O
hyperactivity O
of O
the O
liver B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
pain B-PHE
in O
stomach O
duct O
, O
wound O
swelling B-PHE
from O
knocks B-PHE
and O
falls B-PHE
, O
fracture B-PHE
, O
bleeding B-PHE
due O
to O
external O
injury B-PHE
. O

-DOCSTART- O


Rhizoma O
Coptidis O
( O
processed O
with O
wine O
) O
Inflammation B-PHE
of O
the O
eye O
, O
ulcers B-PHE
in O
the O
mouth O
. O

-DOCSTART- O


painful O
urinary B-PHE
dysfunction I-PHE
; O
stranguria B-PHE
a O
syndrome O
characterized O
by O
frequent O
, O
painful B-PHE
and I-PHE
dripping I-PHE
urination I-PHE
. O

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE
. O

-DOCSTART- O


Acetaminophen O
acts O
primarily O
in O
the O
CNS B-PHE
, O
by O
increasing O
the O
pain B-PHE
threshold I-PHE
by O
inhibiting O
both O
isoforms B-PHE
of I-PHE
cyclooxygenase I-PHE
, O
COX-1 B-PHE
, O
COX-2 B-PHE
, O
and O
COX-3 B-PHE
enzymes O
involved O
in O
prostaglandin B-PHE
( I-PHE
PG I-PHE
) I-PHE
synthesis I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Reproductive B-PHE
systems I-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Endurance B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Metabolism B-PHE
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Strength O
and O
power O
, O
Others O
, O
Quality O
of O
life O
, O
Protective O
immunity B-PHE
, O
Body B-PHE
fat I-PHE
deposition I-PHE
( O
total O
amount O

-DOCSTART- O


Liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
determination O
of O
arsenic O
species O
in O
dog O
plasma O
and O
its O
application O
to O
a O
pharmacokinetic O
study O
after O
oral O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
. O

-DOCSTART- O


Human B-PHE
Immunodeficiency I-PHE
Virus I-PHE
Infection I-PHE

-DOCSTART- O


Spasticity B-PHE

-DOCSTART- O


Digestant O
. O

-DOCSTART- O


To O
purge O
pathogenic B-PHE
fire I-PHE
and O
lessen O
virulence O
of O
any O
pathogenic O
organism O
. O

-DOCSTART- O


delirium B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
dampness B-PHE
, O
promote O
blood B-PHE
circulation I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
: O
For O
jaundice B-PHE
of O
dampness-heat B-PHE
type O
and O
abdominal B-PHE
mass I-PHE
. O

Recently O
used O
for O
acute B-PHE
and I-PHE
chronic I-PHE
hepatitis I-PHE
, O
cirrhosis B-PHE
, O
cholecysitis B-PHE
, O
etc O
. O
, O
also O
for O
diarrhea B-PHE
, O
desentery B-PHE
and O
leucorrhagia B-PHE
of O
dampness-heat B-PHE
type O
, O
ough O
of O
lung-heat B-PHE
type O
, O
sorethroat B-PHE
, O
silicosis B-PHE
, O
and O
tumors B-PHE
such O
as O
lung B-PHE
cancer I-PHE
, O
nasopharyngeal B-PHE
carcinoma I-PHE
, O
chorionic B-PHE
epithelioma I-PHE
, O
tumor B-PHE
of O
the O
digestive O
tract O
, O
etc O
. O
2 O
To O
stop O
bleeding B-PHE
. O

For O
hematemesis B-PHE
, O
hemafecia B-PHE
, O
hemoptysis B-PHE
and O
epistaxis B-PHE
. O

External O
use O
for O
bleeding B-PHE
after O
trauma B-PHE
and O
after O
separation O
of O
umbilical O
cord O
in O
infants O
. O

-DOCSTART- O


polydipsia B-PHE
due O
to O
high B-PHE
fever I-PHE

-DOCSTART- O


To O
nourish O
vital O
energy O
, O
strengthen O
spleen B-PHE
, O
invigorate O
the O
heart B-PHE
and O
nourish O
blood B-PHE
. O

-DOCSTART- O


To O
induce O
diaphoresis B-PHE
, O
to O
ease O
the O
mind B-PHE
, O
and O
to O
relieve O
fever B-PHE
. O

-DOCSTART- O


The O
coldness B-PHE
of O
hands O
and O
feet O

-DOCSTART- O


Thioridazine O
blocks O
postsynaptic O
mesolimbic O
dopaminergic O
D1 O
and O
D2 O
receptors O
in O
the O
brain B-PHE
; O
blocks O
alpha-adrenergic O
effect O
, O
depresses O
the O
release O
of O
hypothalamic O
and O
hypophyseal O
hormones O
and O
is O
believed O
to O
depress O
the O
reticular B-PHE
activating I-PHE
system I-PHE
thus O
affecting O
basal O
metabolism B-PHE
, O
body B-PHE
temperature I-PHE
, O
wakefulness B-PHE
, O
vasomotor B-PHE
tone I-PHE
, O
and O
emesis B-PHE
. O

-DOCSTART- O


Used O
for O
the O
treatment O
of O
individual O
patients O
with O
certain O
filarial B-PHE
diseases I-PHE
including O
tropical B-PHE
pulmonary I-PHE
eosinophilia I-PHE
, O
loiasis B-PHE
, O
and O
lymphatic B-PHE
filariasis I-PHE
caused O
by O
infection O
with O
Wuchereria B-PHE
bancrofti I-PHE
, O
Brugia B-PHE
malayi I-PHE
, O
or O
Brugia B-PHE
timori I-PHE
. O

-DOCSTART- O


arrest O
vomiting B-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Strength O
and O
power O
, O
Others O
, O
Protective O
immunity B-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Metabolism B-PHE
, O
Man O

-DOCSTART- O


Hyperkalemia B-PHE

-DOCSTART- O


diarrhea B-PHE

dysentery B-PHE

-DOCSTART- O


1 O
Its O
decoction O
can O
lower O
blood B-PHE
pressure I-PHE

2 O
. O
Inhibiting O
the O
growth B-PHE
of I-PHE
(a)-streptococcus I-PHE

3 O
. O
Shortening O
the O
bleeding B-PHE
time O
. O

4 O
. O
Anti-inflammatory B-PHE

5 O
. O
Diuretic O
. O

-DOCSTART- O


To O
nourish O
yin O
; O
To O
relieve O
fire O
; O
To O
smooth O
heart B-PHE
and O
kidney B-PHE

-DOCSTART- O


To O
lessen O
contracture B-PHE
, O
regulate O
stomach B-PHE
function I-PHE
, O
and O
dispel O
contracture B-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Hypersensitivity B-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


Woman O
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Kidney O
Transplantation O

-DOCSTART- O


Linezolid O
selectively O
inhibits O
bacterial B-PHE
protein I-PHE
synthesis I-PHE
through O
binding O
to O
sites O
on O
the O
bacterial O
ribosome O
and O
prevents O
the O
formation B-PHE
of I-PHE
a I-PHE
functional I-PHE
70S-initiation I-PHE
complex I-PHE
. O

Isoniazid O
appears O
to O
block O
the O
synthesis B-PHE
of I-PHE
mycolic I-PHE
acids I-PHE
, O
major O
components O
of O
the O
mycobacterial O
cell O
wall O
. O

This O
agent O
is O
only O
active O
against O
actively O
growing O
mycobacteria B-PHE
because O
, O
as O
a O
pro-drug O
, O
it O
requires O
activation O
in O
susceptible O
mycobacterial O
species O
. O

Rifampin O
acts O
via O
the O
inhibition O
of O
DNA-dependent B-PHE
RNA I-PHE
polymerase I-PHE
, O
leading O
to O
a O
suppression B-PHE
of I-PHE
RNA I-PHE
synthesis I-PHE
and O
cell B-PHE
death I-PHE
. O

-DOCSTART- O


For O
tonifying O
weakness B-PHE
. O

-DOCSTART- O


To O
break O
qi O
and O
move O
phlegm B-PHE
, O
harmonize O
stomach B-PHE
and O
disperse O
accumulation B-PHE
. O

-DOCSTART- O


vomiting B-PHE
due O
to O
dysphagia B-PHE

-DOCSTART- O


Sarcoma B-PHE

-DOCSTART- O


morbid B-PHE
leukorrhea I-PHE
; O

gynecological B-PHE
diseases I-PHE
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O


Sermorelin O
binds O
to O
the O
growth O
hormone O
releasing O
hormone O
receptor O
and O
mimics O
native O
GRF O
in O
its O
ability O
to O
stimulate O
growth B-PHE
hormone I-PHE
secretion I-PHE
. O

-DOCSTART- O


1 O
Broad-spectrum O
antibacteric O
. O
Its O
antibacterial O
components O
are O
para-hydroxyphenylacetic O
acid O
, O
salicylic O
acid O
, O
vanillic O
acid O
, O
pyromucic O
acid O
and O
hydroquinone O
. O

2 O
. O
Its O
1/1800-1/1600 O
decoction O
inhibits O
the O
growth B-PHE
of I-PHE
leptospira I-PHE
. O

3 O
. O
Anti-trichomonas B-PHE
vaginalis I-PHE
in O
vitro O
. O

4 O
. O
Its O
component O
, O
senecionine O
, O
is O
anticarcinogenic O
on O
Walker O
sarcoma256 O
. O

-DOCSTART- O


heavy B-PHE
sensation I-PHE
of O
the O
body O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
HIV B-PHE
infection I-PHE
. O

-DOCSTART- O


dysenteric B-PHE
disorder I-PHE
; O
dysentery B-PHE

-DOCSTART- O


Propranolol O
competes O
with O
sympathomimetic B-PHE
neurotransmitters I-PHE
such O
as O
catecholamines O
for O
binding O
at O
beta(1)-adrenergic O
receptors O
in O
the O
heart O
, O
inhibiting O
sympathetic O
stimulation O
. O

Hydrochlorothiazide O
, O
a O
thiazide O
diuretic O
, O
inhibits O
water B-PHE
reabsorption I-PHE
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-PHE
symporter I-PHE
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
0.05 O
of O
total O
sodium B-PHE
reabsorption I-PHE
. O

-DOCSTART- O


Adult B-PHE
Erythroleukemia I-PHE

-DOCSTART- O


Ocular B-PHE
Hypertension I-PHE

-DOCSTART- O


Fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
class O
, O
and O
blocks O
the O
reuptake B-PHE
of I-PHE
serotonin I-PHE
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-PHE
of I-PHE
serotonin I-PHE
on O
5HT<sub>1A</sub> O
autoreceptors O
. O

Quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism O
at O
D2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5HT2A O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O


To O
remove O
blood B-PHE
stasis I-PHE
, O
promote O
the O
subsidence O
of O
swelling B-PHE
, O
relieve O
pain B-PHE
and O
arrest O
bleeding B-PHE
. O

-DOCSTART- O


Treatment O
of O
anorexia B-PHE
, O
lassitude B-PHE
and O
loose B-PHE
stools I-PHE
in O
deficiency B-PHE
syndrome I-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
hysteria O
in O
women O
. O

-DOCSTART- O


Metastatic B-PHE
Cancer I-PHE

-DOCSTART- O


Bone O
metabolism/density B-PHE
, O
Intelligence O
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Overall O
CVD B-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


1 O
Inhibiting O
experimental O
arthritis B-PHE
in O
mice O
and O
decreasing O
capillary B-PHE
permeability I-PHE
. O

2 O
. O
Anti-allergric B-PHE
. O

3 O
. O
Inducing O
transient O
hypotensive B-PHE
effect I-PHE
. O

-DOCSTART- O


Type B-PHE
2 I-PHE
Diabetes I-PHE
Mellitus I-PHE

-DOCSTART- O


expel O
worm B-PHE

-DOCSTART- O


An O
inhibition O
of O
DNA B-PHE
polymerase I-PHE
. O

-DOCSTART- O


For O
the O
treatment O
of O
documented O
ventricular B-PHE
arrhythmias I-PHE
, O
such O
as O
sustained O
ventricular B-PHE
tachycardia I-PHE
, O
that O
, O
in O
the O
judgment O
of O
the O
physician O
, O
are O
life-threatening O
. O

-DOCSTART- O


bleeding B-PHE
in O
the O
hemorrhoids O

-DOCSTART- O


Familial B-PHE
Adenomatous I-PHE
Polyposis I-PHE

-DOCSTART- O


furuncle B-PHE
; O
boil B-PHE

-DOCSTART- O


disperse O
goiter B-PHE
core O

-DOCSTART- O


Kworeum O
headache B-PHE
caused O
by O
disorders O
of O
Kworeum O
channel O
and O
aching B-PHE
along O
the O
Kworeum O
channel O
over O
the O
head O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Lipid O
profile O
, O
Quality O
of O
life O
, O
Overall O
CVD B-PHE
, O
Others O

-DOCSTART- O


Promoting O
phagocytosis B-PHE
of I-PHE
macrophage I-PHE
. O

-DOCSTART- O


fullness B-PHE
of O
chest O
and O
abdomen O
. O

Indigestion B-PHE
caused O
by O
that O
cold O
pathogen B-PHE
of O
the O
middle-Cho O
disturb O
function O
of O
stomach B-PHE
and O
spleen B-PHE
. O
Feel O
tiring B-PHE
and O
heavy O
, O
pain B-PHE
in O
joint O
due O
to O
damp O
pathogen B-PHE

-DOCSTART- O


Croup B-PHE

-DOCSTART- O


Interferon O
alpha O
binds O
to O
type O
I O
interferon O
receptors O
which O
activate O
two O
Jak1 O
and O
Tyk2 O
and O
activate O
multiple O
dowmstream O
immunomodulatory B-PHE
and O
antiviral O
proteins O
. O

Ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine B-PHE
monophosphate I-PHE
dehydrogenase I-PHE
, O
viral B-PHE
RNA I-PHE
polymerase I-PHE
and O
mRNA B-PHE
guanylyltransferase I-PHE
( O
viral O
) O
and O
can O
be O
incorporated O
into O
RNA O
in O
RNA O
viral O
species O
. O

Telaprevir O
is O
an O
inhibitor O
of O
the O
HCV B-PHE
NS3/4A I-PHE
serine I-PHE
protease I-PHE
, O
necessary O
for O
the O
proteolytic O
cleavage O
of O
the O
HCV O
encoded O
polyprotein O
into O
mature O
forms O
of O
the O
NS4A O
, O
NS4B O
, O
NS5A O
and O
NS5B O
proteins O
and O
essential O
for O
viral O
replication O
. O

-DOCSTART- O


a O
disease O
with O
dry B-PHE
cough I-PHE
with O
little O
amount O
of O
phlegm B-PHE

-DOCSTART- O


Tsumura O
Hachimijiogan O
, O
7.5 O
g O
a O
day O
, O
was O
administered O
to O
30 O
patients O
with O
benign B-PHE
prostatic I-PHE
hypertrophy I-PHE
( O
BPH B-PHE
) O
. O

Clinical O
effects O
were O
estimated O
based O
on O
subjective O
symptoms O
and O
objective O
findings O
obtained O
by O
uroflowmetry O
. O

Twenty O
patients O
( O
0.667 O
) O
showed O
improvement O
of O
subjective O
symptoms O
and O
14 O
patients O
( O
0.467 O
) O
showed O
good O
response O
in O
uroflowmetry O
. O

An O
improvement O
of O
overall O
clinical O
efficacy O
was O
observed O
in O
21 O
patients O
( O
0.7 O
) O
. O

These O
results O
were O
better O
than O
those O
obtained O
with O
5 O
g O
a O
day O
doses O
of O
Tsumura O
Hachimijiogan O
. O

No O
significant O
relation O
between O
the O
Sho O
in O
Chinese O
medicine O
and O
the O
clinical O
effects O
of O
Hachimijiogan O
was O
detected O
. O

No O
side O
effects O
or O
abnormal O
laboratory O
data O
were O
found O
in O
any O
of O
these O
30 O
patients O
. O

-DOCSTART- O


Dental B-PHE
Plaque I-PHE

-DOCSTART- O


Phlegm B-PHE
stagnation I-PHE
in O
chest O
and O
diaphragm O
, O
glomus B-PHE
in I-PHE
chest I-PHE
, O
distention B-PHE
in I-PHE
rib-side I-PHE
, O
food B-PHE
accumulation I-PHE
, O
retching B-PHE
counterflow I-PHE
. O

-DOCSTART- O


Its O
decoction O
in O
1:3000-1:200 O
concentration B-PHE
inhibits O
the O
growth O
of O
influenzae B-PHE
virus I-PHE
and O
Bacillus B-PHE
dysenteriae I-PHE
in O
vitr O
. O

Promoting O
the O
secretion O
of O
gastric B-PHE
juice I-PHE
and O
enhancing O
the O
digestive B-PHE
function I-PHE
, O
also O
as O
an O
astringent B-PHE
. O

-DOCSTART- O


Hyperlipidemia B-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE

-DOCSTART- O


all O
kinds O
of O
pain B-PHE
due O
to O
disorder O
of O
Gi O

-DOCSTART- O


major O
cold B-PHE
and O
heat B-PHE

-DOCSTART- O


pain B-PHE
in O
throat O
and O
hypochondrium O

-DOCSTART- O


promote O
the O
small B-PHE
intestine I-PHE

-DOCSTART- O


edema B-PHE
edema B-PHE
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-PHE
of I-PHE
the I-PHE
lung I-PHE
, I-PHE
spleen I-PHE
and I-PHE
kidney I-PHE
. O

-DOCSTART- O


Postpartum B-PHE
Depressive I-PHE
Mood I-PHE

-DOCSTART- O


muscular B-PHE
twitching I-PHE
and O
cramp B-PHE
; O

twitching B-PHE
of I-PHE
muscles I-PHE

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
psoriasis B-PHE
and O
psoriatic B-PHE
disorders I-PHE
. O

-DOCSTART- O


HIV B-PHE
Infections I-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
Infection I-PHE

-DOCSTART- O


Cough B-PHE
in O
phthisis B-PHE
, O
dyspnea B-PHE
in O
the O
aged O
, O
depressed B-PHE
sensation I-PHE
and O
stuffiness B-PHE
in O
the O
chest O
. O

-DOCSTART- O


bald B-PHE
white I-PHE
scalp I-PHE
sore I-PHE
; O
tinea B-PHE
alba I-PHE
; O
white B-PHE
ringworm I-PHE

-DOCSTART- O


Since O
it O
is O
not O
degraded O
in O
the O
neuromuscular O
junction O
, O
the O
depolarized O
membrance O
remains O
depolarized O
and O
unresponsive O
to O
any O
other O
impulse O
, O
causing O
muscle B-PHE
paralysis I-PHE
. O

-DOCSTART- O


frequent B-PHE
urination I-PHE

-DOCSTART- O


Trachoma B-PHE

-DOCSTART- O


Ticarcillin's O
antibiotic O
properties O
arise O
from O
its O
ability O
to O
prevent O
cross-linking O
of O
peptidoglycan O
during O
cell B-PHE
wall I-PHE
synthesis I-PHE
when O
the O
bacteria O
tries O
to O
divide O
, O
causing O
death B-PHE
. O

-DOCSTART- O


The O
symptom O
of O
disease O
where O
the O
skin B-PHE
turns I-PHE
yellow I-PHE
because O
dampness O
and O
heat O
tangle O
together O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Mood O
, O
Quality O
of O
life O
, O
Inflammation B-PHE
, O
Other B-PHE
system I-PHE
health I-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


disease O
due O
to O
wind-dampness B-PHE
; O
rheumatism B-PHE

-DOCSTART- O


This O
is O
kinds O
of O
consciousness B-PHE
disorder I-PHE
with O
a O
light O
stupor B-PHE
. O

It O
is O
sleeping O
at O
nights O
and O
days O
, O
and O
responding O
with O
opening O
an O
eye O
. O

It O
is O
cause O
by O
palsy B-PHE
. O

-DOCSTART- O


Prostate B-PHE
Cancer I-PHE

-DOCSTART- O


Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
has O
been O
used O
to O
cure O
neuropsychological B-PHE
disorders I-PHE
. O

In O
the O
present O
study O
, O
the O
effect O
of O
Yokukansan O
on O
social B-PHE
isolation I-PHE
- I-PHE
induced I-PHE
aggressive I-PHE
behavior I-PHE
was O
examined O
in O
zinc-deficient O
mice O
, O
which O
were O
fed O
a O
zinc-deficient O
diet O
and O
a O
drinking O
water O
containing O
Yokukansan O
for O
2 O
weeks O
. O

In O
the O
resident-intruder O
test O
, O
the O
rate O
of O
mice O
that O
exhibited O
aggressive B-PHE
behavior I-PHE
in O
zinc-deficient O
mice O
, O
which O
was O
significantly O
higher O
than O
that O
in O
the O
control O
mice O
, O
was O
significantly O
decreased O
by O
administration O
of O
Yokukansan O
. O

The O
basal O
level O
of O
serum B-PHE
glucocorticoid I-PHE
, O
which O
was O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
was O
lowered O
by O
administration O
of O
Yokukansan O
. O

On O
the O
other O
hand O
, O
serum B-PHE
glucocorticoid I-PHE
levels I-PHE
after O
the O
resident-intruder O
test O
were O
almost O
the O
same O
between O
the O
control O
and O
zinc-deficient O
mice O
. O

However O
, O
administration O
of O
Yokukansan O
to O
zinc-deficient O
mice O
significantly O
increased O
serum B-PHE
glucocorticoid I-PHE
level I-PHE
after O
the O
resident-intruder O
test O
and O
the O
significant O
difference O
in O
the O
rate O
of O
serum B-PHE
corticosterone I-PHE
level I-PHE
after O
the O
test O
to O
the O
basal O
level O
between O
the O
control O
and O
zinc-deficient O
mice O
was O
abolished O
. O

Dietary O
zinc O
deficiency O
increases O
the O
basal O
levels B-PHE
of I-PHE
serum I-PHE
glucocorticoid I-PHE
, O
while O
may O
insufficiently O
increase O
serum B-PHE
glucocorticoid I-PHE
levels I-PHE
in O
the O
resident-intruder O
test O
. O

The O
concentrations O
of O
glutamate B-PHE
and O
GABA B-PHE
( O
y-aminobutyric B-PHE
acid I-PHE
) O
in O
the O
brain O
were O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
while O
Yokukansan O
ameliorated O
the O
significant O
increases O
. O

These O
results O
indicate O
that O
Yokukansan O
ameliorates O
social B-PHE
isolation-induced I-PHE
aggressive I-PHE
behavior I-PHE
of O
zinc-deficient O
mice O
, O
probably O
via O
amelioration O
of O
abnormal B-PHE
glucocorticoid I-PHE
secretion I-PHE
. O

The O
ameliorative O
effect O
seems O
to O
be O
linked O
to O
the O
modification O
of O
glutamatergic B-PHE
neuron I-PHE
activity I-PHE
after O
administration O
of O
Yokukansan O
. O

-DOCSTART- O


dissipate O
stasis B-PHE

-DOCSTART- O


Nephrotic B-PHE
Syndrome I-PHE

-DOCSTART- O


retention B-PHE
or I-PHE
stagnancy I-PHE
of I-PHE
undigested I-PHE
food I-PHE

-DOCSTART- O


Eldery O
, O
Others O

-DOCSTART- O


Chronic B-PHE
ulcers I-PHE
. O
Dragon's O
blood O
( O
Xuejie O
) O
is O
used O
with O
Frankincense O
( O
Ruxiang O
) O
and O
Myrrh O
( O
Moyao O
) O
for O
external O
use O
. O

-DOCSTART- O


Clarithromycin O
is O
first O
metabolized O
to O
14-OH O
clarithromycin O
, O
which O
is O
active O
and O
works O
synergistically O
with O
its O
parent O
compound O
. O

-DOCSTART- O


The O
target O
of O
LX6171 O
is O
a O
membrane B-PHE
protein I-PHE
that O
is O
expressed O
exclusively O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
. O

Its O
activity O
is O
associated O
with O
synaptic B-PHE
vesicles I-PHE
and O
presynaptic B-PHE
membranes I-PHE
. O

-DOCSTART- O


To O
relieve O
exterior B-PHE
syndrome I-PHE
. O

-DOCSTART- O


invigorate O
blood B-PHE
and O
regulate O
menstruation B-PHE

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Mood O

-DOCSTART- O


Imipenem O
acts O
as O
an O
antimicrobial O
through O
the O
inhibition O
of O
cell B-PHE
wall I-PHE
synthesis I-PHE
which O
leads O
to O
rapid O
cell B-PHE
lysis I-PHE
and O
death O
without O
filament B-PHE
formation I-PHE
. O

Cilastatin O
helps O
imipenem O
work O
more O
effectively O
by O
preventing O
the O
breakdown O
of O
the O
antibiotic O
in O
the O
kidneys O
. O

-DOCSTART- O


aversion B-PHE
to I-PHE
heat I-PHE
during O
fever B-PHE

-DOCSTART- O


resolve O
phlegm B-PHE
and O
relieve O
cough B-PHE

-DOCSTART- O


Delta1-dihydrotestosterone O
binds O
to O
the O
androgen O
receptor O
, O
a O
nuclear O
receptor O
which O
binds O
the O
androgenic B-PHE
hormones I-PHE
testosterone I-PHE
and O
dihydrotestosterone B-PHE
. O

-DOCSTART- O


Used O
as O
an O
analgesic O
adjunct O
in O
anesthesia O
and O
as O
a O
primary O
anesthetic O
drug O
in O
procedures O
requiring O
assisted O
ventilation O
and O
in O
the O
relief O
of O
pain B-PHE
. O

-DOCSTART- O


diabetics B-PHE
due O
to O
interior O
heat B-PHE

-DOCSTART- O


Pain B-PHE
in O
joints O
due O
to O
rheumatalgia B-PHE
, O
aching B-PHE
in O
lumbus O
and O
legs O
, O
kidney B-PHE
vacuity I-PHE
and O
edema B-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
knocks O
and O
falls O
, O
fracture O
, O
pain O
in O
stomach O
duct O
, O
blood B-PHE
ejection I-PHE
, O
spontaneous O
external B-PHE
bleeding I-PHE
, O
malaria B-PHE
, O
lacquer O
sore B-PHE
, O
medullitis B-PHE
, O
deep O
pus B-PHE
ulcer I-PHE
. O

-DOCSTART- O


Used O
to O
prolong O
the O
time O
to O
recurrence O
of O
paroxysmal B-PHE
atrial I-PHE
fibrillation/flutter I-PHE
( O
PAF B-PHE
) O
associated O
with O
disabling O
symptoms O
in O
patients O
without O
structural B-PHE
heart I-PHE
disease I-PHE
. O

Also O
used O
for O
the O
treatment O
of O
life-threatening O
documented O
ventricular B-PHE
arrhythmias I-PHE
, O
such O
as O
sustained B-PHE
ventricular I-PHE
tachycardia I-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
to O
remove O
damp B-PHE
, O
to O
clear O
the O
stuffed B-PHE
nose I-PHE
, O
to O
relieve O
pain B-PHE
, O
and O
to O
promote O
the O
subsidence O
of O
swelling B-PHE
and O
drainage O
of O
pus B-PHE
. O

-DOCSTART- O


To O
dissipate O
wind-cold B-PHE
, O
quicken O
network O
vessels B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Liver B-PHE
, O
Liver B-PHE
health I-PHE

-DOCSTART- O


expel O
malign B-PHE
blood I-PHE

-DOCSTART- O


This O
is O
having O
a O
lot O
of O
phlegm B-PHE
due O
to O
carbuncle B-PHE
and O
cellulites B-PHE
. O

-DOCSTART- O


Doxapram O
produces O
respiratory B-PHE
stimulation I-PHE
mediated O
through O
the O
peripheral O
carotid O
chemoreceptors O
. O

It O
is O
thought O
to O
stimulate O
the O
carotid B-PHE
body I-PHE
by O
inhibiting O
certain B-PHE
potassium I-PHE
channels I-PHE
. O

-DOCSTART- O


Injury B-PHE
of I-PHE
Bladder I-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Monoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


move O
drug O
effect O

-DOCSTART- O


Hypertension B-PHE

-DOCSTART- O


Eye B-PHE
, O
Blood B-PHE
pressure I-PHE
, O
Lipid O
profile O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Inflammation B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
absorption B-PHE
, O
UV O
protection O
, O
motility B-PHE
, O
Others O
, O
Urinary B-PHE
systems I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Overall O
CVD B-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Eye B-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


Dextromethorphan O
is O
an O
opioid-like O
drug O
that O
binds O
to O
and O
acts O
as O
antagonist O
to O
the O
NMDA O
glutamatergic O
receptor O
, O
and O
targets O
the O
serotonin O
reuptake O
pump O
. O

-DOCSTART- O


hematemesis B-PHE
and O
epistaxis B-PHE

-DOCSTART- O


clear O
the O
liver B-PHE

-DOCSTART- O


Multiple B-PHE
Sclerosis I-PHE

-DOCSTART- O


Dihydroergotamine O
is O
a O
5-HT1D O
receptor O
agonists O
used O
for O
migraine B-PHE
, O
activation O
of O
5-HT1D O
receptors O
located O
on O
intracranial O
blood O
vessels O
, O
leads O
to O
vasoconstriction B-PHE
; O
activation O
of O
5-HT1D O
receptors O
on O
sensory O
nerve O
endings O
of O
the O
trigeminal B-PHE
system I-PHE
results O
in O
the O
inhibition O
of O
pro-inflammatory B-PHE
neuropeptide I-PHE
release I-PHE
. O

-DOCSTART- O


normalize O
Gi O
( O
Qi O
) O
and O
relieve O
pain B-PHE

-DOCSTART- O


1 O
Applicable O
to O
summer B-PHE
fever I-PHE
in O
children O
manifested O
as O
prolonged B-PHE
fever I-PHE
, O
restlessness B-PHE
, O
thirst B-PHE
, O
fatigue B-PHE
, O
red B-PHE
tongue I-PHE
with O
little O
fur O
, O
hollow O
and O
rapid B-PHE
pulse I-PHE
, O
which O
is O
attributed O
to O
comsumption O
of O
both O
vital B-PHE
energy I-PHE
and O
body B-PHE
fluid I-PHE
by O
summer-heat O
evil O
. O

In O
this O
case O
, O

-DOCSTART- O


menstrual B-PHE
irregularities I-PHE
; O
menstrual B-PHE
disorders I-PHE
; O
abnormal B-PHE
menstruation I-PHE

-DOCSTART- O


The O
bactericidal O
action O
of O
lomefloxacin O
results O
from O
interference O
with O
the O
activity B-PHE
of I-PHE
the I-PHE
bacterial I-PHE
enzymes I-PHE
DNA I-PHE
gyrase I-PHE
and O
topoisomerase B-PHE
IV I-PHE
, O
which O
are O
needed O
for O
the O
transcription O
and O
replication O
of O
bacterial O
DNA O
, O
as O
a O
result O
of O
inhibition O
of O
DNA B-PHE
replication I-PHE
and I-PHE
transcription I-PHE
. O

Furosemide O
blocks O
the O
Na-K-Cl B-PHE
cotransporter I-PHE
( O
NKCC B-PHE
) O
in O
the O
luminal O
membrane O
of O
the O
thick O
ascending O
limb O
of O
the O
loop O
of O
Henle O
in O
the O
kidney O
, O
by O
binding O
to O
the O
Cl-binding O
site O
located O
in O
the O
cotransporter's O
transmembrane O
domain O
, O
thereby O
inhibiting O
reabsorption B-PHE
of I-PHE
sodium I-PHE
, O
chloride B-PHE
, O
potassium B-PHE
ions I-PHE
and O
water O
. O

This O
agent O
reduces O
plasma B-PHE
and O
extracellular B-PHE
fluid I-PHE
volume I-PHE
resulting O
in O
decreased O
blood B-PHE
pressure I-PHE
and O
cardiac B-PHE
output I-PHE
. O

-DOCSTART- O


Methdilazine O
binds O
to O
the O
histamine O
H O
1 O
receptor O
. O

-DOCSTART- O


ecchymosis B-PHE

-DOCSTART- O


The O
bactericidal O
action O
of O
dalbavancin O
results O
primarily O
from O
inhibition O
of O
cell-wall B-PHE
biosynthesis I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Quality O
of O
life O
, O
Endocrine B-PHE
system I-PHE
, O
Others O
, O
Memory O
, O
Protective O
immunity B-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


aphasia B-PHE
with O
stiffness B-PHE
of I-PHE
the I-PHE
tongue I-PHE

-DOCSTART- O


Relaxing O
the O
smooth B-PHE
muscles I-PHE
of I-PHE
blood I-PHE
vessels I-PHE
and O
stimulating O
those O
of O
uterus B-PHE
, O
urinary B-PHE
bladder I-PHE
bronchus B-PHE
and O
gastrointestines B-PHE
. O

-DOCSTART- O


slight O
thirst B-PHE
and O
redness B-PHE
of I-PHE
the I-PHE
face I-PHE

-DOCSTART- O


For O
induction O
and O
maintenance O
in O
the O
treatment O
of O
cytomegalovirus B-PHE
( O
CMV B-PHE
) O
retinitis B-PHE
in O
immunocompromised O
patients O
, O
including O
patients O
with O
acquired B-PHE
immunodeficiency I-PHE
syndrome I-PHE
( O
AIDS B-PHE
) O
. O

Also O
used O
in O
the O
treatment O
of O
severe O
cytomegalovirus B-PHE
( O
CMV B-PHE
) O
disease B-PHE
, O
including O
CMV B-PHE
pneumonia I-PHE
, O
CMV B-PHE
gastrointestinal I-PHE
disease I-PHE
, O
and O
disseminated O
CMV B-PHE
infections I-PHE
, O
in O
immunocompromised O
patients O
. O

-DOCSTART- O


Non B-PHE
Small I-PHE
Cell I-PHE
Lung I-PHE
Carcinoma I-PHE

-DOCSTART- O


numbness B-PHE
of O
the O
limbs O

-DOCSTART- O


a O
symptom O
of O
pruritis B-PHE
due O
to O
smallpox B-PHE

-DOCSTART- O


night B-PHE
sweat I-PHE
; O
night B-PHE
sweating I-PHE
spontaneous B-PHE
sweating I-PHE
during O
asleep O
and O
no B-PHE
sweating I-PHE
while O
awake O
, O
chiefly O
caused O
by O
deficiency B-PHE
of I-PHE
vital I-PHE
essence I-PHE
and O
presence B-PHE
of I-PHE
internal I-PHE
heat I-PHE
. O

-DOCSTART- O


Acute B-PHE
Gastroenteritis I-PHE
in O
Adult O
Travelers O

-DOCSTART- O


Pain B-PHE
in O
lumbus O
and O
legs O
. O

-DOCSTART- O


Urgency B-PHE
Incontinence I-PHE

-DOCSTART- O


stop O
sweating B-PHE

-DOCSTART- O


Purging O

-DOCSTART- O


Wind-damp B-PHE
bone I-PHE
pain I-PHE
, O
knocks O
and O
falls O
, O
bleeding B-PHE
due O
to O
external O
injury B-PHE
, O
child O
gan O
accumulation O
. O

-DOCSTART- O


dry B-PHE
heat I-PHE
and O
cough B-PHE
with O
much O
expectoration B-PHE

-DOCSTART- O


cool O
the O
blood B-PHE

-DOCSTART- O


Keishibukuryogan O
, O
one O
of O
the O
traditional O
herbal O
formulations O
, O
is O
used O
clinically O
to O
improve O
blood B-PHE
circulation I-PHE
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
keishibukuryogan O
on O
glucose B-PHE
and I-PHE
lipids I-PHE
metabolism I-PHE
in O
Otsuka O
Long-Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
, O
an O
animal O
model O
of O
type B-PHE
2 I-PHE
diabetes I-PHE
. O

Forty-five-week-old O
male O
OLETF O
rats O
were O
divided O
into O
three O
groups O
: O
diabetic O
control O
rats O
given O
a O
standard O
chow O
; O
diabetic O
rats O
given O
keishibukuryogan O
( O
0.03 O
, O
w/w O
in O
chow O
) O
; O
diabetic O
rats O
given O
pioglitazone O
( O
0.0001 O
, O
w/w O
in O
chow O
) O
. O

Oral O
administration O
of O
keishibukuryogan O
produced O
significant O
improvement O
against O
impaired B-PHE
glucose I-PHE
tolerance I-PHE
. O

On O
the O
other O
hand O
, O
fasting O
serum B-PHE
glucose I-PHE
and I-PHE
insulin I-PHE
levels I-PHE
, O
and O
the O
homeostasis B-PHE
index I-PHE
of O
insulin B-PHE
resistance I-PHE
did O
not O
change O
by O
keishibukuryogan O
treatment O
. O

Against O
lipid O
parameters O
, O
keishibukuryogan O
significantly O
lowered O
serum B-PHE
total I-PHE
cholesterol I-PHE
and O
triglyceride B-PHE
levels I-PHE
, O
and O
the O
hepatic B-PHE
total I-PHE
cholesterol I-PHE
level I-PHE
. O

Keishibukuryogan O
treatment O
also O
significantly O
reduced O
the O
serum B-PHE
leptin I-PHE
level I-PHE
, O
but O
it O
had O
no O
effect O
on O
the O
serum B-PHE
adiponectin I-PHE
level I-PHE
. O

Additionally O
, O
keishibukuryogan O
showed O
significant O
effects O
on O
epididymal B-PHE
adipose I-PHE
tissue I-PHE
by O
decreasing O
the O
size O
of O
fat B-PHE
cells I-PHE
and O
on O
skeletal B-PHE
muscle I-PHE
by O
reducing O
TNF-alpha B-PHE
protein I-PHE
content I-PHE
. O

From O
these O
results O
, O
it O
was O
suggested O
that O
keishibukuryogan O
exerts O
beneficial O
effects O
on O
the O
features O
associated O
with O
type B-PHE
2 I-PHE
diabetes I-PHE
. O

-DOCSTART- O


To O
cool O
blood B-PHE
and O
stanch O
bleeding B-PHE
, O
quicken O
blood B-PHE
and O
transform O
stasis O
. O

-DOCSTART- O


Bofutsushosan O
( O
BOF O
) O
, O
a O
traditional O
Chinese O
formulation O
( O
Kampo O
formulation O
in O
Japanese O
) O
, O
is O
widely O
used O
for O
patients O
with O
obesity B-PHE
and O
hyperlipidemia B-PHE
resulting O
from O
long-term O
inappropriate O
lifestyles O
. O

Since O
atherosclerosis B-PHE
, O
a O
lifestyle-related B-PHE
disease I-PHE
, O
is O
accompanied O
by O
an O
abnormal O
accumulation O
of O
vascular B-PHE
smooth I-PHE
muscle I-PHE
cells I-PHE
( O
VSMCs B-PHE
) O
in O
the O
intimal O
area O
of O
the O
artery O
, O
we O
investigated O
the O
preventive O
effect O
of O
BOF O
on O
intimal O
thickening O
. O

Oral O
administration O
of O
BOF O
extracts O
3 O
d O
before O
and O
7 O
d O
after O
balloon O
endothelial O
denudation O
dose O
dependently O
suppressed O
the O
intimal O
thickening O
and O
proliferation O
of O
VSMCs B-PHE
in O
the O
intimal O
area O
in O
rat O
carotid O
arteries O
. O

This O
model O
has O
a O
similar O
pathologic O
process O
to O
atherosclerosis B-PHE
and O
is O
considered O
to O
be O
an O
accelerated O
atherosclerosis B-PHE
model O
. O

BOF O
extract O
also O
dose O
dependently O
inhibited O
the O
migration O
of O
cultured O
VSMCs B-PHE
. O

BOF O
extract O
suppressed O
serum B-PHE
lipid I-PHE
levels I-PHE
, O
which O
are O
a O
major O
risk O
factor O
for O
atherosclerosis B-PHE
. O

These O
findings O
clarified O
the O
usefulness O
of O
BOF O
in O
cardiovascular O
risk-reduction O
therapy O
. O

-DOCSTART- O


Treatment O
of O
headache B-PHE
, O
particularly O
pain B-PHE
in O
the O
forehead O
, O
and O
stuffed B-PHE
nose I-PHE
due O
to O
colds B-PHE
, O
sinusitis B-PHE
, O
toothache B-PHE
, O
excessive O
leukorrhea B-PHE
, O
swelling B-PHE
and O
pain B-PHE
of O
sores B-PHE
and O
wounds B-PHE
. O

-DOCSTART- O


cool O
the O
blood B-PHE
and O
move O
the O
blood B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
move O
water O
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


amenorrhea B-PHE
; O
menstrual B-PHE
block I-PHE
absence I-PHE
or O
suppression B-PHE
of I-PHE
menstruation I-PHE
. O

-DOCSTART- O


distribution O
) O
, O
absorption B-PHE
, O
Endurance B-PHE
, O
Body B-PHE
weight I-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Mimmuietabolic B-PHE
rate I-PHE
/ I-PHE
energy I-PHE
expenditure I-PHE
, O
motility B-PHE
, O
Others O

-DOCSTART- O


hematemesis B-PHE
; O
blood B-PHE
vomiting I-PHE
; O
spitting B-PHE
blood I-PHE
; O
blood B-PHE
vomiting I-PHE

-DOCSTART- O


harmonize O
blood B-PHE
vessel I-PHE

-DOCSTART- O


To O
promote O
diuresis B-PHE
, O
treat O
stranguria B-PHE
, O
remove O
urinary B-PHE
calculus I-PHE
. O

-DOCSTART- O


Chai O
Hu O
( O
Radix O
Burpleuri O
) O
, O
a O
major O
ingredient O
in O
many O
traditional O
Chinese O
medicine O
formulas O
, O
such O
as O
Xiao O
Yan O
Wan O
, O
is O
used O
in O
the O
treatment O
of O
liver B-PHE
stagnation I-PHE
and O
spleen B-PHE
deficiency I-PHE
syndrome I-PHE
( O
LSSDS B-PHE
) O
. O

The O
objectives O
of O
this O
study O
were O
to O
examine O
the O
effects O
of O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
on O
the O
changes O
of O
plasma B-PHE
indices I-PHE
in O
patients O
with O
LSSDS B-PHE
. O

Fifty-eight O
cases O
of O
LSSDS B-PHE
were O
randomly O
divided O
into O
two O
groups O
: O
41 O
cases O
in O
the O
experimental O
group O
were O
treated O
with O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
and O
17 O
cases O
in O
the O
control O
group O
were O
treated O
with O
Zhi O
Bai O
Di O
Huang O
Wan O
for O
one O
consecutive O
month O
in O
a O
single O
blind O
design O
. O

Before O
and O
after O
treatment O
, O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
was O
applied O
to O
determine O
the O
changes O
of O
plasma B-PHE
norepinephrine I-PHE
( O
NE B-PHE
) O
, O
epinephrine B-PHE
( O
E B-PHE
) O
and O
dopamine B-PHE
( O
DA B-PHE
) O
. O

Radioimmunoassay O
was O
performed O
to O
measure O
the O
amount O
of O
plasma B-PHE
beta-endorphin I-PHE
( O
beta-EP B-PHE
) O
, O
adrenocorticotropin B-PHE
hormone I-PHE
( O
ACTH B-PHE
) O
, O
estradiol B-PHE
( O
E2 B-PHE
) O
and O
testosterone B-PHE
( O
T B-PHE
) O
, O
and O
laser O
nephelometry O
was O
also O
conducted O
to O
measure O
plasma B-PHE
immunoglobulin I-PHE
A I-PHE
( O
Ig B-PHE
A) I-PHE
and O
G O
( O
Ig B-PHE
G I-PHE
) O
. O

Compared O
to O
baseline O
levels O
, O
plasma B-PHE
beta-EP I-PHE
was O
significantly O
increased O
(p O
< O
0.01 O
) O
, O
while O
E B-PHE
and O
DA B-PHE
were O
markedly O
decreased O
(p O
< O
0.01 O
) O
after O
the O
administration O
of O
Xiao O
Yao O
Wan O
in O
the O
experimental O
group O
. O

The O
other O
indices O
did O
not O
change O
. O

This O
is O
the O
first O
evidence O
showing O
that O
the O
effect O
of O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
on O
the O
treatment O
of O
patients O
with O
LSSDS B-PHE
may O
be O
through O
enhancing O
plasma B-PHE
beta-EP I-PHE
and O
decreasing O
E B-PHE
and O
DA B-PHE
release O
. O

We O
conclude O
that O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
regulates O
nervous B-PHE
and I-PHE
endocrine I-PHE
systems I-PHE
and O
contributes O
to O
the O
improvement O
of O
the O
clinical O
status O
of O
patients O
with O
LSSDS B-PHE
. O

-DOCSTART- O


This O
study O
was O
conducted O
to O
evaluate O
the O
importance O
of O
intraoperative O
smear O
examinations O
for O
the O
final O
diagnosis O
of O
intracerebral O
stereotaxic O
procedures O
. O

125 O
consecutive O
patients O
with O
suspect O
intracerebral B-PHE
lesions I-PHE
underwent O
stereotaxic O
frame-based O
biopsies O
after O
acquisition O
of O
computer O
tomographic O
and O
magnetic O
resonance O
images O
. O

After O
secondary O
image O
processing O
, O
including O
multiplanar O
visualization O
of O
the O
target O
region O
and O
target O
definition O
, O
a O
serial O
biopsy O
was O
realized O
using O
an O
aspiration O
Sedan O
needle O
. O

Biopsy O
taking O
was O
repeated O
as O
long O
as O
pathological O
tissue O
samples O
were O
obtained O
according O
to O
the O
visual O
impression O
of O
the O
neurosurgeon O
( O
group O
I) O
or O
to O
the O
first O
neuropathological O
result O
of O
a O
smear O
examination O
( O
group O
II O
) O
. O

Retrospective O
analysis O
of O
all O
cases O
showed O
that O
intraoperative O
microscopic O
diagnostics O
could O
improve O
the O
conditions O
for O
a O
definitive O
neuropathological O
diagnosis O
from O
0.918 O
( O
56/61 O
patients O
, O
group O
I) O
to O
0.969 O
( O
62/64 O
patients O
, O
group O
II O
) O
( O
t>0.05 O
) O
. O

The O
number O
of O
biopsy O
specimens O
and O
the O
rate O
of O
CT-detectable O
small B-PHE
bleedings I-PHE
differed O
slightly O
between O
both O
groups O
and O
were O
higher O
in O
group O
II O
. O

The O
duration O
of O
surgery O
and O
anaesthesia O
as O
well O
as O
the O
final O
neurological O
outcomes O
were O
comparable O
in O
both O
groups O
. O

In O
conclusion O
, O
intraoperative O
smear O
examination O
as O
a O
kind O
of O
bedside O
diagnostics O
confers O
a O
better O
diagnostic O
safety O
and O
improves O
the O
reliability O
of O
this O
minimal O
invasive O
manoeuvre O
. O

-DOCSTART- O


lubricate O
the O
intestines B-PHE

-DOCSTART- O


Patients O
with O
squamous B-PHE
cell I-PHE
carcinoma I-PHE
of O
the O
head O
and O
neck O
. O

-DOCSTART- O


Objectives O
Mycobacterium B-PHE
avium I-PHE
subspecies I-PHE
paratuberculosis I-PHE
( O
MAP B-PHE
) O

-DOCSTART- O


Sirolimus O
inhibits O
T B-PHE
lymphocyte I-PHE
activation I-PHE
and I-PHE
proliferation I-PHE
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine B-PHE
( O
Interleukin B-PHE
IL-2 B-PHE
, O
IL-4 B-PHE
, O
and O
IL-15 B-PHE
) O
stimulation O
by O
a O
mechanism O
that O
is O
distinct O
from O
that O
of O
other O
immunosuppressants O
. O

-DOCSTART- O


To O
nourish O
blood B-PHE
. O

-DOCSTART- O


It O
is O
designed O
to O
mimic O
the O
molecular O
shape O
of O
adrenaline O
. O

It O
binds O
to O
alpha-adrenergic O
receptors O
in O
the O
nasal O
mucosa O
. O

Here O
it O
can O
, O
therefore O
, O
cause O
vasoconstriction B-PHE

-DOCSTART- O


bloody B-PHE
dysentery I-PHE

-DOCSTART- O


A O
traditional O
Japanese O
herbal O
( O
Kampo O
) O
medicine O
, O
Hochuekkito O
( O
Bu-Zhong-Yi-Qi-Tang O
in O
Chinese O
, O
TJ-41 O
) O
is O
a O
well-known O
Kampo O
formula O
, O
and O
has O
been O
found O
to O
enhance O
antigen-specific B-PHE
antibody I-PHE
response I-PHE
in O
not O
only O
local O
mucosal B-PHE
immune I-PHE
system I-PHE
in O
upper O
respiratory O
tract O
, O
but O
also O
systemic B-PHE
immune I-PHE
system I-PHE
through O
upper O
respiratory B-PHE
mucosal I-PHE
immune I-PHE
system I-PHE
. O

Although O
this O
immunopharmacological O
effect O
has O
been O
proposed O
to O
express O
by O
modulation O
of O
intestinal B-PHE
immune I-PHE
system I-PHE
including O
Peyer's B-PHE
patches I-PHE
and O
intestinal B-PHE
epithelial I-PHE
cells I-PHE
, O
active O
ingredients O
are O
not O
known O
. O

TJ-41 O
directly O
affected O
the O
production O
of O
bone B-PHE
marrow I-PHE
cell I-PHE
- O
proliferative O
growth B-PHE
factors I-PHE
from O
murine O
Peyer's O
patch O
immunocompetent O
cells O
in O
vitro O
. O

Among O
low O
molecular O
, O
intermediate O
size O
and O
macromolecular O
weight O
fractions O
prepared O
from O
TJ-41 O
, O
only O
fraction O
containing O
macromolecular O
weight O
ingredients O
showed O
Peyer's B-PHE
patch I-PHE
- O
mediated O
bone B-PHE
marrow I-PHE
cell I-PHE
- O
proliferation O
enhancing O
activity O
. O

Anion-exchange O
chromatography O
and O
gel O
filtration O
gave O
17 O
subfractions O
comprising O
polysaccharides O
and O
lignins O
from O
the O
macromolecular O
weight O
fraction O
of O
TJ-41 O
, O
and O
some O
of O
the O
subfractions O
showed O
significant O
enhancing O
activities O
having O
different O
degrees O
. O

Some O
of O
the O
subfractions O
also O
expressed O
stimulating O
activity O
on O
G-CSF B-PHE
- I-PHE
production I-PHE
from O
colonic O
epithelial O
cells O
, O
and O
statistically O
significant O
positive O
correlation O
was O
observed O
among O
enhancing O
activities O
of O
the O
subfractions O
against O
Peyer's B-PHE
patch I-PHE
immunocompetent I-PHE
cells I-PHE
and O
epithelial B-PHE
cells I-PHE
. O

Among O
the O
fractions O
from O
TJ-41 O
oral O
administration O
of O
macromolecular O
weight O
ingredient O
fraction O
to O
mice O
succeeded O
to O
enhance O
antigen-specific B-PHE
antibody I-PHE
response I-PHE
in O
systemic B-PHE
immune I-PHE
system I-PHE
through O
upper O
respiratory B-PHE
mucosal I-PHE
immune I-PHE
system I-PHE
, O
but O
all O
the O
separated O
fractions O
failed O
to O
enhance O
the O
in O
vivo O
antibody B-PHE
response I-PHE
in O
upper O
respiratory O
tract O
. O

-DOCSTART- O


Native O
Americans O
residing O
in O
a O
broad O
region O
downwind O
from O
the O
Nevada O
Test O
Site O
during O
the O
1950s O
and O
1960s O
received O
significant O
radiation O
exposures O
from O
nuclear O
weapons O
testing O
. O

Because O
of O
differences O
in O
diet O
, O
activities O
, O
and O
housing O
, O
their O
radiation O
exposures O
are O
only O
very O
imperfectly O
represented O
in O
the O
Department O
of O
Energy O
dose O
reconstructions O
. O

There O
are O
important O
missing O
pathways O
, O
including O
exposures O
to O
radioactive O
iodine O
from O
eating O
small O
game O
. O

The O
dose O
reconstruction O
model O
assumptions O
about O
cattle O
feeding O
practices O
across O
a O
year O
are O
unlikely O
to O
apply O
to O
the O
native O
communities O
as O
are O
other O
model O
assumptions O
about O
diet O
. O

Thus O
exposures O
from O
drinking O
milk O
and O
eating O
vegetables O
have O
not O
yet O
been O
properly O
estimated O
for O
these O
communities O
. O

Through O
consultations O
with O
members O
of O
the O
affected O
communities O
, O
these O
deficiencies O
could O
be O
corrected O
and O
the O
dose O
reconstruction O
extended O
to O
Native O
Americans O
. O

An O
illustration O
of O
the O
feasibility O
of O
extending O
the O
dose O
reconstruction O
is O
provided O
by O
a O
sample O
calculation O
to O
estimate O
radiation O
exposures O
to O
the O
thyroid B-PHE
from O
eating O
radio-iodine-contaminated O
rabbit O
thyroids B-PHE
after O
the O
Sedan O
test O
. O

The O
illustration O
is O
continued O
with O
a O
discussion O
of O
how O
the O
calculation O
results O
may O
be O
used O
to O
make O
estimates O
for O
other O
tests O
and O
other O
locations O
. O

-DOCSTART- O


The O
antiinflammatory B-PHE
effects I-PHE
of O
tenoxicam O
may O
result O
from O
the O
inhibition O
of O
the O
enzyme O
cycooxygenase O
and O
the O
subsequent O
peripheral O
inhibition O
of O
prostaglandin B-PHE
synthesis I-PHE
. O

As O
prostaglandins O
sensitize O
pain B-PHE
receptors O
, O
their O
inhibition O
accounts O
for O
the O
peripheral O
analgesic O
effects O
of O
tenoxicam O
. O

Antipyresis O
may O
occur O
by O
central O
action O
on O
the O
hypothalamus B-PHE
, O
resulting O
in O
peripheral O
dilation O
, O
increased O
cutaneous O
blood B-PHE
flow O
, O
and O
subsequent O
heat B-PHE
loss I-PHE
. O

-DOCSTART- O


epilepsy B-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Body B-PHE
weight I-PHE

-DOCSTART- O


Diaphragmatic B-PHE
Dysfunction I-PHE

-DOCSTART- O


moisten O
the O
lung B-PHE
and O
send O
Gi(Qi O
) O
downward O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Intelligence O
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Strength O
and O
power O
, O
Neurological B-PHE
systems I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


Cardiac B-PHE
Output I-PHE
, I-PHE
Low I-PHE

-DOCSTART- O


Pancreatic B-PHE
cancer I-PHE

-DOCSTART- O


Inhibiting O
the O
growth O
of O
various O
kinds O
of O
dermatomyces B-PHE
. O

-DOCSTART- O


urticaria B-PHE

-DOCSTART- O


Swelling B-PHE
pain I-PHE
in O
throat O
, O
red O
eyes O
with O
gall O
, O
lung O
heat O
cough B-PHE
, O
mastitis B-PHE
, O
damp-heat B-PHE
jaundice B-PHE
, O
wind-damp B-PHE
impediment O
pain B-PHE
, O
bleeding B-PHE
due O
to O
external B-PHE
injury I-PHE
. O

-DOCSTART- O


Treatment O
of O
stroke B-PHE
with O
gurgling B-PHE
in I-PHE
the I-PHE
throat I-PHE
, O
deviation B-PHE
of I-PHE
the I-PHE
eye I-PHE
and I-PHE
the I-PHE
mouth I-PHE
, O
and O
impairment B-PHE
of I-PHE
speech I-PHE
, O
upward O
invasion O
of O
phlegm B-PHE
causing O
headache B-PHE
accompanied O
with O
dizziness B-PHE
, O
heaviness B-PHE
of I-PHE
the I-PHE
body I-PHE
, O
restlessness B-PHE
, O
fidgetness B-PHE
, O
nausea B-PHE
and O
cold B-PHE
extremities I-PHE
, O
or O
migraine B-PHE
, O
sore B-PHE
throat I-PHE
, O
tetanus B-PHE
, O
external O
use O
for O
scrofula B-PHE
, O
venomous B-PHE
snake I-PHE
bite I-PHE
. O

-DOCSTART- O


hoarseness B-PHE

-DOCSTART- O


alleviate O
edema B-PHE
and O
toxin B-PHE

-DOCSTART- O


Juzentaihoto O
( O
JTT O
) O
is O
a O
well-known O
Japanese O
herbal O
medicine O
, O
which O
has O
been O
reported O
to O
modulate O
immune B-PHE
responses I-PHE
and O
enhance O
antitumor B-PHE
immunity I-PHE
in O
animal O
models O
. O

However O
, O
it O
is O
not O
clear O
whether O
JTT O
has O
similar O
effects O
on O
humans O
. O

In O
particular O
, O
there O
is O
little O
information O
on O
the O
effects O
of O
JTT O
in O
antigen-specific B-PHE
immunity I-PHE
in O
cancer B-PHE
patients O
. O

Here O
we O
conducted O
a O
randomized O
clinical O
study O
to O
investigate O
whether O
combined O
usage O
of O
JTT O
could O
affect O
antigen-specific B-PHE
immunity I-PHE
and O
clinical O
findings O
in O
advanced O
pancreatic B-PHE
cancer I-PHE
patients O
undergoing O
personalized O
peptide O
vaccination O
( O
PPV O
) O
, O
in O
which O
HLA-matched O
vaccine O
antigens O
were O
selected O
based O
on O
the O
preexisting B-PHE
host I-PHE
immunity I-PHE
. O

Fifty-seven O
patients O
were O
randomly O
assigned O
to O
receive O
PPV O
with O
(n O
= O
28 O
) O
or O
without O
(n O
= O
29 O
) O
JTT O
. O

Unexpectedly O
, O
JTT O
did O
not O
significantly O
affect O
cellular B-PHE
or I-PHE
humoral I-PHE
immune I-PHE
responses I-PHE
specific O
to O
the O
vaccine O
antigens O
, O
which O
were O
determined O
by O
antigen B-PHE
- I-PHE
specific I-PHE
interferon I-PHE
- I-PHE
y I-PHE
secretion I-PHE
in O
T B-PHE
cells I-PHE
and O
antigen B-PHE
- I-PHE
specific I-PHE
IgG I-PHE
titers I-PHE
in O
plasma O
, O
respectively O
. O

Nevertheless O
, O
JTT O
prevented O
deterioration O
of O
patients' O
conditions O
, O
such O
as O
anemia B-PHE
, O
lymphopenia B-PHE
, O
hypoalbuminemia B-PHE
, O
plasma B-PHE
IL-6 I-PHE
elevation I-PHE
, O
and O
reduction O
of O
performance O
status O
, O
which O
are O
frequently O
observed O
in O
advanced O
cancers B-PHE
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
clinical O
study O
that O
examined O
the O
immunological O
and O
clinical O
effects O
of O
JTT O
in O
cancer B-PHE
patients O
undergoing O
immunotherapy O
in O
humans O
. O

-DOCSTART- O


injury B-PHE
by O
wind B-PHE
pathogen I-PHE
and O
headache B-PHE

-DOCSTART- O


Measles B-PHE
papules O
with O
complicated O
pneumonia B-PHE
, O
throat B-PHE
erosion I-PHE
. O

-DOCSTART- O


spasmodic B-PHE
contraction I-PHE
of I-PHE
tendons I-PHE
and I-PHE
meridian I-PHE

-DOCSTART- O


Used O
to O
produce O
controlled B-PHE
hypotension I-PHE
during O
surgical O
procedures O
and O
in O
hypertensive B-PHE
crises I-PHE
. O

-DOCSTART- O


difficulty B-PHE
in I-PHE
feces I-PHE
and I-PHE
urine I-PHE

-DOCSTART- O


attack O
and O
expel O

-DOCSTART- O


( O
1 O
) O
morbid B-PHE
leukorrhea I-PHE
; O
( O
2 O
) O
gynecological B-PHE
diseases I-PHE
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Others O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Respiratory B-PHE
systems I-PHE
, O
Respiratory B-PHE
systems I-PHE
health I-PHE
, O
motility B-PHE
, O
absorption B-PHE
, O
Others O
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


Acute B-PHE
Mania I-PHE

-DOCSTART- O


To O
relax O
the O
bowels B-PHE
( O
sthenia-syndrome B-PHE
with O
constipation B-PHE
due O
to O
accumulation O
of O
cold B-PHE
, O
dysentery B-PHE
of I-PHE
cold I-PHE
type O
) O
. O

-DOCSTART- O


weakness B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE

-DOCSTART- O


purge O
heat B-PHE
and O
treat O
gam B-PHE
( O
gan O
) O

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective O
immunity B-PHE
, O
Liver B-PHE

-DOCSTART- O


Its O
decoction O
promotes O
the O
secretion B-PHE
of I-PHE
pepsin I-PHE
and I-PHE
gastric I-PHE
juice I-PHE
. O

-DOCSTART- O


To O
invigorate O
blood B-PHE
and O
remove O
stagnation B-PHE
. O

-DOCSTART- O


Macular B-PHE
Edema I-PHE

-DOCSTART- O


illness B-PHE

-DOCSTART- O


Pharyngitis B-PHE
, O
excessive B-PHE
sputum I-PHE
blocking O
the O
windpipe O
, O
rapid B-PHE
breathing I-PHE
and O
even O
suffocation B-PHE
. O

-DOCSTART- O


ulcer B-PHE

-DOCSTART- O


ulceration B-PHE
in O
the O
gum O

-DOCSTART- O


metrorrhagia B-PHE
and O
metrostaxis B-PHE

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE

-DOCSTART- O


For O
promoting O
diuresis B-PHE
and O
desolving O
inflammation B-PHE

-DOCSTART- O


Used O
to O
provide O
skeletal B-PHE
muscle I-PHE
relaxation I-PHE
as O
an O
adjunct O
to O
general B-PHE
anesthesia I-PHE
, O
for O
endotracheal O
intubation O
or O
to O
facilitate O
mechanical O
ventilation O
. O

-DOCSTART- O


Cystic B-PHE
Fibrosis I-PHE

-DOCSTART- O


malaria B-PHE
; O
malarial B-PHE
disorder I-PHE
malaria B-PHE
and O
other O
disease O
characterized O
by O
intermittent O
rigor B-PHE
, O
high O
fever B-PHE
and O
sweating B-PHE
. O

-DOCSTART- O


( O
1 O
) O
hernia B-PHE
( O
2 O
) O
diseases B-PHE
of I-PHE
genitalia I-PHE
( O
3 O
) O
severe O
pain B-PHE
in O
the O
lower O
abdomen O

-DOCSTART- O


Esophageal B-PHE
Varices I-PHE

-DOCSTART- O


nfantile O
malnutrition B-PHE
with O
diarrhea B-PHE

-DOCSTART- O


Polycystic B-PHE
Ovary I-PHE
Syndrome I-PHE

-DOCSTART- O


promote O
water O
and O
purge O
/ O
relieve O
toxicity B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
gastroesophageal B-PHE
reflux I-PHE
disease I-PHE
( O
GERD B-PHE
) O
. O

It O
is O
also O
used O
in O
treating O
nausea B-PHE
and O
vomiting B-PHE
, O
and O
to O
increase O
gastric B-PHE
emptying I-PHE
. O

Occasionally O
used O
in O
Cushing's B-PHE
syndrome I-PHE
. O

-DOCSTART- O


bloodshot B-PHE
eyes I-PHE
; O
congestion B-PHE
of I-PHE
the I-PHE
eye I-PHE
; O
red B-PHE
eyes I-PHE
; O
redness B-PHE
of I-PHE
the I-PHE
eye I-PHE

-DOCSTART- O


postpartum B-PHE
debility I-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment I-PHE
pain I-PHE
, O
swelling B-PHE
pain I-PHE
in I-PHE
throat I-PHE
, O
scrofula B-PHE
, O
mammary B-PHE
welling I-PHE
abscess I-PHE
, O
sore B-PHE
and O
boil B-PHE
, O
eczema B-PHE
, O
innominate B-PHE
toxin I-PHE
swelling I-PHE
, O
poisonous B-PHE
snake I-PHE
bite I-PHE
. O

-DOCSTART- O


insomnia B-PHE

-DOCSTART- O


Advanced B-PHE
Breast I-PHE
Cancer I-PHE

-DOCSTART- O


Cerebral B-PHE
thrombosis I-PHE

-DOCSTART- O


venomous O
snake-bite B-PHE

-DOCSTART- O


nourish O
the O
stomach B-PHE
stop O
dysentery B-PHE

-DOCSTART- O


Lymphoma B-PHE
, I-PHE
Lymphoblastic I-PHE

-DOCSTART- O


Binds O
to O
the O
nicotinic O
acetycholine O
receptors O
( O
by O
virtue O
of O
its O
similarity O
to O
acetylcholine O
) O
in O
the O
motor O
endplate O
and O
blocks O
access O
to O
the O
receptors O
. O

-DOCSTART- O


affection O
due O
to O
wind-cold B-PHE
; O
common O
cold B-PHE
caused O
by O
wind B-PHE
and O
cold B-PHE

-DOCSTART- O


cough B-PHE
due O
to O
phlegm B-PHE

-DOCSTART- O


1 O
An O
active O
component O
arcitiin O
is O
a O
vasodilator O
and O
hypotensive O
. O
2 O
. O
Over O
dosage O
of O
arctiin O
may O
lead O
to O
convulsion B-PHE
and O
respiratory B-PHE
failure I-PHE
. O

-DOCSTART- O


Dalbavancin O
has O
a O
spectrum O
and O
mechanism O
of O
action O
similar O
to O
vancomycin B-PHE
, O
a O
naturally O
formed O
glycopeptide B-PHE
antimicrobial I-PHE
. O

-DOCSTART- O


This O
is O
a O
symptom O
that O
the O
body O
becomes O
thin O
due O
to O
exhaustion B-PHE
syndrome I-PHE
. O

-DOCSTART- O


Chlorothiazide O
is O
indicated O
as O
adjunctive O
therapy O
in O
edema B-PHE
associated O
with O
congestive B-PHE
heart I-PHE
failure I-PHE
, O
hepatic B-PHE
cirrhosis I-PHE
, O
and O
corticosteroid O
and O
estrogen O
therapy O
. O

It O
is O
also O
indicated O
in O
the O
management O
of O
hypertension B-PHE
either O
as O
the O
sole O
therapeutic O
agent O
or O
to O
enhance O
the O
effectiveness O
of O
other O
antihypertensive O
drugs O
in O
the O
more O
severe O
forms O
of O
hypertension B-PHE
. O

-DOCSTART- O


Vaginal B-PHE
Atrophy I-PHE

-DOCSTART- O


abdominal B-PHE
pain I-PHE
due O
to O
stagnation O
of O
Gi O

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


Extemal O
use O
for O
carbuncle B-PHE
, O
pyogenic B-PHE
infection I-PHE
of O
skin O
, O
ulcera B-PHE
tive I-PHE
gingivitis I-PHE
and O
dental B-PHE
caries I-PHE
. O

Recently O
, O
also O
for O
carcinoma B-PHE
of I-PHE
breast I-PHE
, I-PHE
cervix I-PHE
and I-PHE
pancreas I-PHE
and O
malignant B-PHE
lymphoma I-PHE

-DOCSTART- O


Anemia B-PHE

-DOCSTART- O


cosolidate O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


Hypertrophy B-PHE
, I-PHE
Left I-PHE
Ventricular I-PHE

-DOCSTART- O


disperse O
accumulation B-PHE
and O
kill O
worm B-PHE

-DOCSTART- O


Ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine B-PHE
monophosphate I-PHE
dehydrogenase I-PHE
, O
viral O
RNA O
polymerase O
and O
mRNA O
guanylyltransferase O
( O
viral O
) O
and O
can O
be O
incorporated O
into O
RNA O
in O
RNA O
viral O
species O
. O

Sofosbuvir O
is O
a O
nucleotide O
analogue O
inhibitor O
of O
the O
hepatitis O
C O
virus O
polymerase O
which O
is O
a O
RNA-dependent O
RNA O
polymerase O
critical O
for O
the O
viral O
cycle O
. O

Alfa O
interferons O
bind O
to O
specific O
cell-surface O
receptors O
, O
resulting O
in O
the O
transcription O
and O
translation O
of O
genes O
whose O
protein O
products O
mediate O
antiviral B-PHE
, O
antiproliferative B-PHE
, O
anticancer B-PHE
, O
and O
immune-modulating B-PHE
effects O
. O

-DOCSTART- O


jaundice B-PHE
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-PHE
pigmentation I-PHE
of I-PHE
the I-PHE
skin I-PHE
and I-PHE
sclera I-PHE
and O
dark B-PHE
yellow I-PHE
colored I-PHE
urine I-PHE
, O
and O
classified O
into O
two O
types O
, O
Yang B-PHE
jaundice I-PHE
and O
Eum B-PHE
jaundice I-PHE
; O

one O
of O
the O
five O
types O
of O
jaundice B-PHE
. O

-DOCSTART- O


deafness B-PHE

-DOCSTART- O


Bladder B-PHE
, I-PHE
Neurogenic I-PHE

-DOCSTART- O


alleviate O
edema B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Its O
biochemical O
mechanism O
of O
action O
is O
unknown O
, O
although O
data O
are O
available O
to O
suggest O
that O
the O
drug O
modifies O
the O
peripheral B-PHE
metabolism I-PHE
of O
steroids O
as O
well O
as O
directly O
suppressing O
the O
adrenal B-PHE
cortex I-PHE
. O

-DOCSTART- O


Kidney B-PHE
disease I-PHE
of O
diabetes B-PHE
type O

-DOCSTART- O


plum-stone B-PHE
syndrome I-PHE
; O
globus B-PHE
hystericus I-PHE
a O
subjective O
sensation O
as O
if O
a O
plum O
pit O
is O
stuck O
in O
the O
throat O
is O
compressed O
. O

-DOCSTART- O


Intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-PHE
effect I-PHE
on O
experimental O
animals O
. O

-DOCSTART- O


Ovarian B-PHE
Cancer I-PHE

-DOCSTART- O


a O
disease O
that O
has O
watery B-PHE
and I-PHE
chronic I-PHE
defecation I-PHE

-DOCSTART- O


Diabetic B-PHE
Neuropathy I-PHE
, O
Painful O

-DOCSTART- O


To O
calm O
asthma B-PHE
, O
dispel O
wind B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


Postreperfusion B-PHE
Syndrome I-PHE

-DOCSTART- O


hemiplegia B-PHE
; O

paralysis B-PHE

-DOCSTART- O


Hemodialysis B-PHE

-DOCSTART- O


fever B-PHE
with O
overstrain B-PHE

-DOCSTART- O


Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Rhubarb O
( O
Dahuang O
) O
and O
Dried O
ginger O
( O
Ganjiang O
) O
in O
the O
formula O
Sanwu O
Beiji O
Wan O
. O

-DOCSTART- O


ascites B-PHE
; O
abdominal B-PHE
distention I-PHE
due O
to O
accumulation O
of O
liquid B-PHE

-DOCSTART- O


Analysis O
of O
the O
constituents O
in O
the O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
by O
UPLC/Q-TOF-MS/MS O
. O

-DOCSTART- O


Blood B-PHE
vaculty I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
amenorrhea B-PHE
, O
postpartum B-PHE
vacuity I-PHE
weakness I-PHE
, O
aching B-PHE
in I-PHE
lumbus I-PHE
and I-PHE
legs I-PHE
, O
fracture B-PHE
due O
to O
knocks O
and O
falls O
. O

-DOCSTART- O


eliminate O
vexation B-PHE
and O
thirst B-PHE

-DOCSTART- O


hypochondriac B-PHE
pain I-PHE

-DOCSTART- O


invigorate O
waist B-PHE
and O
limbs B-PHE

-DOCSTART- O


ISS O
1018 O
signals O
through O
Toll-like O
receptor O
9 O
( O
TLR9 O
) O
to O
induce O
the O
production O
of O
immunoglobulin O
by O
B O
cells O
and O
interferon O
( O
IFN O
) O
#NAME? O
, O
IFN-beta B-PHE
, O
interleukin-12 B-PHE
( O
IL-12 B-PHE
) O
, O
and O
tumor B-PHE
necrosis I-PHE
factor I-PHE
- I-PHE
alpha I-PHE
( O
TNF-alpha B-PHE
) O
by O
plasmacytoid O
dendritic O
cells O
( O
pDC O
) O
. O

pDC O
and O
IFN-alpha O
and O
#NAME? O
then O
induce O
natural B-PHE
killer I-PHE
( O
NK B-PHE
) O
cell B-PHE
proliferation I-PHE
, O
NK B-PHE
cell I-PHE
production I-PHE
of O
IFN-gamma B-PHE
, O
and O
NK B-PHE
cell-mediated I-PHE
cytotoxicity I-PHE
. O

Secreted O
IFNs O
also O
stimulate O
bystander O
T B-PHE
cell I-PHE
activation I-PHE
and O
differentiation O
of O
naive O
CD4+ O
T O
cells O
into O
T-helper O
1 O
cells O
on O
specific O
antigen O
challenge O
. O

-DOCSTART- O


Diabetes B-PHE
Mellitus I-PHE
, I-PHE
Type I-PHE
2 I-PHE

-DOCSTART- O


clear O
the O
lung B-PHE
and O
discharge O
fire B-PHE

-DOCSTART- O


Pregnancy B-PHE

-DOCSTART- O


promote O
the O
stomach B-PHE
and O
disperse O
food O

-DOCSTART- O


pain B-PHE
in O
the O
supraorbital O
bone O

-DOCSTART- O


Gabapentin O
interacts O
with O
cortical B-PHE
neurons I-PHE
at O
auxillary O
subunits O
of O
voltage-sensitive O
calcium O
channels O
and O
increases O
the O
synaptic B-PHE
concentration I-PHE
of I-PHE
GABA I-PHE
, O
enhances O
GABA B-PHE
responses I-PHE
at O
non-synaptic O
sites O
in O
neuronal O
tissues O
, O
and O
reduces O
the O
release O
of O
mono-amine B-PHE
neurotransmitters I-PHE
. O

Duloxetine O
selectively O
prevents O
the O
reuptake B-PHE
of I-PHE
5-HT I-PHE
and I-PHE
NE I-PHE
via O
transporter O
complexes O
on O
the O
pre-synaptic B-PHE
membrane I-PHE
, O
thereby O
increasing O
the O
level O
of O
these O
neurotransmitters B-PHE
within O
the O
synaptic O
cleft O
. O

-DOCSTART- O


an O
illness O
in O
which O
phlegm B-PHE
formed O
on O
chest O

-DOCSTART- O


Psoriatic B-PHE
Arthritis I-PHE

-DOCSTART- O


invigorate O
the O
spleen B-PHE
and O
resolve O
accumulation O

-DOCSTART- O


BACKGROUND O
_ O
AIMS O
: O
Chemotherapy O
with O
an O
anticancer O
agent O
generally O
causes O
gastrointestinal B-PHE
tract I-PHE
disorders I-PHE
such O
as O
vomiting B-PHE
and O
anorexia B-PHE
, O
but O
the O
mechanism O
remains O
unclear O
. O

Rikkunshito O
, O
a O
kampo O
preparation O
, O
is O
known O
to O
alleviate O
such O
adverse O
reactions O
. O

In O
this O
study O
, O
we O
attempted O
to O
clarify O
the O
mechanism O
. O

METHODS O
: O
We O
investigated O
the O
decreases O
of O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
and O
food O
intake O
caused O
by O
cisplatin O
, O
serotonin B-PHE
( O
5-HT B-PHE
) O
, O
5-HT O
agonists O
, O
and O
vagotomy O
as O
well O
as O
the O
decrease-suppressing O
effects O
of O
rikkunshito O
and O
5-HT O
antagonists O
. O

In O
addition O
, O
binding O
affinities O
of O
rikkunshito O
components O
were O
determined O
in O
receptor-binding O
assays O
using O
5-HT2B O
and O
5-HT2C O
receptors O
. O

RESULTS O
: O
Cisplatin O
, O
5-HT B-PHE
, O
BW723C86 O
( O
5-HT2B-receptor O
agonist O
) O
, O
and O
m-chlorophenylpiperazine O
HCl O
( O
5-HT2C O
agonist O
) O
markedly O
decreased O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
levels I-PHE
, O
although O
5-HT3 O
and O
5-HT4 O
agonists O
had O
no O
effect O
. O

In O
contrast O
, O
5-HT2B O
and O
5-HT2C O
antagonists O
suppressed O
the O
cisplatin-induced O
decrease O
of O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
and O
food O
intake O
. O

Administration O
of O
rat O
ghrelin B-PHE
improved O
the O
cisplatin-induced O
decrease O
in O
food O
intake O
. O

Vagotomy O
decreased O
the O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
, O
which O
was O
decreased O
further O
by O
cisplatin O
. O

Rikkunshito O
suppressed O
such O
cisplatin-induced O
decreases O
of O
plasma B-PHE
acylated- I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
and O
food O
intake O
. O

The O
suppressive O
effect O
of O
rikkunshito O
was O
blocked O
by O
a O
ghrelin O
antagonist O
. O

Components O
of O
rikkunshito O
, O
3,3',4',5,6,7,8-heptamethoxyflavone O
, O
hesperidin O
, O
and O
iso-liquiritigenin O
showed O
a O
5-HT2B-antagonistic O
effect O
in O
vitro O
, O
and O
oral O
administration O
of O
rikkunshito O
suppressed O
the O
cisplatin-induced O
decrease O
in O
the O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
. O

CONCLUSIONS O
: O
The O
cisplatin-induced O
decreases O
of O
the O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
and O
food O
intake O
are O
mediated O
by O
5-HT2B/2C O
receptors O
and O
suppressed O
by O
flavonoids O
in O
rikkunshito O
. O

-DOCSTART- O


The O
symptomatic O
relief O
of O
cough B-PHE
. O

-DOCSTART- O


Its O
alcoholic O
extract O
relaxes O
the O
spasm B-PHE
of I-PHE
smooth I-PHE
muscles I-PHE
of O
gastrointestine O
, O
gallbladder O
and O
bronchus. O
. O

-DOCSTART- O


Hwansodan O
has O
been O
used O
as O
a O
prescription O
for O
senile B-PHE
and O
vascular B-PHE
dementia I-PHE
in O
Oriental O
medicine O
. O

We O
investigated O
the O
neuroprotective B-PHE
effects I-PHE
of O
Hwansodan O
water O
extract O
on O
the O
apoptotic B-PHE
death I-PHE
of O
PC12 O
cells O
by O
serum O
deprivation O
. O

Hwansodan O
significantly O
rescued O
PC12 O
cells O
from O
apoptotic B-PHE
death I-PHE
by O
serum O
deprivation O
in O
a O
dose-dependent O
manner O
. O

The O
nuclear O
staining O
of O
PC12 O
cells O
clearly O
showed O
that O
Hwansodan O
attenuated O
nuclear O
condensation O
and O
fragmentation O
, O
which O
represents O
typical O
neuronal O
apoptotic O
characteristics O
. O

Hwansodan O
also O
prevents O
DNA O
fragmentation O
and O
caspase-3-like O
protease O
activation O
in O
serum-deprived O
PC12 O
cells O
and O
induces O
the O
tyrosine O
phosphorylation O
of O
proteins O
around O
44 O
kDa O
, O
which O
was O
identified O
as O
ERK1 O
with O
electrophoretic O
gel O
mobility O
shift O
by O
Western O
blot O
. O

In O
addition O
, O
MEK O
inhibitor O
PD98059 O
and O
Ras O
inactivator O
, O
alpha-hydroxyfarnesylphosphonic O
acid O
and O
mevastatin O
, O
attenuated O
the O
neuroprotective O
effects O
of O
Hwansodan O
in O
serum-deprived O
PC12 O
cells O
. O

These O
results O
indicate O
that O
Ras O
/ O
MEK O
/ O
ERK O
signaling O
pathway O
plays O
a O
role O
in O
neuroprotective B-PHE
effects I-PHE
of O
Hwansodan O
in O
serum-deprived O
PC12 O
cells O
. O

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility B-PHE
. O

-DOCSTART- O


asthma B-PHE

-DOCSTART- O


1 O
Treatment O
of O
rheumatism B-PHE
, O
trauma B-PHE
, O
headache B-PHE
, O
and O
other O
pains B-PHE
. O

Recently O
, O
also O
used O
for O
abdominal B-PHE
and I-PHE
biliary I-PHE
colics I-PHE
, O
and O
trigeminal B-PHE
neuralgia I-PHE
. O

2 O
. O
Treatment O
of O
bronchial B-PHE
asthma I-PHE
and O
asthmatic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Hernioplasty O

-DOCSTART- O


infantile B-PHE
malnutrition I-PHE
an O
infantile B-PHE
disease I-PHE
due O
to O
digestive B-PHE
disturbance I-PHE
or O
intestinal B-PHE
parasites I-PHE
with O
symptoms O
of O
wasting O
, O
pallor B-PHE
or O
sallowness B-PHE
, O
potbelly B-PHE
, O
and O
chronic B-PHE
diarrhea I-PHE
. O

-DOCSTART- O


To O
benefit O
qi O
; O
To O
soothe O
stomach B-PHE
; O
To O
reduce O
lump B-PHE
; O
To O
stop O
vomiting B-PHE

-DOCSTART- O


soothe O
the O
sinews B-PHE
and O
invigorate O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


thicken O
the O
intestine B-PHE
and O
stomach B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
feeling O
like O
vomiting B-PHE
caused O
by O
ascending O
stomach B-PHE
Gi O
. O

-DOCSTART- O


Its O
chief O
component O
is O
berberine O
. O

Possessing O
broad-spectrum O
antibacterial B-PHE
and O
antiprotozoal B-PHE
effects O
. O

Intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-PHE
effect O
on O
experimental O
animals O
. O

Small O
dosage O
of O
berberine O
enhances O
the O
action O
of O
acetylcholine O
on O
animals' O
hearts B-PHE
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

Relaxing O
the O
smooth B-PHE
muscles I-PHE
of O
blood O
vessels O
and O
stimulating O
those O
of O
uterus B-PHE
, O
urinary B-PHE
bladderl I-PHE
bronchus I-PHE
and O
gastrointestines B-PHE
. O

Promoting O
bile B-PHE
secretion I-PHE
. O

Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic O
cancer B-PHE
and O
lymphoma B-PHE
. O

-DOCSTART- O


Used O
in O
surgical O
procedures O
where O
a O
rapid O
onset O
and O
brief O
duration O
of O
muscle B-PHE
relaxation I-PHE
is O
needed O
( O
includes O
intubation O
, O
endoscopies O
, O
and O
ECT O
) O

-DOCSTART- O


Keishibukuryogan O
ameliorates O
glucose B-PHE
intolerance I-PHE
and O
hyperlipidemia B-PHE
in O
Otsuka O
Long-Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
. O

-DOCSTART- O


relieve O
lactation O
and O
disperse O
edema B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
benign B-PHE
prostatic I-PHE
hyperplasia I-PHE
. O

-DOCSTART- O


fever B-PHE
with O
affection O
by O
cold B-PHE

-DOCSTART- O


Myelodysplastic B-PHE
Syndrome I-PHE

-DOCSTART- O


Portal B-PHE
Hypertension I-PHE

-DOCSTART- O


May O
be O
used O
to O
treat O
primary O
, O
secondary O
or O
tertiary O
hypothyroidism B-PHE
. O

May O
also O
be O
used O
to O
suppress O
thyroid B-PHE
stimulating O
hormone O
( O
TSH O
) O
secretion O
in O
patients O
with O
simple O
( O
nontoxic O
) O
goiter B-PHE
, O
subacute O
or O
chronic O
lymphocytic B-PHE
thyroiditis I-PHE
multinodular I-PHE
goiter I-PHE
, O
and O
in O
the O
management O
of O
thyroid B-PHE
cancer I-PHE
. O

May O
be O
used O
in O
conjunction O
with O
other O
antithyroid O
agents O
to O
treat O
thyrotoxicosis B-PHE
to O
prevent O
goitrogenesis O
and O
hypothyroidism B-PHE
. O

May O
also O
be O
used O
for O
differential O
diagnosis O
of O
suspected O
mild O
hyperthyroidism B-PHE
or O
thyroid B-PHE
gland I-PHE
autonomy O
. O

-DOCSTART- O


hasten O
delivery O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
regulate O
menstruation B-PHE
. O

-DOCSTART- O


consumption B-PHE
; O

deficiency B-PHE
syndrome I-PHE
; O

disease O
due O
to O
asthenia B-PHE
of O
the O
viscera O

-DOCSTART- O


1 O
For O
cases O
attributive O
to O
deficiency B-PHE
and O
collapse O
of O
vital O
energy O
and O
downward O
flowing O
of O
essential O
substance,which O
manifest O
as O
prolonged O
discharge O
of O
rice-water O
like O
urine B-PHE
, O
pale B-PHE
complexion I-PHE
, O
fatigue B-PHE
, O
pale B-PHE
tongue I-PHE
and O
feeble B-PHE
pulse I-PHE
, O
add O
Fructus O
Corni O
to O
keep O
t O

-DOCSTART- O


Treatment O
haematemesis B-PHE
, O
epistaxis B-PHE
and O
hematuria B-PHE
due O
to O
heat B-PHE
in O
the O
blood B-PHE
, O
febrile B-PHE
diseases I-PHE
with O
thirst B-PHE
, O
jaundice B-PHE
, O
urinary B-PHE
infection I-PHE
with O
difficult O
painful B-PHE
urination I-PHE
, O
edema B-PHE
in O
acute B-PHE
nephritis I-PHE
. O

-DOCSTART- O


Lopinavir O
inhibits O
HIV B-PHE
protease I-PHE
. O

Ritonavir O
inhibits O
the O
CYP3A O
mediated O
metabolism B-PHE
of I-PHE
lopinavir I-PHE
, O
thereby O
providing O
increased O
plasma O
level O
of O
lopinavir O
. O

-DOCSTART- O


vertigo B-PHE
due O
to O
wind-phlegm B-PHE

-DOCSTART- O


In O
order O
to O
better O
understand O
the O
characteristics O
of O
atmospheric O
carbonaceous O
aerosol O
at O
a O
background O
site O
in O
Northeast O
Asia O
, O
semicontinuous O
organic O
carbon O
( O
OC O
) O
and O
elemental O
carbon O
( O
EC O
) O
, O
and O
time-resolved O
water-soluble O
organic O
carbon O
( O
WSOC O
) O
were O
measured O
by O
a O
Sunset O
OC O
/ O
EC O
and O
a O
PILS-TOC O
( O
particle-into-liquid O
sampler O
coupled O
with O
an O
online O
total O
organic O
carbon O
) O
analyzer O
, O
respectively O
, O
at O
the O
Gosan O
supersite O
on O
Jeju O
Island O
, O
Korea O
, O
in O
the O
summer O
( O
May O
42914 O
17 O
) O
and O
fall O
( O
August O
43002 O
30 O
) O
of O
2009 O
. O

Hourly O
average O
OC O
concentration O
varied O
in O
the O
range O
of O
approximately O
0.87-28.38 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
4.07+/- O
2.6 O
microgC O
m-3 O
, O
while O
the O
hourly O
average O
EC O
concentration O
ranged O
approximately O
from O
0.04 O
to O
8.19 O
. O

microgC O
m-3 O
, O
with O
a O
mean O
of O
1.35 O
+/- O
0.71 O
microgC O
m-3 O
, O
from O
May O
28 O
to O
June O
17 O
, O
2009 O
. O
During O
the O
fall O
season O
, O
OC O
varied O
in O
the O
approximate O
range O
0.9-9.6 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
2.3 O
+/-0.80 O
microgC O
m-3 O
, O
whereas O
EC O
ranged O
approximately O
from O
0.01 O
to O
5.4 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
0.66 O
+/- O
0.38 O
microgC O
m-3 O
. O

Average O
contributions O
of O
EC O
to O
TC O
and O
WSOC O
to O
OC O
were O
0.26 O
+/- O
0.097 O
and O
0.206 O
+/-7.4% O
, O
and O
0.376 O
+/- O
0.235 O
and O
0.572 O
+/- O
0.222 O
during O
summer O
and O
fall O
seasons O
, O
respectively O
. O

As O
expected O
, O
clear O
diurnal O
variation O
of O
WSOC/OC O
was O
found O
in O
summer O
, O
varying O
from O
0.22 O
during O
the O
nighttime O
up O
to O
0.72 O
during O
the O
daytime O
, O
mainly O
due O
to O
the O
photo-oxidation O
process O
. O

In O
order O
to O
investigate O
the O
effect O
of O
air O
mass O
pathway O
on O
the O
characteristics O
of O
carbonaceous O
aerosol O
, O
5-day O
back-trajectory O
analysis O
was O
conducted O
using O
the O
HYSPLIT O
model O
. O

The O
air O
mass O
pathways O
were O
classified O
into O
four O
types O
: O
Continental O
( O
CC O
) O
, O
Marine O
( O
M O
) O
, O
East O
Sea O
( O
ES O
) O
and O
Korean O
Peninsula O
( O
KP O
) O
. O

The O
highest O
OC/EC O
ratio O
of O
3.63 O
was O
observed O
when O
air O
mass O
originated O
from O
the O
Continental O
area O
( O
CC O
) O
. O

The O
lowest O
OC/EC O
ratio O
of O
0.79 O
was O
measured O
when O
air O
mass O
originated O
from O
the O
Marine O
area O
( O
M O
) O
. O

A O
high O
OC O
concentration O
was O
occasionally O
observed O
at O
Gosan O
due O
to O
local O
biomass O
burning O
activities O
. O

The O
contribution O
of O
secondary O
OC O
to O
total O
OC O
varied O
approximately O
between O
0.084 O
and O
0.322 O
and O
depended O
on O
air O
mass O
type O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
move O
qi O
and O
quicken O
blood B-PHE
. O

-DOCSTART- O


illness B-PHE
that O
occurs O
on O
teeth O

-DOCSTART- O


Muscle B-PHE
Fatigue I-PHE

-DOCSTART- O


anticancer B-PHE

-DOCSTART- O


repel O
all O
malign O
sore B-PHE

-DOCSTART- O


1 O
Flavonoid O
glycoside O
, O
one O
of O
its O
components O
, O
increases O
coronary B-PHE
flow I-PHE
, O
reduces O
myocardial B-PHE
oxygen I-PHE
consumption I-PHE
and O
lowers O
arterial B-PHE
pressure I-PHE
. O

2 O
. O
Cardiotonic O
on O
frogs' O
hearts O
in O
vitro O
; O
low O
concentration O
of O
its O
extract O
exerts O
a O
vasoconstrictive O
effect O
on O
the O
vessels O
of O
frogs' O
leg O
and O
high O
concentration O
, O
vasodilative O

3 O
. O
Its O
liquid O
extract O
shortens B-PHE
clotting I-PHE
time I-PHE
and O
exerts O
hemostatic B-PHE
effect I-PHE
in O
rabbit O
. O

-DOCSTART- O


affection O
by O
cold B-PHE
1 O
common O
cold B-PHE
2 O
influenza B-PHE

-DOCSTART- O


Complications B-PHE
due O
to O
blood B-PHE
stagnation I-PHE

-DOCSTART- O


settle O
the O
pain B-PHE

-DOCSTART- O


inability B-PHE
to O
turn O
over O

-DOCSTART- O


headache B-PHE

-DOCSTART- O


Treatment O
of O
endemic B-PHE
goiter I-PHE
, O
hyperthyroidism B-PHE
, O
whooping B-PHE
cough I-PHE
, O
cough B-PHE
of O
lung-heat O
type O
, O
thyroid B-PHE
adenoma I-PHE
, O
thyroid B-PHE
cancer I-PHE
, O
tumour B-PHE
of O
digestive O
tract O
, O
lung B-PHE
and I-PHE
mammary I-PHE
cancer I-PHE
, O
etc O
. O

-DOCSTART- O


stop O
bleeding B-PHE

-DOCSTART- O


HIV-1 B-PHE
Infection I-PHE

-DOCSTART- O


Possessing O
broad-spectrum O
antibacterial B-PHE
and I-PHE
antiprotozoal I-PHE
effects I-PHE
. O

-DOCSTART- O


severe O
palpitation I-PHE
; O

continuous O
violent O
palpitation B-PHE

-DOCSTART- O


impotence B-PHE

-DOCSTART- O


Unspecified O
Childhood O
Solid B-PHE
Tumor I-PHE
, O
Protocol O
Specific O

-DOCSTART- O


strengthen O
tooth B-PHE

-DOCSTART- O


stop O
bleeding B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


To O
remove O
toxic B-PHE
heat I-PHE
, O
to O
soothe O
the O
sore B-PHE
throat I-PHE
, O
to O
resolve O
phlegm B-PHE
, O
and O
to O
relieve O
dysuria B-PHE
. O

-DOCSTART- O


Polysaccharide-Containing O
Macromolecules O
in O
a O
Kampo O
( O
Traditional O
Japanese O
Herbal O
) O
Medicine O
, O
Hochuekkito O
: O
Dual O
Active O
Ingredients O
for O
Modulation O
of O
Immune O
Functions O
on O
Intestinal B-PHE
Peyer's I-PHE
Patches I-PHE
and O
Epithelial B-PHE
cells I-PHE
. O

-DOCSTART- O


cool O
blood B-PHE
and O
stop O
dysentery B-PHE

-DOCSTART- O


Promethazine O
hydrochloride O
selectively O
blocks O
peripheral O
H1 O
receptors O
thereby O
diminishing O
the O
effects B-PHE
of I-PHE
histamine I-PHE
on O
effector O
cells O
. O

-DOCSTART- O


difficulty B-PHE
in I-PHE
urination I-PHE
and I-PHE
defecation I-PHE
; O
constipation B-PHE
and O
ischuria B-PHE

-DOCSTART- O


difficulty B-PHE
in I-PHE
urination I-PHE

-DOCSTART- O


reinforce O
bone B-PHE
fracture I-PHE

-DOCSTART- O


Healthy B-PHE

-DOCSTART- O


The O
Chinese O
herb O
modified O
Yi O
Guan O
Jian O
( O
mYGJ O
) O
is O
an O
effective O
regimen O
that O
is O
usually O
used O
in O
outpatients O
with O
chronic B-PHE
liver I-PHE
diseases I-PHE
such O
as O
fibrosis B-PHE
and O
cirrhosis B-PHE
. O

However O
, O
the O
mechanism O
for O
the O
action O
of O
mYGJ O
on O
liver B-PHE
fibrosis I-PHE
is O
not O
yet O
clear O
. O

In O
this O
study O
, O
we O
found O
that O
mYGJ O
induced O
hepatic B-PHE
stellate I-PHE
cells I-PHE
( O
HSCs B-PHE
) O
apoptosis O
concomitant O
with O
the O
downregulation O
of O
Bcl-2 B-PHE
expression I-PHE
and O
slight O
elevation O
of O
Bax B-PHE
level I-PHE
. O

Moreover O
, O
the O
reactive O
oxygen O
species O
( O
ROS O
) O
were O
generated O
in O
the O
early O
stages O
of O
mYGJ-induced B-PHE
HSCs I-PHE
apoptosis I-PHE
to O
facilitate O
calcium O
and O
cytochrome O
c O
release O
from O
the O
mitochondria O
to O
cytosol O
. O

Subsequently O
, O
caspase B-PHE
9 I-PHE
and O
caspase B-PHE
3 I-PHE
were O
activated O
. O

Furthermore O
, O
the O
activation O
of O
ER O
stress-associated O
caspase B-PHE
12 I-PHE
in O
HSCs B-PHE
was O
also O
evaluated O
. O

Together O
, O
we O
report O
the O
first O
evidence-based O
study O
to O
demonstrate O
that O
mYGJ O
decoction O
induces O
HSCs B-PHE
apoptosis O
through O
ROS O
accumulation O
and O
the O
intrinsic O
apoptosis O
pathway O
. O

These O
findings O
provide O
rationale O
for O
further O
clinical O
investigation O
of O
traditional O
Chinese O
medicine O
recipes O
against O
liver B-PHE
fibrosis I-PHE
. O

-DOCSTART- O


Diagnostic O
agent O
for O
radionuclide O
myocardial O
perfusion O
imaging O
( O
MPI O
) O

-DOCSTART- O


Otitis B-PHE
Media I-PHE

-DOCSTART- O


Dilating O
the O
coronary B-PHE
artery I-PHE
and O
blood B-PHE
vessels I-PHE
of O
hind O
legs O
in O
dogs O
. O

Lowering O
blood B-PHE
pressure I-PHE
transiently O
. O

Inhibiting O
the O
intestines B-PHE
in O
rabbits O
in O
vitro O
. O

Its O
component O
paeoniflorin O
inhibits O
the O
central B-PHE
nervous I-PHE
systems I-PHE
. O

-DOCSTART- O


Hydrocortisone O
binds O
to O
the O
cytosolic O
glucocorticoid O
receptor O
and O
promotes O
protein B-PHE
catabolism I-PHE
, O
gluconeogenesis B-PHE
, O
capillary B-PHE
wall I-PHE
stability I-PHE
, O
renal B-PHE
excretion I-PHE
of I-PHE
calcium I-PHE
, O
and O
suppresses O
immune B-PHE
and I-PHE
inflammatory I-PHE
responses I-PHE
. O

Polymyxin O
B O
sulfate O
interacts O
with O
the O
lipopolysaccharide B-PHE
of O
the O
cytoplasmic O
outer O
membrane O
of O
Gram-negative O
bacteria O
, O
altering O
membrane B-PHE
permeability I-PHE
and O
causing O
cell B-PHE
death I-PHE
. O

Chloramphenicol O
reversibly O
binds O
to O
the O
L16 O
protein O
of O
the O
50S O
subunit O
of O
bacterial O
ribosomes O
, O
thus O
inhibits O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


Its O
component O
oleanolic O
acid O
can O
prevent O
and O
relieve O
cyclophosphamide-induced B-PHE
leukocytopenia I-PHE
in O
mice O
. O

Enhancing O
the O
anoxia B-PHE
tolerance I-PHE
of O
mice O
under O
atmospheric O
pressure O
. O

Increasing O
coronary B-PHE
flow I-PHE
in O
rabbits O
in O
vitro O
. O

Relaxing O
adrenaline-induced B-PHE
vasocontricyion I-PHE
in O
rabbits O
in O
vitro O
. O

Lowering O
the O
level O
of O
blood B-PHE
lipid I-PHE
. O

-DOCSTART- O


reinforce O
marrow B-PHE

-DOCSTART- O


deficiency B-PHE
and I-PHE
cold I-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
stomach I-PHE
; O
hypofunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
with O
cold B-PHE
manifestations O

-DOCSTART- O


Benzodiazepines O
, O
in O
this O
way O
, O
block O
the O
cortical B-PHE
and I-PHE
limbic I-PHE
arousal I-PHE
that O
occurs O
following O
stimulation O
of O
the O
reticular O
pathways O
. O

-DOCSTART- O


red B-PHE
face I-PHE

-DOCSTART- O


all O
kinds O
of O
malignant B-PHE
furuncle I-PHE

-DOCSTART- O


declination O
of O
the O
fire O
of O
the O
vital O
gate O
dysfunction O
of O
reproduction O
due O
to O
insufficiency O
of O
the O
kidney-yang O
. O

-DOCSTART- O


precipitation B-PHE
of I-PHE
blood I-PHE
during O
pregnancy B-PHE

-DOCSTART- O


distention B-PHE
and I-PHE
pain I-PHE
in I-PHE
chest I-PHE
and I-PHE
abdomen I-PHE
with O
driving O
up O
Qi O

-DOCSTART- O


boil B-PHE
in O
the O
throat O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
hepatitis B-PHE
( O
viral B-PHE
, I-PHE
B I-PHE
) O
. O

-DOCSTART- O


Asthma B-PHE
, O
chronic B-PHE
bronchitis I-PHE
, O
stomachache B-PHE
, O
wind-damp B-PHE
pain I-PHE
, O
scrofula B-PHE
, O
cold B-PHE
suppurative I-PHE
sore I-PHE
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Diabetes B-PHE
, O
annoyment O
, O
thirst B-PHE
, O
easy O
to O
get O
hungry B-PHE
, O
tiredness B-PHE
and O
underweight B-PHE
, O
dry B-PHE
mouth I-PHE
and I-PHE
throat I-PHE
, O
short B-PHE
breath I-PHE
and O
nervousness B-PHE
, O
sweating B-PHE
, O
dry B-PHE
stool I-PHE
, O
red B-PHE
tong I-PHE
and O
lack B-PHE
of I-PHE
saliva I-PHE
, O
weak O
and O
frequent B-PHE
pulse I-PHE

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Overall O
CVD B-PHE
, O
Other O
system B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


Ceftazidime O
inhibits O
the O
bacteria B-PHE
cell I-PHE
wall I-PHE
synthesis I-PHE
via O
affinity O
for O
penicillin B-PHE
- I-PHE
binding I-PHE
proteins I-PHE
( O
PBPs B-PHE
) O
. O

The O
reduced O
metronidazole O
then O
covalently O
binds O
to O
DNA O
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial B-PHE
nucleic I-PHE
acid I-PHE
synthesis I-PHE
and O
resulting O
in O
bacterial B-PHE
cell I-PHE
death I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Woman O
, O
Endocrine B-PHE
system I-PHE
, O
Lipid B-PHE
profile I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
General O
woman O

-DOCSTART- O


Secretin O
binds O
to O
the O
secretin O
receptor O
found O
on O
the O
lining O
of O
S O
cells O
in O
the O
duodenum O
and O
G O
cells O
in O
the O
stomach O
. O

Binding O
leads O
to O
the O
secrection O
of O
bicarbonate O
or O
the O
reduction O
of O
the O
secretion B-PHE
of I-PHE
gastrin I-PHE
. O

Properly O
functioning O
organs O
( O
duodenum B-PHE
, O
pancreas B-PHE
and O
stomach B-PHE
) O
should O
be O
responsive O
to O
this O
hormone O

-DOCSTART- O


Cough B-PHE
and O
shortness B-PHE
of I-PHE
breath I-PHE
, O
wind-damp B-PHE
impediment I-PHE
pain I-PHE
, O
itchy B-PHE
skin I-PHE
, O
innominate O
toxin B-PHE
swelling I-PHE
. O

-DOCSTART- O


For O
eliminating O
toxic B-PHE
materials I-PHE
, O
dissolving O
rottenness B-PHE
and O
growing O
new O
muscles B-PHE

-DOCSTART- O


The O
mechanism O
of O
action O
and O
receptor O
for O
PCK3145 O
suggests O
PCK3145 O
to O
be O
a O
signal O
transduction O
inhibitor O
with O
multiple O
ways O
( O
apoptosis B-PHE
, O
anti-angiogenesis B-PHE
and O
anti-metastasis B-PHE
) O
to O
restrict O
disease B-PHE
development I-PHE
. O

-DOCSTART- O


menstrual B-PHE
abdominal I-PHE
pain I-PHE

-DOCSTART- O


Treatment O
of O
arthralgia B-PHE
with O
weakness B-PHE
of O
the O
loins O
and O
knees O
, O
excessive B-PHE
menstrual I-PHE
flow I-PHE
, O
chronic B-PHE
phthisical I-PHE
cough I-PHE
. O

-DOCSTART- O


For O
the O
treatment O
of O
rheumatoid B-PHE
arthritis I-PHE
( O
RA B-PHE
) O
. O

-DOCSTART- O


Fever B-PHE
, O
Sweats B-PHE
, O
and O
Hot B-PHE
Flashes I-PHE

-DOCSTART- O


Damp-heat B-PHE
diarrhea I-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
hemorrhoids B-PHE
, O
pain B-PHE
from O
swollen O
welling O
abscess B-PHE
, O
scrofula B-PHE
. O

-DOCSTART- O


1 O
Inhibiting O
sarcoma180 B-PHE
and O
cervix B-PHE
carcinoma14 I-PHE
in O
mice O
and O
L16 O
cells O
isolated O
from O
human O
liver B-PHE
cancer I-PHE
. O

2 O
. O
Promoting O
the O
adrenocortical B-PHE
function I-PHE
in O
mice O
. O

3 O
. O
Promoting O
metabolism B-PHE
and O
reticuloendothelial B-PHE
function I-PHE
. O

-DOCSTART- O


Vaccination O
of O
humans O
with O
CYT006-AngQb O
has O
been O
shown O
to O
induce O
angiotensin B-PHE
II I-PHE
specific O
antibodies O
that O
should O
inhibit O
binding O
of O
angiotensin B-PHE
II I-PHE
to O
its O
receptors O
and O
thus O
reduce O
the O
narrowing B-PHE
of I-PHE
blood I-PHE
vessels I-PHE
. O

-DOCSTART- O


warm O
the O
middle O
and O
disperse O
cold B-PHE

-DOCSTART- O


Mycophenolate O
stops O
T-cell B-PHE
and I-PHE
B-cell I-PHE
proliferation I-PHE
through O
selective O
inhibition O
of O
the O
de O
novo O
pathway O
of O
purine B-PHE
biosynthesis I-PHE
. O

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
regulate O
menstruation B-PHE
, O
dissipate O
stasis B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


For O
relieving O
exterior B-PHE
syndrome I-PHE

-DOCSTART- O


anhidrosis B-PHE
and O
aversion B-PHE
to I-PHE
cold I-PHE

-DOCSTART- O


To O
Disperse O
the O
stagnated O
liver-qi O
, O
to O
remove O
heat B-PHE
, O
invigorate O
the O
spleen B-PHE
and O
nourishing O
blood B-PHE
. O

-DOCSTART- O


Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective O
immunity B-PHE
, O
Overall O
CVD B-PHE

-DOCSTART- O


dispel O
stasis B-PHE

-DOCSTART- O


For O
activating O
blood B-PHE
and O
reducing O
pain B-PHE
. O

-DOCSTART- O


abdominal B-PHE
distension I-PHE
; O
abdominal B-PHE
fullness I-PHE

-DOCSTART- O


nfantile B-PHE
convulsive I-PHE
seizure I-PHE
due O
to O
fright O

-DOCSTART- O


damage B-PHE
of I-PHE
kidney I-PHE

-DOCSTART- O


Urologic B-PHE
Diseases I-PHE

-DOCSTART- O


Treatment O
of O
stagnation O
of O
qi O
of O
the O
liver B-PHE
and O
stomach B-PHE
marked O
by O
distension B-PHE
and O
pain B-PHE
in O
the O
chest O
and O
hypochondriac O
regions O
, O
stuffiness B-PHE
feeling O
in O
the O
stomach O
, O
anorexia B-PHE
and O
vomiting B-PHE
. O

-DOCSTART- O


have O
no B-PHE
menstruation I-PHE
due O
to O
static B-PHE
blood I-PHE
. O

-DOCSTART- O


In O
countries O
with O
high O
rates O
of O
hepatitis B-PHE
B I-PHE
infection I-PHE
, O
vaccination O
of O
newborns O
has O
not O
only O
reduced O
the O
risk O
of O
infection B-PHE
, O
but O
has O
also O
led O
to O
marked O
reduction O
in O
liver B-PHE
cancer I-PHE
. O

-DOCSTART- O


Gastric B-PHE
Cancer I-PHE

-DOCSTART- O


rigidity B-PHE
of O
the O
limbs O
; O

contracture B-PHE
; O

subjective B-PHE
sensation I-PHE
of O
contraction O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Body B-PHE
weight I-PHE

-DOCSTART- O


Pseudoephedrine O
relaxes O
bronchial B-PHE
smooth I-PHE
muscle I-PHE
by O
stimulating O
beta2-adrenergic O
receptors O
. O

Hydrocodone O
exerts O
its O
analgesic O
activity O
by O
binding O
to O
the O
mu-receptors O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
( O
CNS B-PHE
) O
, O
thereby O
mimicking O
the O
effects O
of O
endogenous O
opioids O
. O

-DOCSTART- O


move O
blood B-PHE

-DOCSTART- O


white B-PHE
vaginal I-PHE
discharge I-PHE
; O
leukorrhea B-PHE

-DOCSTART- O


Blood B-PHE
stasis I-PHE
in O
the O
hypochondriac O
region O
due O
to O
traumatic B-PHE
injury I-PHE
characterised O
by O
hypochondriac B-PHE
pain I-PHE
. O

Traumatic O
swelling O
pain B-PHE
, O
intercostal B-PHE
neuralgia I-PHE
, O
costal B-PHE
chrondritis I-PHE
marked O
by O
accumulation O
of O
blood B-PHE
stasis I-PHE
can O
be O
treated O
by O
the O
modified O
recipe O
. O

-DOCSTART- O


1 O
Containing O
potassium O
acetate O
and O
chloride O
which O
exert O
diuretic B-PHE
effect I-PHE
. O

2 O
. O
Orall O
adminstration O
of O
its O
decoction O
or O
infusion O
( O
2g/kg O
) O
can O
reduce O
vaccine-induced O
fever B-PHE
in O
rabbits O
. O

3 O
. O
Cardiotonic O
on O
the O
heart O
of O
frog O
weakened O
by O
quinine O
. O

Also O
causing O
constriction B-PHE
of I-PHE
blood I-PHE
vessels I-PHE
and O
rising O
of O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Different O
poisoning B-PHE
, O

-DOCSTART- O


abdominal B-PHE
pain I-PHE

-DOCSTART- O


five O
colored O
dysentery B-PHE
; O
dysentery B-PHE
with O
multi-colored O
stools O

-DOCSTART- O


a O
symptom B-PHE
of I-PHE
perspiration I-PHE
. O

-DOCSTART- O


affection O
by O
summer O
heat O
; O
exposure O
to O
summer O
heat O

-DOCSTART- O


Dalfopristin O
inhibits O
the O
early O
phase O
of O
protein B-PHE
synthesis I-PHE
by O
acting O
on O
bacterial O
ribosome O
. O

Quinupristin O
binds O
to O
a O
nearby O
site O
on O
the O
50S O
ribosomal O
subunit O
and O
prevents O
elongation O
of O
the O
polypeptide O
as O
well O
as O
causing O
incomplete O
chains O
to O
be O
released O
. O

-DOCSTART- O


Childhood B-PHE
T I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Polythiazide O
is O
a O
thiazide O
diuretic O
used O
to O
decrease O
edema B-PHE
and O
decrease O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Lymphocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
eliminate O
pus B-PHE
. O

-DOCSTART- O


Japanese O
herbal O
( O
Kampo O
) O
medicine O
, O
Hochuekkito O
( O
Bu-Zhong-Yi-Qi-Tang O
in O
Chinese O
, O
TJ-41 O
) O
and O
Juzentaihoto O
( O
Shi-Quan-Da-Bu-Tang O
in O
Chinese O
, O
TJ-48 O
) O
are O
well-known O
Kampo O
formulas O
used O
as O
tonic O
. O

Although O
these O
medicines O
have O
separately O
been O
applied O
to O
the O
patients O
clinically O
depending O
on O
their O
symptoms O
, O
the O
differences O
of O
the O
pharmacological O
activities O
for O
these O
medicines O
have O
not O
been O
fully O
understood O
. O

TJ-48 O
and O
TJ-41 O
were O
compared O
for O
their O
effects O
on O
antibody B-PHE
response I-PHE
in O
upper O
respiratory B-PHE
mucosal I-PHE
immune I-PHE
system I-PHE
in O
vivo O
. O

Oral O
administration O
of O
TJ-41 O
( O
100 O
mg O
kg(-1 O
) O
per O
day O
) O
to O
early O
aged O
BALB/c O
mice O
, O
which O
were O
nasally O
sensitized O
with O
influenza O
hemagglutinin O
vaccine O
, O
significantly O
enhanced O
influenza O
virus-specific O
IgA B-PHE
and I-PHE
IgG I-PHE
antibody I-PHE
titers O
in O
nasal O
cavity O
and O
sera O
, O
respectively O
. O

However O
, O
oral O
administration O
of O
TJ-48 O
( O
100 O
mg O
kg(-1 O
) O
per O
day O
) O
failed O
to O
show O
the O
enhancing O
activity O
. O

TJ-41 O
increased O
not O
only O
influenza O
virus-specific O
IgA B-PHE
antibody I-PHE
titer O
but O
also O
total O
IgA B-PHE
antibody I-PHE
titer O
in O
nasal O
cavity O
. O

The O
stimulating O
activity O
of O
TJ-41 O
disappeared O
after O
treatment O
with O
methotrexate O
. O

The O
present O
study O
strongly O
suggests O
that O
TJ-41 O
can O
stimulate O
the O
mucosal B-PHE
immune I-PHE
system I-PHE
of O
upper O
respiratory O
tract O
, O
and O
results O
in O
enhancement O
of O
antigen-specific B-PHE
antibody I-PHE
response I-PHE
in O
upper O
respiratory B-PHE
mucosal I-PHE
and O
systemic B-PHE
immune I-PHE
systems I-PHE
. O

-DOCSTART- O


To O
nourish O
blood B-PHE
, O
stanch O
bleeding B-PHE
, O
calm O
liver B-PHE
, O
moisten O
dryness B-PHE
. O

-DOCSTART- O


Thin B-PHE
Eyebrow I-PHE

-DOCSTART- O


Infant B-PHE
, I-PHE
Large I-PHE
for I-PHE
Gestational I-PHE
Age I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
chest O
, O
to O
eliminate O
the O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
, O
relieve O
vomiting B-PHE
. O

-DOCSTART- O


1 O
To O
moisurize O
the O
lung B-PHE
and O
relieve O
cough B-PHE
( O
lung-dryness B-PHE
with O
cough B-PHE
and O
hemoptysis B-PHE
) O
. O
2 O
To O
relieve O
cardiac B-PHE
heat I-PHE
and O
tranquilize O
the O
mind O
( O
convalescence O
of O
febrile B-PHE
diseases I-PHE
or O
yin-deficiency O
with O
heat B-PHE
manifested O
as O
irritability B-PHE
, O
insomnia B-PHE
, O
dreaminess B-PHE
, O
palpitation B-PHE
and O
absent-mindedness B-PHE
) O
. O

-DOCSTART- O


Svere O
nodular B-PHE
acne I-PHE

-DOCSTART- O


To O
remove O
toxic B-PHE
heat I-PHE
, O
to O
promote O
the O
drainage B-PHE
of I-PHE
pus I-PHE
, O
and O
to O
relieve O
dysuria B-PHE
. O

-DOCSTART- O


moisten O
skin B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
a O
fever B-PHE
, O
shortness B-PHE
of I-PHE
breath I-PHE
, O
irritability B-PHE
and O
restlessness B-PHE
, O
mania B-PHE
derange I-PHE
due O
to O
blocked B-PHE
chest I-PHE
and O
diaphragm B-PHE
. O

It O
has O
a O
sever O
pain B-PHE
when O
pushing O
. O

-DOCSTART- O


anti-inflammatory B-PHE
effects O
of O
the O
Chinese O
herbal O
formula O
FAHF-2 O
in O
experimental O
and O
human O
IBD O
. O

-DOCSTART- O


To O
warm O
and O
replenish O
qi O
and O
blood B-PHE
. O

-DOCSTART- O


distension B-PHE
and O
pain B-PHE
of O
the O
breast O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
a O
pain B-PHE
, I-PHE
bloat I-PHE
, I-PHE
and I-PHE
fullness I-PHE
in I-PHE
abdominal I-PHE
region I-PHE
. O

-DOCSTART- O


lumbago B-PHE
due O
to O
the O
kidney B-PHE
deficiency I-PHE

-DOCSTART- O


relieve O
stasis B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


de O
Novo O
Kidney O
Transplantation O

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
, O
resuscitate O
, O
tranquilize O
, O
suppress O
wind B-PHE
and O
relieve O
convulsion B-PHE
. O

-DOCSTART- O


1 O
Its O
purgative O
effect O
is O
as O
three O
times O
as O
castor O
oil O
. O
2 O
. O

Its O
fresh O
preparation O
may O
inhibit O
the O
progress O
of O
acute B-PHE
lymphatic I-PHE
leukemia I-PHE
, O
acute O
and O
chronic B-PHE
granulocytic I-PHE
leukemia I-PHE
and O
acute B-PHE
monocytic I-PHE
leukemia I-PHE
. O

-DOCSTART- O


bleeding B-PHE
before O
defecation B-PHE

-DOCSTART- O


unblock O
blood B-PHE
vessel I-PHE

-DOCSTART- O


Wind-cold B-PHE
common O
cold B-PHE
, O
summerheat O
damage O
, O
vomiting B-PHE
diarrhea B-PHE
with O
abdominal B-PHE
pain I-PHE
, O
dribbling O
pain B-PHE
of I-PHE
urination I-PHE
, O
wind-damp B-PHE
impediment O
pain B-PHE
, O
cough B-PHE
and O
asthma B-PHE
, O
bronchial B-PHE
asthma I-PHE
. O

-DOCSTART- O


anhidrosis B-PHE
; O
adiaphoria B-PHE
; O
adiaphoresis B-PHE

-DOCSTART- O


Stage O
III O
Childhood B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
a O
pain B-PHE
under O
the O
side O
. O

-DOCSTART- O


tidal B-PHE
fever I-PHE
in O
the O
afternoon O

-DOCSTART- O


Eye B-PHE
health I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Eye B-PHE
, O
Diet B-PHE
cardiovascular I-PHE
disease I-PHE

-DOCSTART- O


Bleeding B-PHE
due O
to O
blood B-PHE
heat I-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
knocks O
and O
falls B-PHE
, O
impediment O
pain B-PHE
in O
joints O
. O

-DOCSTART- O


constipation B-PHE
and O
difficulty B-PHE
in I-PHE
urination I-PHE

-DOCSTART- O


To O
desolve O
stagnation B-PHE
; O

To O
stop O
bleeding B-PHE
; O

To O
modulate O
period O

-DOCSTART- O


Cold B-PHE
pain I-PHE
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-PHE
, O
cold O
mounting O
with O
abdominal B-PHE
pain I-PHE
, O
menstrual O
disorder O
. O

-DOCSTART- O


1 O
For O
cases O
of O
malaria B-PHE
with O
splenomegaly B-PHE
, O
epicgastric B-PHE
fullness I-PHE
, O
whitish B-PHE
fur I-PHE
on I-PHE
the I-PHE
tongue I-PHE
, O
wiry B-PHE
pulse I-PHE
, O
which O
are O
attributive O
to O
dysfunction B-PHE
of I-PHE
spleen I-PHE
and O
stagnation O
of O
vital O
energy O
and O
blood B-PHE
, O
omit O
Glycyrrhizae O
and O
add O
Ramulus O
cinnamoni O
, O
carapax O
trionycis O
to O
ac O

-DOCSTART- O


Recently O
, O
also O
used O
for O
biliary B-PHE
ascariasis I-PHE
, O
biliary B-PHE
infection I-PHE
and O
cholelithiasis B-PHE
with O
abdominal B-PHE
pain I-PHE
( O
adhesive O
ascarial O
and O
paralytic B-PHE
ileus I-PHE
) O
. O

-DOCSTART- O


Treatment O
of O
carbuncle O
, O
boil B-PHE
and O
other O
pyogenic B-PHE
infections I-PHE
of O
the O
skin O
, O
sore B-PHE
throat I-PHE
, O
scrofula B-PHE
, O
constipation B-PHE
. O

-DOCSTART- O


Tardive B-PHE
Dyskinesia I-PHE
. O

-DOCSTART- O


tonify O
the O
bladder B-PHE

-DOCSTART- O


tinea B-PHE

-DOCSTART- O


Haemostasis B-PHE

-DOCSTART- O


This O
is O
insanity B-PHE
caused O
by O
hurt O
of O
mind O
due O
to O
vexation B-PHE
and O
stuffiness B-PHE
. O

-DOCSTART- O


The O
previous O
experimental O
studies O
have O
demonstrated O
that O
addition O
of O
Huang O
Qi O
( O
[symbol O
: O
see O
text] O
Radix O
Astragali O
) O
to O
the O
formulated O
recipe O
Sheng O
Mai O
Yin O
( O
[symbol O
: O
see O
text] O
Decoction O
for O
Pulse-activation O
) O
exerts O
the O
effects O
of O
strengthening O
the O
myodynamia B-PHE
, O
increasing O
the O
coronary B-PHE
flow I-PHE
, O
improving O
myocardial B-PHE
metabolism I-PHE
, O
and O
resisting O
the O
arrhythmia B-PHE
. O

The O
active O
component O
of O
Huang O
Lian O
( O
[symbol O
: O
see O
text] O
Rhizoma O
Coptidis O
) O
can O
prolong O
the O
myocardial B-PHE
action I-PHE
potential O
and O
antagonize O
the O
chloroform- O
, O
aconitine- O
, O
barium O
chloride- O
, O
epinephrine- O
or O
coronary B-PHE
ligation-induced I-PHE
arrhythmia I-PHE
by O
blocking O
the O
calcium O
channel O
. O

Ku O
Shen O
( O
[symbol O
: O
see O
text] O
Radix O
Sophorae O
Flavescentis O
) O
contains O
matrine O
and O
flavones O
, O
which O
act O
as O
quinidine O
to O
decrease O
the O
excitability B-PHE
of I-PHE
the I-PHE
myocardium I-PHE
, O
prolong O
the O
refractory O
period O
, O
and O
inhibit O
the O
ectopic B-PHE
cardiac I-PHE
rhythm I-PHE
. O

And O
Dan O
Shen O
( O
[symbol O
: O
see O
text] O
Radix O
Salviae O
Miltiorrhizae O
) O
has O
the O
action O
of O
improving O
the O
ischemic B-PHE
state I-PHE
of O
the O
myocardium B-PHE
by O
dilating O
the O
coronary B-PHE
vessels I-PHE
. O

In O
conclusion O
, O
the O
definite O
therapeutic O
effects O
of O
Huang O
Lian O
Sheng O
Mai O
Yin O
in O
treating O
ventricular B-PHE
, I-PHE
atrial I-PHE
and I-PHE
nodal I-PHE
arrhythmia I-PHE
suggests O
that O
the O
prescription O
is O
rational O
and O
accords O
with O
the O
therapeutic O
principle O
of O
TCM O
. O

Except O
discomfort B-PHE
in O
the O
gastric B-PHE
cavity I-PHE
and O
poor O
appetite B-PHE
experienced O
by O
some O
patients O
, O
there O
is O
no B-PHE
toxic I-PHE
or O
adverse O
reaction O
. O

-DOCSTART- O


To O
relieve O
muscle B-PHE
; O
To O
clear O
heat B-PHE
, O
To O
accelerate O
rash B-PHE
, O
To O
stop O
cough B-PHE

-DOCSTART- O


clear O
heat B-PHE
and O
cool O
blood B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
breast B-PHE
cancer I-PHE
, O
head B-PHE
and I-PHE
neck I-PHE
cancer I-PHE
, O
and O
lung B-PHE
cancer I-PHE
. O

-DOCSTART- O


1 O
To O
reduce O
heat B-PHE
caused O
by O
deficient O
yin O
; O
2 O
To O
clear O
heat B-PHE
in O
infants O
caused O
by O
malnutrition B-PHE

-DOCSTART- O


Tuberculosis B-PHE
, O
weak O
yin O
and O
agitated O
fire O
, O
thin B-PHE
and I-PHE
hot I-PHE
body I-PHE
, O
cough B-PHE
, O
phlegm B-PHE
, O
spitting B-PHE
blood I-PHE
, O
chest B-PHE
pain I-PHE
, O
dry B-PHE
mouth I-PHE
, O
frequent B-PHE
pulse I-PHE

-DOCSTART- O


dyspnea B-PHE
due O
to O
lung-heat B-PHE

-DOCSTART- O


Treatment O
of O
toothache B-PHE
due O
to O
caries B-PHE
, O
sores B-PHE
, O
ulcers B-PHE
, O
mastitis B-PHE
, O
scrofula B-PHE
, O
ringworm B-PHE
, O
tinea B-PHE
unguium I-PHE
. O

-DOCSTART- O


wind B-PHE
stroke I-PHE

apoplexy B-PHE

invasion B-PHE
of I-PHE
wind I-PHE
pathogen I-PHE

wind-stroke B-PHE
syndrome I-PHE
syndrome O
due O
to O
external O
affection O
by O
the O
pathogenic B-PHE
wind I-PHE
, O
manifested O
by O
fever B-PHE
, O
headache B-PHE
, O
perspiration B-PHE
, O
slow B-PHE
and I-PHE
floating I-PHE
pulse I-PHE
. O

-DOCSTART- O


Diabetes B-PHE
Mellitus I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE

-DOCSTART- O


Inhibiting O
the O
excessive O
secretion B-PHE
of I-PHE
bronchi I-PHE
and I-PHE
uterus I-PHE
. O

-DOCSTART- O


Qi O
vacuity O
, O
yin O
depletion O
and O
effulgent O
fire O
, O
cough B-PHE
and O
asthma B-PHE
with O
phlegm-blood B-PHE
, O
vacuity O
heat B-PHE
and O
vexation O
fatigue B-PHE
, O
diabetes B-PHE
mellitus I-PHE
due O
to O
internal O
heat B-PHE
, O
thirst B-PHE
with O
dry B-PHE
throat I-PHE
. O

-DOCSTART- O


For O
the O
treatment O
of O
bacterial B-PHE
infections I-PHE
. O

-DOCSTART- O


Known O
or O
Suspected O
Focal B-PHE
Liver I-PHE
Lesions I-PHE

-DOCSTART- O


clear O
heat B-PHE
and O
relieve O
toxicity B-PHE

-DOCSTART- O


join O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


stop O
tearing O

-DOCSTART- O


sores B-PHE
; O
boil B-PHE
suppurative I-PHE
infection I-PHE
on O
the O
body O
surface O
. O
including O
carbuncle B-PHE
, O
furuncle B-PHE
, O
deep-rooted O
carbuncle B-PHE
, O
multiple O
abscess B-PHE
, O
scrofula B-PHE
, O
ulcer B-PHE
. O

-DOCSTART- O


1 O
To O
dispel O
cold B-PHE
and O
stop O
pain B-PHE
; O
2 O
To O
regulate O
qi O
and O
harmonize O
the O
stomach B-PHE

-DOCSTART- O


Treatment O
of O
chronic B-PHE
rheumatiod I-PHE
arthritis I-PHE
with O
numbness B-PHE
and O
ankylosis B-PHE
, O
hemiplegia B-PHE
in O
stroke O
, O
convulsion B-PHE
, O
tetanus B-PHE
, O
leprosy B-PHE
, O
scabies B-PHE
, O
scrofula B-PHE
with O
suppuration B-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
disinhibit O
urine B-PHE
, O
relieve O
cough B-PHE
, O
stanch O
bleeding B-PHE
. O

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
, O
relieve O
cough B-PHE
and O
eliminate O
phlegm B-PHE
. O

-DOCSTART- O


Untreated O
Childhood B-PHE
Myeloid I-PHE
Neoplasm I-PHE

-DOCSTART- O


sores B-PHE
of O
the O
mouth O
or O
tongue O
; O
aphthae B-PHE
and O
boil B-PHE
of O
mouth O
and O
tongue O

-DOCSTART- O


Treatment O
of O
dry B-PHE
cough I-PHE
caused O
by O
heat B-PHE
in O
the O
lung O
, O
bloody B-PHE
sputum I-PHE
in O
phthisis B-PHE
, O
thirst B-PHE
in O
febrile B-PHE
diseases I-PHE
. O

-DOCSTART- O


To O
suppress O
cough B-PHE
and O
calm O
asthma B-PHE
, O
dissipate O
stasis B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Lidocaine O
alters O
signal O
conduction O
in O
neurons B-PHE
by O
blocking O
the O
fast O
voltage B-PHE
gated I-PHE
sodium I-PHE
( I-PHE
Na+ I-PHE
) I-PHE
channels I-PHE
in O
the O
neuronal B-PHE
cell I-PHE
membrane I-PHE
that O
are O
responsible O
for O
signal O
propagation O
. O

Ceftriaxone O
works O
by O
inhibiting O
the O
mucopeptide B-PHE
synthesis I-PHE
and O
results O
in O
the O
formation O
of O
defective B-PHE
cell I-PHE
walls I-PHE
and O
cell B-PHE
death I-PHE
. O

-DOCSTART- O


flatulence B-PHE
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O

-DOCSTART- O


thirst B-PHE

-DOCSTART- O


105AD7 O
vaccine O
is O
a O
human O
anti-idiotype O
which O
mimics O
the O
antigen B-PHE
791Tgp72 I-PHE
. O

The O
mechanism O
of O
action O
of O
the O
vaccine O
has O
recently O
been O
clarified O
. O

The O
anti-idiotype O
is O
rapidly O
internalized O
on O
antigen B-PHE
presenting O
cells O
by O
Fc O
mediated O
endocytosis O
as O
both O
Fab O
and O
Ab O
complexed O
to O
alum O
are O
processed O
1000 O
fold O
less O
efficiently O
than O
whole O
Ab O
. O

Sequencing O
of O
the O
Ab O
have O
revealed O
that O
the O
CDR-H3 B-PHE
is O
hypermutated O
and O
contains O
HLA B-PHE
A1 I-PHE
, I-PHE
A3 I-PHE
and I-PHE
A24 I-PHE
, O
and O
HLA-DR1 B-PHE
, I-PHE
3 I-PHE
and I-PHE
7 I-PHE
MHC O
binding O
motifs O
. O

105AD7 O
is O
an O
antibody-based O
vaccine O
that O
mimics O
a O
target O
( O
CD55 B-PHE
) O
which O
is O
over-expressed O
in O
numerous O
cancers B-PHE
including O
those O
of O
the O
prostate B-PHE
, O
colon B-PHE
and O
pancreas B-PHE
. O

-DOCSTART- O


disperse O
glomus B-PHE

-DOCSTART- O


spontaneous B-PHE
sweating I-PHE
( O
perspiration B-PHE
) O
frequent B-PHE
sweating I-PHE
due O
to O
lowered B-PHE
superficial I-PHE
resistance I-PHE
brought O
on O
by O
deficiency O
of O
Gi O
. O

-DOCSTART- O


To O
warm O
the O
spleen B-PHE
and O
stomach B-PHE
, O
to O
regulate O
the O
adverse O
flow O
of O
the O
stomach O
qi O
, O
and O
to O
restore O
the O
kidney O
yang O
. O

-DOCSTART- O


warm O
the O
stomach B-PHE

-DOCSTART- O


hematuria B-PHE
; O
bloody B-PHE
urine I-PHE
without O
pain O

-DOCSTART- O


metrorrhagia B-PHE
and O
bloody B-PHE
stool I-PHE

-DOCSTART- O


invigorate O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


retention B-PHE
of I-PHE
the I-PHE
dead I-PHE
fetus I-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Others O

-DOCSTART- O


phlegm B-PHE
syndrome I-PHE
induced O
by O
fright O

-DOCSTART- O


When O
administered O
, O
G17DT O
induces O
an O
immune B-PHE
response I-PHE
producing O
antibodies O
which O
bind O
with O
the O
peptide O
and O
also O
cross-react O
and O
neutralise O
gastrin B-PHE
17 I-PHE
thus O
inhibiting O
the O
growth B-PHE
of I-PHE
cancers I-PHE
and O
metastasis B-PHE
. O

In O
addition O
the O
product O
neutralizes O
glycine-extended B-PHE
gastrin I-PHE
17 I-PHE
which O
is O
also O
a O
stomach O
and O
pancreatic O
cancer O
growth O
factor O
. O

-DOCSTART- O


General O
Anesthetic O
Drug O
Adverse O
Reaction O

-DOCSTART- O


tetanus B-PHE

-DOCSTART- O


Venous B-PHE
Insufficiency I-PHE

-DOCSTART- O


To O
drain O
the O
pus B-PHE
, O
eradicate O
toxicity B-PHE
, O
eliminate O
the O
dead B-PHE
tissue I-PHE
and O
promote O
the O
growth B-PHE
of I-PHE
new I-PHE
tissue I-PHE
. O

-DOCSTART- O


For O
clearing O
heat B-PHE
and O
removing O
toxic B-PHE
substances I-PHE

-DOCSTART- O


eliminate O
melasma B-PHE

-DOCSTART- O


A O
symptom O
that O
a O
person O
has O
tightness B-PHE
in I-PHE
the I-PHE
chest I-PHE
and O
does O
not O
feel O
hungry O
. O

-DOCSTART- O


To O
remove O
phlegm B-PHE
, O
disperse O
the O
lumps B-PHE
, O
detoxify O
and O
relieve O
swelling B-PHE
. O

-DOCSTART- O


G4544 O
reduces O
bone B-PHE
loss I-PHE
by O
inhibiting O
calcium B-PHE
resorption I-PHE
from I-PHE
bone I-PHE
. O

Preclinical O
evidence O
suggests O
that O
the O
mechanism O
of O
G4544 O
action O
is O
multifactorial O
and O
different O
from O
other O
current O
therapies O
used O
to O
treat O
bone B-PHE
loss I-PHE
, O
such O
as O
estrogen B-PHE
or O
selective O
estrogen O
receptor O
modulators O
( O
SERMs O
) O
, O
calcitonin O
, O
or O
bisphosphonates O
( O
e.g O
. O
, O
Zometa O
or O
Fosamax O
) O
. O

G4544 O
preferentially O
accumulates O
in O
metabolically O
active O
regions O
of O
bone O
, O
inhibits O
osteoclast-mediated B-PHE
bone I-PHE
resorption I-PHE
, O
and O
favorably O
alters O
bone B-PHE
mineral I-PHE
composition I-PHE
and O
properties O
. O

-DOCSTART- O


T'aeyang B-PHE
meridian I-PHE
affected O
by O
the O
wind B-PHE
; O

invasion B-PHE
of I-PHE
wind I-PHE
pathogen I-PHE
in O
T'aeyang O
meridian O

-DOCSTART- O


the O
four O
limbs O
are O
swollen B-PHE
and O
they O
feel O
painful O

-DOCSTART- O


constipation B-PHE
; O
suffer B-PHE
from I-PHE
constipation I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Others O
, O
Overall O
CVD O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Body B-PHE
weight I-PHE
, O
Evacuation B-PHE
, O
Hemostatic B-PHE
function I-PHE
. O

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
Overactive I-PHE

-DOCSTART- O


Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


Diarrhea B-PHE
, O
dysentery B-PHE
, O
leprosy B-PHE
, O
scrotal B-PHE
wind I-PHE
, O
itchy B-PHE
skin I-PHE
. O

-DOCSTART- O


tonify O
marrow B-PHE

-DOCSTART- O


rhIGFBP-3 O
is O
a O
protein O
that O
is O
normally O
found O
in O
our O
bloodstream O
that O
has O
been O
shown O
to O
induce O
cancer O
cell O
death O
in O
a O
variety O
of O
experimental O
systems O
. O

Several O
studies O
have O
demonstrated O
that O
cancer B-PHE
risk O
increases O
with O
decreasing O
levels O
of O
circulating O
IGFBP-3 B-PHE
. O

IGFBP-3 B-PHE
can O
induce O
cell B-PHE
cycle I-PHE
arrest I-PHE
and O
enhance O
the O
efficacy O
of O
chemotherapeutic O
agents O
. O

-DOCSTART- O


pain B-PHE
of O
back O
and O
vertebra O

-DOCSTART- O


Dragon's O
blood O
( O
Xuejie O
) O
is O
used O
with O
Frankincense O
( O
Ruxiang O
) O
and O
Myrrh O
( O
Moyao O
) O
in O
the O
formula O
Qili O
San O
. O

-DOCSTART- O


stagnation O
of O
milk O
without O
secretion O
after O
delivery O
. O

-DOCSTART- O


critical B-PHE
symptom I-PHE
complex I-PHE
with O
complicated O
, O
changable O
and O
serious O
conditions O
; O

disease B-PHE
due O
to O
the O
poisonous B-PHE

-DOCSTART- O


Treatment O
of O
menstrual B-PHE
disorders I-PHE
, O
anemia B-PHE
, O
numbness B-PHE
and O
paralysis B-PHE
, O
rheumatic B-PHE
arthralgia I-PHE
. O

-DOCSTART- O


To O
tonify O
the O
spleen B-PHE
, O
to O
relieve O
diarrhea B-PHE
, O
to O
replenish O
the O
kidney B-PHE
, O
to O
arrest O
seminal B-PHE
emission I-PHE
, O
and O
to O
nourish O
the O
heart B-PHE
, O
to O
induce O
tranquillization B-PHE
. O

-DOCSTART- O


clear O
heat B-PHE
and O
moisten O
the O
lung B-PHE

-DOCSTART- O


Acute O
Gout B-PHE
Flare O

-DOCSTART- O


To O
open O
orifices O
and O
arouse O
spirit O
, O
break O
phlegm B-PHE
and O
repel O
foulness O
, O
move O
qi O
and O
quicken O
blood B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


This O
is O
a O
symptom O
with O
bleeding B-PHE
in O
the O
gum O
and O
root O
of O
tooth O
that O
comes O
out O
of O
the O
gums O
caused O
by O
a O
crack B-PHE
of I-PHE
the I-PHE
gum I-PHE
. O

-DOCSTART- O


Adult B-PHE
T I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


GSK716155 O
, O
a O
GLP-1 O
receptor O
agonist O
, O
has O
been O
shown O
to O
have O
multiple O
physiologic O
activities O
in O
the O
central O
nervous O
system O
and O
gastrointestinal O
system O
that O
could O
lower O
A1C O
. O

It O
increases O
peripheral B-PHE
glucose I-PHE
uptake I-PHE
, O
enhances O
insulin B-PHE
secretion I-PHE
, O
decreases O
glucagon B-PHE
secretion I-PHE
, O
delays O
gastric B-PHE
emptying I-PHE
, O
reduces O
food O
intake O
and O
induces O
satiety B-PHE
at O
CNS O
. O

-DOCSTART- O


( O
1 O
) O
pain B-PHE
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O
( O
2 O
) O
upper B-PHE
abdominal I-PHE
pain I-PHE

-DOCSTART- O


This O
is O
passing B-PHE
urine I-PHE
unconsciously I-PHE
. O

-DOCSTART- O


Pain B-PHE

-DOCSTART- O


tinnitus B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
poor B-PHE
appetite I-PHE
, O
vomiting B-PHE
, O
and O
diarrhea B-PHE
due O
to O
various O
reasons O
. O

-DOCSTART- O


warm O
the O
kidney B-PHE
and O
support O
Yang O

-DOCSTART- O


Multiple B-PHE
Myeloma I-PHE
and O
Plasma B-PHE
Cell I-PHE
Neoplasm I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Blood B-PHE
pressure I-PHE
, O
Lipid B-PHE
profile I-PHE
, O
Overall O
CVD B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE

-DOCSTART- O


warm O
the O
kidney B-PHE

-DOCSTART- O


retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
; O
dyspepsia B-PHE
retention O
of O
food O
resulting O
from O
dysfunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE

-DOCSTART- O


Treatment O
of O
impotence B-PHE
, O
seminal B-PHE
emission I-PHE
, O
enuresis B-PHE
, O
frequent B-PHE
urination I-PHE
, O
aching B-PHE
of I-PHE
the I-PHE
loins I-PHE
and I-PHE
knees I-PHE
with O
cold B-PHE
sensation O
, O
asthma B-PHE
in O
deficiency B-PHE
syndromes I-PHE
of O
the O
kidney O
, O
diarrhea B-PHE
occurring O
before O
dawn O
daily O
. O

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Liver B-PHE
, O
Lipid O
profile O
, O
Quality O
of O
life O
, O
absorption B-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD O
, O
Liver B-PHE
health I-PHE
, O
Diet B-PHE
related B-PHE
cardiovascular I-PHE
disease I-PHE
, O
Inflammation B-PHE
, O
Other B-PHE
system I-PHE
health I-PHE
, O
Others O
, O
Neurological B-PHE
systems I-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
motility B-PHE

-DOCSTART- O


Lower O
the O
level B-PHE
of I-PHE
serum I-PHE
cholesterol I-PHE
and O
( O
B)-lipoprotein O
in O
experimental O
animals O
with O
hyperlipidemia. B-PHE
. O

-DOCSTART- O


Nepafenac O
is O
a O
prodrug O
. O

After O
penetrating O
the O
cornea O
, O
nepafenac O
undergoes O
rapid O
bioactivation O
to O
amfenac O
, O
which O
is O
a O
potent O
NSAID O
that O
uniformly O
inhibits O
the O
COX1 B-PHE
and I-PHE
COX2 I-PHE
activity I-PHE
. O

-DOCSTART- O


Thyroid B-PHE
tumor I-PHE
, O
lump B-PHE
in O
neck O
, O
slight B-PHE
yellow I-PHE
tong I-PHE
, O
heavy B-PHE
pulse I-PHE

-DOCSTART- O


scrofula B-PHE
; O
tuberculosis B-PHE
of I-PHE
the I-PHE
cervical I-PHE
lymphic I-PHE
node I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Eye B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Quality O
of O
life O
, O
Eye B-PHE
health I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
General O
woman O
, O
General B-PHE
skin I-PHE
health I-PHE
, O
Others O
, O
Protective B-PHE
immunity I-PHE
, O
Intelligence B-PHE
, O
Endurance B-PHE

-DOCSTART- O


To O
remove O
heat B-PHE
, O
to O
promote O
the O
production O
of O
body B-PHE
fluid I-PHE
, O
and O
to O
facilitate O
the O
drainage O
of O
pus O
and O
the O
subsidence O
of O
swelling B-PHE
. O

-DOCSTART- O


Hypogonadotropic B-PHE
Hypogonadism I-PHE

-DOCSTART- O


forceful O
pulse O

-DOCSTART- O


Esophageal B-PHE
Bleeding I-PHE

-DOCSTART- O


For O
nutritional O
supplementation O
, O
also O
for O
treating O
dietary B-PHE
shortage I-PHE
or I-PHE
imbalance I-PHE
. O

-DOCSTART- O


nourish O
the O
liver B-PHE
and O
kidney B-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Motivation O
, O
Mood O
, O
Endocrine B-PHE
system I-PHE
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


relieve O
toxicity B-PHE

-DOCSTART- O


phlegm-retention B-PHE
syndrome I-PHE
; O
congested B-PHE
fluids I-PHE
; O
retention B-PHE
of I-PHE
phlegm I-PHE
and O
fluid O
( O
1 O
) O
morbid B-PHE
conditions I-PHE
characterized O
by O
accumulation O
of O
dampness O
as O
a O
pathological O
product O
resulting O
from O
dysfunction B-PHE
of I-PHE
the I-PHE
lung I-PHE
, O
spleen B-PHE
md O
kidney B-PHE
or O
from O
disturbance B-PHE
of I-PHE
water I-PHE
circulation I-PHE
in O
the O
passage O
of O
Triple O
Ch'o O
. O

The O
thicker O
dampness B-PHE
is O
called O
phlegm O
, O
while O
the O
thinner O
fluid O
. O

Retention B-PHE
of I-PHE
phlegm I-PHE
and O
fluid O
can O
give O
rise O
to O
various O
diseases B-PHE
, O
one O
of O
the O
four O
kinds O
of O
fluid B-PHE
retention I-PHE
. O

( O
2 O
) O
a O
morbid B-PHE
condition I-PHE
due O
to O
fluid B-PHE
retention I-PHE
in O
the O
stomach O
and O
intestines O
. O

-DOCSTART- O


restrain O
Aconiti B-PHE
Tuber I-PHE

-DOCSTART- O


To O
tonify O
the O
kidney B-PHE

-DOCSTART- O


Lidocaine O
alters O
signal O
conduction O
in O
neurons O
by O
blocking O
the O
fast O
voltage O
gated O
sodium O
( O
Na+ O
) O
channels O
in O
the O
neuronal O
cell O
membrane O
that O
are O
responsible O
for O
signal O
propagation O
. O

-DOCSTART- O


Treatment O
of O
lung B-PHE
abscess I-PHE
with O
purulent B-PHE
expectoration I-PHE
, O
heat B-PHE
in I-PHE
the I-PHE
lung I-PHE
with O
cough B-PHE
and O
dyspnea B-PHE
, O
acute B-PHE
dysentery I-PHE
, O
acute B-PHE
urinary I-PHE
infection I-PHE
, O
carbuncles B-PHE
and O
sores B-PHE
. O

-DOCSTART- O


redness B-PHE
, I-PHE
swelling I-PHE
and I-PHE
pain I-PHE
of I-PHE
the I-PHE
eyes I-PHE

-DOCSTART- O


Persistent B-PHE
Asthma I-PHE

-DOCSTART- O


invigorate O
blood B-PHE
and O
move O
stasis B-PHE

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
cancer/tumors B-PHE
( O
unspecified O
) O
, O
lung B-PHE
cancer I-PHE
, O
myelodysplastic B-PHE
syndrome I-PHE
, O
and O
prostate B-PHE
cancer I-PHE
. O

-DOCSTART- O


Treatment O
of O
stagnancy B-PHE
of I-PHE
undigested I-PHE
food I-PHE
with O
abdominal B-PHE
distension I-PHE
and O
constipation B-PHE
, O
weakness B-PHE
and O
edema B-PHE
of O
the O
legs O
with O
oliguria B-PHE
. O

-DOCSTART- O


1 O
For O
cases O
of O
metrorrhagia B-PHE
attributive O
to O
failure O
of O
the O
spleen B-PHE
to O
control O
blood B-PHE
, O
subtract O
Aucklandiae O
and O
polygalae O
and O
add O
Fructus O
Corni O
to O
nourish O
liver B-PHE
and O
stop O
metrorrhagia B-PHE
. O

2 O
For O
cases O
with O
bloody B-PHE
stools I-PHE
attributive O
to O
hypofunction B-PHE
of I-PHE
spleen I-PHE
with O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Monocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


Treament O
of O
vertigo B-PHE
, O
tinnitus B-PHE
, O
weakness B-PHE
in I-PHE
the I-PHE
loins I-PHE
and I-PHE
knees I-PHE
, O
premature B-PHE
whitening I-PHE
of I-PHE
hair I-PHE
and O
impaired B-PHE
eyesight I-PHE
due O
to O
deficiency O
of O
yin O
of O
the O
liver O
and O
kidney O
. O

-DOCSTART- O


For O
cases O
of O
collapse O
due O
to O
massive O
hemorrhage B-PHE
manifested O
as O
cold B-PHE
limbs I-PHE
, O
oily B-PHE
sweat I-PHE
, O
pale B-PHE
complexion I-PHE
, O
spiritlessness B-PHE
, O
small B-PHE
and I-PHE
indistinct I-PHE
pulse I-PHE
, O
use O
high O
grade O
of O
Radix O
Ginseng O
( O
such O
as O
Ginseng O
Korea O
or O
Ginseng O
Jilin O
) O
instead O
of O
Codonopsis O
Pilosulae O
. O

-DOCSTART- O


1 O
Treatment O
of O
skin B-PHE
infection I-PHE
, O
sorethroat B-PHE
, O
erysipelas B-PHE
, O
appendicitis B-PHE
, O
etc O
. O
Recently O
also O
used O
for O
leptospirosis B-PHE
. O

2 O
Treatment O
of O
conjunctivitis B-PHE
. O
Recently O
used O
for O
acute O
and O
chronic B-PHE
conjunctivitis I-PHE
, O
trachoma B-PHE
, O
keratitis B-PHE
, O
corneal B-PHE
ulcer I-PHE
, O
etc O
. O
, O
orally O
or O
toptically O
. O
diarrhea B-PHE
and O
dysentery B-PHE
of O
dampness-heat B-PHE
type O
, O
skin B-PHE
lesions I-PHE
of O
dampness B-PHE
type O
, O
etc O
. O

-DOCSTART- O


break O
hard B-PHE
mass I-PHE
and O
dissipate O
accumulation B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
absorption B-PHE
, O
Digestion B-PHE
, O
motility B-PHE
, O
Others O
, O
General O
woman O

-DOCSTART- O


sores B-PHE
with O
swelling B-PHE

-DOCSTART- O


arthralgia B-PHE
; O
Pi B-PHE
syndrome I-PHE

-DOCSTART- O


Type B-PHE
2 I-PHE
Diabetes I-PHE
Mellitus I-PHE
. O

-DOCSTART- O


Major B-PHE
Depressive I-PHE
Disorder I-PHE

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
fibromyalgia B-PHE
. O

-DOCSTART- O


warm O
the O
bladder B-PHE

-DOCSTART- O


Benign B-PHE
Prostatic I-PHE
Hyperplasia I-PHE

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
Urinary B-PHE
systems I-PHE

-DOCSTART- O


blood-heat B-PHE

-DOCSTART- O


The O
primary O
activity O
of O
insulin O
is O
the O
regulation O
of O
glucose B-PHE
metabolism I-PHE
. O

Insulin O
promotes O
glucose O
and O
amino O
acid O
uptake O
into O
muscle O
and O
adipose O
tissues O
, O
and O
other O
tissues O
except O
brain O
and O
liver O
. O

It O
also O
has O
an O
anabolic O
role O
in O
stimulating O
glycogen B-PHE
, I-PHE
fatty I-PHE
acid I-PHE
, I-PHE
and I-PHE
protein I-PHE
synthesis I-PHE
. O

Insulin O
inhibits O
gluconeogenesis B-PHE
in O
the O
liver O
. O

Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity I-PHE
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin B-PHE
receptor I-PHE
substrates I-PHE
( O
IRS B-PHE
) O
proteins O
, O
Cbl B-PHE
, O
APS B-PHE
, O
Shc B-PHE
and O
Gab B-PHE

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-PHE
of I-PHE
downstream I-PHE
signaling I-PHE
molecules I-PHE
including O
PI3 B-PHE
kinase I-PHE
and O
Akt B-PHE
. O

Akt O
regulates O
the O
activity B-PHE
of I-PHE
glucose I-PHE
transporter I-PHE
4 I-PHE
( O
GLUT4 B-PHE
) O
and O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
which O
play O
a O
critical O
role O
in O
metabolism B-PHE
and O
catabolism B-PHE
. O

-DOCSTART- O


Infection B-PHE
of O
upper O
respiratory O
tract O
, O
pneumonia B-PHE
, O
acute B-PHE
gastroenteritis I-PHE
, O
dysentery B-PHE
, O
sore B-PHE
and O
boil B-PHE
, O
scab B-PHE
and O
lichen B-PHE
, O
eczema B-PHE
, O
burns B-PHE
and O
scalds B-PHE
, O
infection B-PHE
of O
biliary O
tract O
, O
poisonous B-PHE
insect I-PHE
stings I-PHE
. O

-DOCSTART- O


Heat B-PHE
bind O
and O
accumulation O
, O
constipation B-PHE
w O
ith O
abdominal B-PHE
pain I-PHE
, O
edema B-PHE
distention I-PHE
fullness I-PHE
. O

-DOCSTART- O


vomiting B-PHE
and O
diarrhea B-PHE

-DOCSTART- O


Clarithromycin O
also O
inhibits O
the O
hepatic O
microsomal O
CYP3A4 O
isoenzyme O
and O
P-glycoprotein O
, O
an O
energy-dependent O
drug O
efflux O
pump O
. O

-DOCSTART- O


Untreated O
Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE

-DOCSTART- O


Treatment O
of O
sore B-PHE
throat I-PHE
and O
hoarseness B-PHE
of I-PHE
voice I-PHE
, O
cough B-PHE
with O
yellow B-PHE
sticky I-PHE
sputum I-PHE
, O
dysuria B-PHE
, O
external O
use O
for O
pemphigus B-PHE
and O
eczema B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment I-PHE
pain I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
pain B-PHE
in O
stomach O
duct O
, O
hemiplegia B-PHE
, O
gan B-PHE
accumulation I-PHE
, O
dysentery B-PHE
. O

-DOCSTART- O


Effect O
of O
Hachimijiogan O
( O
HJ O
) O
on O
dopamine B-PHE
( O
DA B-PHE
) O
, O
serotonin B-PHE
( O
5-HT B-PHE
) O
and O
vasoactive B-PHE
intestinal I-PHE
peptide I-PHE
( O
VIP B-PHE
) O
was O
examined O
in O
plasma O
and O
hypothalamic O
tissue O
of O
sulpiride-induced O
hyperprolactinemic O
rats O
( O
SHR O
) O
. O

Similar O
to O
bromocriptine B-PHE
( O
BR B-PHE
) O
, O
HJ O
, O
in O
combination O
with O
sulpiride O
, O
suppressed O
plasma B-PHE
prolactin I-PHE
levels I-PHE
raised O
by O
sulpiride O
alone O
. O

Furthermore O
, O
HJ O
, O
together O
with O
sulpiride O
, O
increased O
plasma B-PHE
DA I-PHE
levels I-PHE
decreased O
by O
sulpiride O
alone O
, O
while O
5-HT B-PHE
in O
plasma O
was O
increased O
by O
sulpiride O
and O
HJ O
, O
individually O
or O
in O
combination O
. O

However O
, O
plasma B-PHE
VIP I-PHE
levels I-PHE
were O
under O
detection O
limits O
on O
some O
occasions O
after O
HJ O
treatment O
. O

Successively O
, O
DA B-PHE
, I-PHE
5-HT I-PHE
and I-PHE
VIP I-PHE
levels I-PHE
in O
the O
hypothalamus O
were O
determined O
. O

Similar O
to O
the O
effect O
caused O
by O
BR B-PHE
, I-PHE
DA I-PHE
and I-PHE
5-HT I-PHE
levels I-PHE
in O
hypothalamic O
tissue O
reduced O
by O
sulpiride O
alone O
were O
also O
significantly O
increased O
by O
HJ O
together O
with O
sulpiride O
, O
while O
VIP B-PHE
levels I-PHE
were O
sometimes O
under O
detection O
levels O
with O
or O
without O
HJ O
. O

These O
results O
suggest O
that O
HJ O
stimulates O
the O
hypothalamus B-PHE
to O
increase O
DA B-PHE
and O
5-HT B-PHE
in O
SHR O
, O
providing O
evidence O
for O
the O
clinical O
efficiency O
of O
HJ O
in O
combating O
hyperprolactinemia B-PHE
. O

The O
effect O
of O
HJ O
on O
VIP B-PHE
in O
plasma O
or O
hypothalamic O
tissue O
is O
, O
however O
, O
questionable O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Quality O
of O
life O
, O
Endocrine B-PHE
system I-PHE
, O
Motivation O
, O
Endurance B-PHE
, O
Memory B-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Liver B-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Liver B-PHE
, O
Others O
, O
Respiratory B-PHE
systems I-PHE
, O
effort O
, O
Respiratory B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
disinhibit O
damp B-PHE
, O
cool O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Oxamniquine O
may O
associate O
with O
an O
irreversible O
inhibition O
of O
the O
nucleic B-PHE
acid I-PHE
metabolism I-PHE
of I-PHE
the I-PHE
parasites I-PHE
. O

A O
hypothesis O
has O
been O
put O
forth O
that O
the O
drug O
is O
activated O
by O
a O
single O
step O
, O
in O
which O
a O
schistosome O
sulfotransferase O
enzyme O
converts O
oxamniquine O
into O
an O
ester O
( O
probably O
acetate O
, O
phosphate O
, O
or O
sulfate O
) O
. O

Subsequently O
, O
the O
ester O
spontaneously O
dissociates O
, O
the O
resulting O
electrophilic O
reactant O
is O
capable O
of O
alkylation O
of O
schistosome O
DNA O
. O

-DOCSTART- O


breast B-PHE
abscess I-PHE
; O
acute B-PHE
mastitis I-PHE

-DOCSTART- O


move O
Gi O
( O
Qi O
) O
and O
break O
blood B-PHE

-DOCSTART- O


Prostate B-PHE
cancer I-PHE

-DOCSTART- O


Simvastatin O
competitively O
inhibits O
HMG-CoA O
reductase O
, O
lowers O
plasma O
cholesterol O
and O
lipoprotein O
levels O
, O
and O
modulates O
immune B-PHE
responses I-PHE
by O
suppressing O
MHC O
II O
on O
interferon O
gamma-stimulated O
, O
antigen-presenting B-PHE
cells I-PHE
such O
as O
human B-PHE
vascular I-PHE
endothelial I-PHE
cells I-PHE
. O

Sitagliptin O
is O
a O
highly O
selective O
DPP-4 O
inhibitor O
, O
and O
increases O
insulin B-PHE
release I-PHE
and O
decreases O
glucagon B-PHE
levels I-PHE
in O
the O
circulation O
in O
a O
glucose-dependent O
manner O
. O

-DOCSTART- O


Rivanicline O
is O
a O
( O
E)-metanicotine O
hemigalactarate O
. O

It O
effectively O
inhibits O
TNF- O
and O
LPS-induced O
IL-8 B-PHE
production O
in O
different O
cell O
types O
. O

-DOCSTART- O


Paclitaxel O
interferes O
with O
the O
normal O
function B-PHE
of I-PHE
microtubule I-PHE
growth I-PHE
. O

Whereas O
drugs O
like O
colchicine O
cause O
the O
depolymerization B-PHE
of I-PHE
microtubules I-PHE
in O
vivo O
, O
paclitaxel O
arrests O
their O
function O
by O
having O
the O
opposite O
effect O
; O

it O
hyper-stabilizes O
their O
structure O
. O

This O
destroys O
the O
cell's O
ability O
to O
use O
its O
cytoskeleton B-PHE
in O
a O
flexible O
manner O
. O

Specifically O
, O
paclitaxel O
binds O
to O
the O
; O

subunit B-PHE
of I-PHE
tubulin I-PHE
. O

Tubulin O
is O
the O
building O
block O
of O
mictotubules O
, O
and O
the O
binding O
of O
paclitaxel B-PHE
locks O
these O
building O
blocks O
in O
place O
. O

The O
resulting O
microtubule B-PHE
/ I-PHE
paclitaxel I-PHE
complex I-PHE
does O
not O
have O
the O
ability O
to O
disassemble O
. O

This O
adversely O
affects O
cell O
function O
because O
the O
shortening O
and O
lengthening O
of O
microtubules B-PHE
( O
termed O
dynamic O
instability O
) O
is O
necessary O
for O
their O
function O
as O
a O
transportation O
highway O
for O
the O
cell O
. O

Chromosomes B-PHE
, O
for O
example O
, O
rely O
upon O
this O
property O
of O
microtubules B-PHE
during O
mitosis O
. O

Further O
research O
has O
indicated O
that O
paclitaxel O
induces O
programmed O
cell B-PHE
death I-PHE
( I-PHE
apoptosis I-PHE
) I-PHE
in I-PHE
cancer I-PHE
cells I-PHE
by O
binding O
to O
an O
apoptosis B-PHE
stopping O
protein O
called O
Bcl-2 O
( O
B-cell O
leukemia O
2 O
) O
and O
thus O
arresting O
its O
function O
. O

-DOCSTART- O


Breast B-PHE
Cancer I-PHE

-DOCSTART- O


Bipolar B-PHE
Disorder I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Mood O
, O
Quality O
of O
life O
, O
absorption O
, O
motility B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


Recurrent O
Adult B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
the O
water O
extract O
of O
Samultang O
( O
SMT O
) O
, O
a O
Chinese O
herb O
, O
on O
apoptotic B-PHE
cell I-PHE
death I-PHE
by O
H(2)O(2)-induced O
oxidative B-PHE
stress I-PHE
in O
SK-N-MC O
cells O
. O

A O
nuclear O
fragmentation O
was O
observed O
via O
fluorescence O
imaging O
12 O
h O
after O
exposure O
to O
30 O
microM O
H(2)O(2 O
) O
and O
DNA O
laddering O
was O
detected O
via O
agarose O
electrophoresis O
gel O
. O

In O
addition O
, O
increases O
in O
sub-G1 O
phase O
and O
cleavage O
of O
the O
PARP O
protein O
were O
observed O
. O

However O
, O
treatment O
with O
SMT O
for O
2 O
h O
prior O
to O
H(2)O(2 O
) O
exposure O
significantly O
reduced O
apoptotic B-PHE
cell I-PHE
death I-PHE
induced O
by O
incubation O
with O
30 O
microM O
H(2)O(2 O
) O
in O
SK-N-MC O
cells O
. O

Pre-incubation O
with O
water O
extract O
of O
SMT O
for O
2 O
h O
prevented O
the O
H(2)O(2)-induced O
decrease O
in O
mitochondrial O
transmembrane O
potential O
. O

SMT O
also O
attenuated O
the O
increase O
in O
caspase-3 B-PHE
activity I-PHE
and O
the O
breakdown O
of O
PARP B-PHE
protein I-PHE
caused O
by O
H(2)O(2)-induced O
oxidative O
stress O
. O

These O
results O
suggest O
that O
the O
water O
extract O
of O
SMT O
provides O
inhibition O
of O
apoptotic B-PHE
cell I-PHE
death I-PHE
against O
oxidative B-PHE
injury I-PHE
in O
SK-N-MC O
cells O
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
t(9;11)(p22;q23 O
) O
; O
MLLT3-MLL O

-DOCSTART- O


Wind-damp B-PHE
impediment I-PHE
pain I-PHE
, O
pain B-PHE
from O
arthritis B-PHE
, O
painful O
swelling B-PHE
from O
knocks O
and O
falls O
, O
amenorrhea B-PHE
, O
dysmenorrhea B-PHE
, O
swollen B-PHE
welling I-PHE
abscess I-PHE
, O
erysipelas B-PHE
, O
goose-foot B-PHE
wind I-PHE
, O
snake B-PHE
or I-PHE
insect I-PHE
bites I-PHE
. O

-DOCSTART- O


weakness B-PHE
of I-PHE
constitution I-PHE

-DOCSTART- O


Treatment O
of O
cough B-PHE
in O
colds O
with O
retention O
of O
phlegm B-PHE
marked O
by O
dyspnea B-PHE
, O
profuse O
expectoration B-PHE
and O
feeling O
of O
stuffiness B-PHE
in O
the O
chest O
, O
external O
use O
for O
pyogenic B-PHE
infections I-PHE
of O
the O
skin O
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption O
, O
Lipid O
profile O
, O
Liver B-PHE
health I-PHE
, O
DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
motility O
, O
Liver B-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


To O
warm O
the O
spleen B-PHE
, O
stop O
vomiting B-PHE
, O
clear O
away O
summer-heat B-PHE
and O
eliminate O
dampness B-PHE
. O

-DOCSTART- O


Immune B-PHE
Thrombocytopenic I-PHE
Purpura I-PHE

-DOCSTART- O


In O
the O
process O
of O
binding O
, O
the O
receptor O
is O
actually O
activated O
- O
causing O
a O
process O
known O
as O
depolarization B-PHE
. O

-DOCSTART- O


1 O
Its O
decoction O
is O
a O
broad-spectrum O
bacteriostatic O
. O

2 O
Stimulating O
the O
mucosa O
of O
respiratory O
tract O
directly O
, O
promoting O
secretion O
and O
expectoration O
. O

3 O
Its O
volatile O
oil O
kills O
trichomonas B-PHE
vaginalis I-PHE
in O
vitro O
. O

4 O
Its O
volatile O
oil O
is O
also O
an O
analgesic O
. O

-DOCSTART- O


cool O
blood B-PHE
and O
relieve O
toxicity B-PHE

-DOCSTART- O


coldness B-PHE
and O
pain B-PHE
in O
the O
lumbar O
and O
knee O
region O

-DOCSTART- O


High-Grade O
Lymphoma B-PHE

-DOCSTART- O


To O
boost O
essence O
, O
brighten O
eyes B-PHE
, O
cool O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Stroke B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
. O

-DOCSTART- O


Ephedrine O
is O
a O
sympathomimetic O
amine O
- O
that O
is O
, O
its O
principal O
mechanism O
of O
action O
relies O
on O
its O
direct O
and O
indirect O
actions O
on O
the O
adrenergic B-PHE
receptor I-PHE
system I-PHE
, O
which O
is O
part O
of O
the O
sympathetic B-PHE
nervous I-PHE
system I-PHE
. O

Ephedrine O
increases O
post-synaptic O
noradrenergic O
receptor O
activity O
by O
( O
weakly O
) O
directly O
activating O
post-synaptic O
receptors O
and O
receptors O
, O
but O
the O
bulk O
of O
its O
effect O
comes O
from O
the O
pre-synaptic B-PHE
neuron I-PHE
being O
unable O
to O
distinguish O
between O
real O
adrenaline B-PHE
or O
noradrenaline B-PHE
from O
ephedrine O
. O

The O
ephedrine O
, O
mixed O
with O
noradrenaline B-PHE
, O
is O
transported O
through O
the O
noradrenaline B-PHE
reuptake I-PHE
complex I-PHE
and O
packaged O
( O
along O
with O
real O
noradrenaline B-PHE
) O
into O
vesicles B-PHE
that O
reside O
at O
the O
terminal O
button O
of O
a O
nerve B-PHE
cell I-PHE
. O

Ephedrine's O
action O
as O
an O
agonist O
at O
most O
major O
noradrenaline O
receptors O
and O
its O
ability O
to O
increase O
the O
release O
of O
both O
dopamine B-PHE
and O
to O
a O
lesser O
extent O
, O
serotonin B-PHE
by O
the O
same O
mechanism O
is O
presumed O
to O
have O
a O
major O
role O
in O
its O
mechanism O
of O
action O
. O

-DOCSTART- O


Allogeneic O
Haplo-Stem O
Cell O
Transplatation O
( O
SCT O
) O

-DOCSTART- O


relieve O
cough B-PHE
and O
dispel O
phlegm B-PHE

-DOCSTART- O


It O
usually O
happens O
by O
the O
liver B-PHE
heat I-PHE
, O
lung B-PHE
heat I-PHE
, O
heart B-PHE
heat I-PHE
, O
insufficiency O
of O
the O
genuine O
Eum O
, O
or O
infiltration O
of O
pathogenic O
wind O
to O
the O
ocular O
connection O
. O

Usually O
disease B-PHE
can O
be O
divided O
by O
the O
coloration O
. O

-DOCSTART- O


Progestins B-PHE
diffuse O
freely O
into O
target O
cells O
and O
bind O
to O
the O
progesterone O
receptor O
. O

Once O
bound O
to O
the O
receptor O
, O
progestins B-PHE
slow O
the O
frequency O
of O
release O
of O
gonadotropin B-PHE
releasing I-PHE
hormone I-PHE
( O
GnRH B-PHE
) O
from O
the O
hypothalamus O
and O
blunt O
the O
pre-ovulatory O
LH B-PHE
surge O
. O

Ethinyl O
estradiol O
is O
a O
synthetic O
derivative O
of O
the O
natural O
estrogen B-PHE
estradiol I-PHE
. O

Estrogens B-PHE
increase O
the O
hepatic B-PHE
synthesis I-PHE
of I-PHE
sex I-PHE
hormone I-PHE
binding I-PHE
globulin I-PHE
, O
thyroid-binding B-PHE
globulin I-PHE
, O
and O
other O
serum B-PHE
proteins I-PHE
and O
suppress O
follicle-stimulating B-PHE
hormone I-PHE
from O
the O
anterior O
pituitary O
. O

-DOCSTART- O


Childhood B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE
With O
t(9;22)(q34;q11.2 O
) O
; O
BCR-ABL1 O

-DOCSTART- O


Neoplasms B-PHE
, I-PHE
Hormone-Dependent I-PHE

-DOCSTART- O


dispel O
wind B-PHE
and O
drain O
dampness B-PHE

-DOCSTART- O


nasal B-PHE
obstruction I-PHE
and O
the O
deep B-PHE
and I-PHE
harsh I-PHE
voice I-PHE

-DOCSTART- O


loss B-PHE
of I-PHE
appetite I-PHE

-DOCSTART- O


blood B-PHE
vacuity I-PHE
, O
septicemia B-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
numbness B-PHE
and O
paralysis B-PHE
, O
aching B-PHE
in O
lumbus O
and O
legs O
. O

-DOCSTART- O


To O
drain O
the O
pus B-PHE
and O
relieve O
swelling B-PHE
( O
external O
use O
for O
various O
kinds O
of O
severe O
skin B-PHE
lesions I-PHE
; O
oral O
use O
of O
Crotonis O
fried O
yellow O
wax O
for O
bone B-PHE
tuberculosis I-PHE
and O
osteomyelitis B-PHE
) O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
remove O
obstruction B-PHE
from O
the O
channels O
and O
to O
remove O
heat B-PHE
from O
blood B-PHE
and O
cause O
subsidence O
of O
swelling B-PHE
. O

-DOCSTART- O


Rescinnamine O
Binds O
to O
and O
inhibits O
the O
angiotensin B-PHE
converting I-PHE
enzyme I-PHE
. O

Rescinnamine O
competes O
with O
angiotensin O
I O
for O
binding O
at O
the O
angiotensin-converting B-PHE
enzyme I-PHE
, O
blocking O
the O
conversion O
of O
angiotensin B-PHE
I I-PHE
to O
angiotensin B-PHE
II I-PHE
. O

Inhibition O
of O
ACE O
results O
in O
decreased O
plasma B-PHE
angiotensin I-PHE
II I-PHE
. O

As O
angiotensin B-PHE
II I-PHE
is I-PHE
a O
vasoconstrictor B-PHE
and O
a O
negative-feedback O
mediator O
for O
renin B-PHE
activity O
, O
lower O
concentrations O
result O
in O
a O
decrease O
in O
blood B-PHE
pressure I-PHE
and O
stimulation O
of O
baroreceptor O
reflex O
mechanisms O
, O
which O
leads O
to O
decreased O
vasopressor B-PHE
activity O
and O
to O
decreased O
aldosterone B-PHE
secretion O
. O

-DOCSTART- O


Liver B-PHE
Cirrhosis I-PHE

-DOCSTART- O


fetal B-PHE
leakage I-PHE

-DOCSTART- O


relax O
tension B-PHE

-DOCSTART- O


invigorate O
blood B-PHE

-DOCSTART- O


BACKGROUND O
: O
The O
diagnosis O
of O
encephalitis B-PHE
is O
usually O
presumptive O
based O
on O
MRI O
, O
cerebrospinal O
fluid O
analysis O
, O
or O
both O
. O

A O
definitive O
diagnosis O
based O
on O
histopathology O
, O
however O
, O
is O
required O
for O
optimizing O
treatment O
strategies O
. O

OBJECTIVE O
: O
To O
investigate O
the O
diagnostic O
yield O
and O
adverse O
effects O
of O
minimally O
invasive O
brain O
biopsies O
in O
dogs O
with O
encephalitis B-PHE
. O

ANIMALS O
: O
Seventeen O
dogs O
with O
suspected O
encephalitis B-PHE
, O
based O
on O
MR O
imaging O
and O
cerebrospinal O
fluid O
analysis O
. O

METHODS O
: O
Retrospective O
study O
. O

Minimally O
invasive O
, O
free-hand O
brain O
biopsy O
specimens O
were O
taken O
from O
forebrain O
lesions O
through O
a O
4-mm O
burr O
hole O
using O
a O
Sedan O
side-cutting O
needle O
. O

Routine O
histopathological O
examination O
was O
performed O
. O

The O
adverse O
effects O
were O
assessed O
by O
MRI O
evaluations O
after O
biopsy O
procedure O
( O
12 17 O
) O
and O
by O
sequential O
neurological O
examinations O
. O

RESULTS O
: O
The O
overall O
diagnostic O
yield O
with O
regard O
to O
a O
specific O
type O
of O
encephalitis B-PHE
was O
0.82 O
. O

Encephalitis B-PHE
was O
evident O
in O
an O
additional O
0.12 O
, O
but O
a O
specific O
disease B-PHE
could O
not O
be O
determined O
. O

There O
were O
no O
deaths O
caused O
by O
the O
biopsy O
procedure O
itself O
, O
but O
the O
indirect O
case O
fatality O
rate O
was O
0.06 O
. O

Morbidity O
was O
0.29 O
, O
including O
stupor B-PHE
, O
seizures B-PHE
, O
tetraparesis B-PHE
, O
hemiparesis B-PHE
, O
ataxia B-PHE
, O
and O
loss B-PHE
of I-PHE
conscious I-PHE
proprioception I-PHE
. O

All O
these O
signs O
resolved O
within O
03 14 O
days O
. O

CONCLUSIONS O
AND O
CLINICAL O
IMPORTANCE O
: O
Minimally O
invasive O
brain O
biopsy O
in O
dogs O
with O
suspected O
encephalitis B-PHE
leads O
to O
a O
definite O
diagnosis O
in O
the O
majority O
of O
dogs O
, O
allowing O
for O
a O
specific O
treatment O
. O

The O
advantages O
of O
a O
definite O
diagnosis O
outweigh O
potential O
case O
fatality O
rate O
and O
temporary O
neurological B-PHE
deficits I-PHE
. O

-DOCSTART- O


paralysis B-PHE
due O
to O
stroke B-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE
Virus I-PHE

-DOCSTART- O


Vaginal B-PHE
Diseases I-PHE

-DOCSTART- O


Clindamycin O
inhibits O
bacterial B-PHE
protein I-PHE
synthesis I-PHE
by O
binding O
to O
bacterial O
50S O
ribosomal O
subunits O
. O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
throat B-PHE
pain I-PHE
due O
to O
Wind-Heat B-PHE
. O

It O
has O
red B-PHE
spots I-PHE
on O
all O
of O
the O
body O
, O
burning B-PHE
heat I-PHE
, O
difficulty B-PHE
in I-PHE
swallowing I-PHE
foods I-PHE
, O
headache B-PHE
, O
and O
aversion B-PHE
to O
cold O
. O

-DOCSTART- O


Encainide O
is O
a O
sodium O
channel O
blocker O
, O
binding O
to O
voltage B-PHE
gated I-PHE
sodium I-PHE
channels I-PHE
. O

It O
stabilizes O
the O
neuronal B-PHE
membrane I-PHE
by O
inhibiting O
the O
ionic B-PHE
fluxes I-PHE
required O
for O
the O
initiation O
and O
conduction O
of O
impulses O
. O

Ventricular O
excitability O
is O
depressed O
and O
the O
stimulation O
threshold O
of O
the O
ventricle B-PHE
is O
increased O
during O
diastole O
. O

-DOCSTART- O


Loratadine O
is O
a O
second-generation O
H1 O
histamine O
antagonist O
drug O
and O
appears O
to O
suppress O
the O
release B-PHE
of I-PHE
histamine I-PHE
and I-PHE
leukotrienes I-PHE
from O
mast O
cells O
, O
and O
the O
release B-PHE
of I-PHE
leukotrienes I-PHE
from O
human O
lung O
fragments O
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Mimmuietabolic B-PHE
rate I-PHE
/ I-PHE
energy I-PHE
expenditure I-PHE

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
Endocrine O
& O
reproductive B-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Others O
, O
Man O

-DOCSTART- O


Tetracycline O
passively O
diffuses O
through O
porin B-PHE
channels I-PHE
in O
the O
bacterial O
membrane O
and O
reversibly O
binds O
to O
the O
30S B-PHE
ribosomal I-PHE
subunit I-PHE
, O
preventing O
binding O
of O
tRNA B-PHE
to O
the O
mRNA-ribosome B-PHE
complex I-PHE
, O
and O
thus O
interfering O
with O
protein B-PHE
synthesis I-PHE
. O

The O
reduced O
metronidazole O
then O
covalently O
binds O
to O
DNA B-PHE
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial B-PHE
nucleic I-PHE
acid I-PHE
synthesis I-PHE
and O
resulting O
in O
bacterial B-PHE
cell I-PHE
death I-PHE
. O

Esomeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-PHE
acid I-PHE
secretion I-PHE
by O
specific O
inhibition O
of O
the O
H<sup>+</sup>/K<sup>+</sup>-ATPase O
in O
the O
gastric O
parietal O
cell O
. O

-DOCSTART- O


swelling B-PHE
and O
pain B-PHE
due O
to O
trauma B-PHE

-DOCSTART- O


gases B-PHE
retention I-PHE
in O
the O
lungs O

-DOCSTART- O


Prednisolone O
can O
inhibit O
leukocyte B-PHE
infiltration I-PHE
at O
the O
site O
of O
inflammation O
, O
interfere O
with O
mediators B-PHE
of I-PHE
inflammatory I-PHE
response I-PHE
, O
and O
suppress O
humoral B-PHE
immune I-PHE
responses I-PHE
. O

-DOCSTART- O


Hepatitis B-PHE
C I-PHE
Recurrence I-PHE
After O
Liver O
Transplant O

-DOCSTART- O


promote O
liquid O

-DOCSTART- O


To O
cool O
lung B-PHE
, O
release O
discomfort B-PHE
in O
pharynx O
, O
remove O
epidemic B-PHE
evils I-PHE
, O
and O
to O
relieve O
cough B-PHE
. O

-DOCSTART- O


Cisplatin O
binds O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA O
, O
inducing O
intrastrand B-PHE
and I-PHE
interstrand I-PHE
DNA I-PHE
cross-links I-PHE
, O
as O
well O
as O
DNA-protein B-PHE
cross-links I-PHE
. O

-DOCSTART- O


epistaxis B-PHE
; O
nosebleed B-PHE

-DOCSTART- O


edema B-PHE
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-PHE
of I-PHE
the I-PHE
lung I-PHE
, I-PHE
spleen I-PHE
and I-PHE
kidney I-PHE
. O

-DOCSTART- O


Hip B-PHE
Fracture I-PHE

-DOCSTART- O


Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Woman O
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


general O
edema B-PHE
with O
abdominal B-PHE
distension I-PHE
of O
body O
and O
extremities O

-DOCSTART- O


To O
eliminate O
blood B-PHE
stasis I-PHE
with O
strong O
effect O
, O
promote O
the O
flow O
of O
qi O
, O
remove O
the O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
, O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Postpartum B-PHE
Sexual I-PHE
Function I-PHE

-DOCSTART- O


Fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
class O
, O
and O
blocks O
the O
reuptake B-PHE
of I-PHE
serotonin I-PHE
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-PHE
of I-PHE
serotonin I-PHE
on O
5HT<sub>1A</sub> O
autoreceptors O
. O

Venlafaxine O
and O
its O
active O
metabolite O
, O
O-desmethylvenlafaxine O
( O
ODV O
) O
, O
inhibit O
the O
reuptake B-PHE
of I-PHE
both I-PHE
serotonin I-PHE
and I-PHE
norepinephrine I-PHE
with O
a O
potency O
greater O
for O
the O
5-HT O
than O
for O
the O
NE O
reuptake O
process O
. O

Quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism B-PHE
at O
D2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5HT2A O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O


To O
strengthen O
the O
spleen B-PHE
. O

-DOCSTART- O


Treament O
of O
cough B-PHE
, O
sore B-PHE
throat I-PHE
and O
hoarseness B-PHE
of I-PHE
voice I-PHE
due O
to O
heat B-PHE
in O
the O
lung O
, O
epigastic B-PHE
pain I-PHE
due O
to O
stagnation B-PHE
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O


fracture B-PHE

-DOCSTART- O


1 O
L-tetrahydropalmatine O
20-40mg/kg O
intraperitoneally O
in O
mice O
and O
15mg/kg O
intravenously O
in O
rabbits O
exert O
analgesic O
and O
sedative O
effects O
. O

2 O
Reducing O
the O
body O
temperature O
in O
healthy O
or O
thyroidectomized O
rats O
. O

-DOCSTART- O


